Investigating the chondrogenic phenotype in clinically relevant cells: the effect of hTERT expression by Dale, Tina Patricia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is protected by copyright and other intellectual property rights and 
duplication or sale of all or part is not permitted, except that material may be 
duplicated by you for research, private study, criticism/review or educational 
purposes. Electronic or print copies are for your own personal, non-
commercial use and shall not be passed to any other individual. No quotation 
may be published without proper acknowledgement. For any other use, or to 
quote extensively from the work, permission must be obtained from the 
copyright holder/s. 
 
  
Investigating the chondrogenic 
phenotype in clinically relevant cells: 
the effect of hTERT expression 
Tina Patricia Dale 
 
Ph.D. Thesis 
Cell and Tissue Engineering 
July 2016 
 
Faculty of Medicine and Health Sciences 
Research Institute for Science and Technology in Medicine 
I 
 
Abstract 
 
Damaged or diseased mature articular cartilage cannot undergo effective tissue repair and due to 
its avascular, hypocellular nature defects become widespread and painful. No ‘gold standard’ 
treatment exists for this indication and the ultimate recourse is prosthetic joint replacement. 
Cartilage is therefore an ideal target for regenerative medicine therapies aiming to recapitulate 
native cartilage.  
 
Despite over fifty years of research and encouraging outcomes, re-creation of the hyaline tissue 
has yet to be consistently achieved, possibly as a result of the application of a sub-optimal cell 
type. Chondrocytes and bone marrow mesenchymal stem cells (MSCs) have been used clinically, 
with future prospects for other alternative MSC sources and human embryonic stem cell (hESC)-
derived cells. Further in vitro study of cellular chondrogenic capacity is desirable but hampered by 
cell changes and senescence. This work examines the hypothesis that the re-introduction of the 
catalytic sub-unit human telomerase reverse transcriptase (hTERT) can extend the proliferative 
cell capacity of cells whilst concomitantly bypassing changes associated with cell aging and 
senescence. The utility of umbilical cord blood (UCB) as a possible alternative source of more 
naive MSCs was also investigated.  
 
Human bone marrow MSCs, chondrocytes, and hESC-derived cells were transduced with hTERT 
and their resulting chondrogenic capacity, assessed principally by extracellular matrix (ECM) 
production and gene expression, examined and compared to that of the three non-transduced, 
parental cell sources. 
 
UCB was not found to be a viable alternative MSC source due to a very low cell number and 
colony recovery; however, foetal bovine serum (FBS) batch and atmospheric oxygen tension were 
II 
 
identified as key to influencing recovery outcomes. Of the three parental cell types examined for 
chondrogenic potential MSCs and chondrocytes produced similar amounts of sGAG but 
chondrocytes produced a more homogeneous ECM with persistent chondrogenesis, whereas 
MSCs became hypertrophic. hESC derived cells had a more muted chondrogenic response with 
similarities to both chondrocytes and MSCs. TERT extended the proliferative capacity of all three 
cell types, two extensively but was also associated with changes in cell phenotype and a 
reduction, although not complete ablation, in the subsequent chondrogenic capacity. 
 
Taken together the results demonstrate that with current differentiation techniques primary 
articular chondrocytes provide the most optimal result, supporting their continued use for clinical 
therapies, and this capacity may not be preserved by the application of hTERT transduction 
strategies.  
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Chapter 1 
 
Introduction 
1 Introduction 
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 The human skeleton 1.1
The human body is supported by the skeletal system that acts as a series of levers which, along 
with the muscles and essential connective tendons and ligaments, enable movement. Typically 
consisting of 270 bones at birth and reducing to 206 at skeletal maturity as a result of the fusion 
of bones the skeleton can be subdivided into the vertebral column, ribcage and skull forming the 
axial skeleton and the pelvis, and bones of the shoulders and limbs forming the appendicular 
component of the skeleton1. Where bones come into contact with each other joints or 
articulations are formed and these can be classified broadly into three types according to the 
resulting anatomy and physiology as shown in Table 1-1. The joints permitting movement are the 
synovial or diarthroidal joints. 
 
Table 1-1. Joint classification. Joints can be classified by both structural characteristics or by the degree 
of movement associated with the joint type; as indicated these usually overlap. (From information in Graaf 
et al, 2001
2
.) 
Joint classification - 
structural 
General features Joint classification – 
by degree of 
movement 
Examples 
Fibrous Immovable – connected by 
fibrous connective tissue 
Synarthroses Cranial sutures 
Cartilaginous Slightly movable – connected 
by fibrocartilage 
Amphiarthroses Pubic symphysis, 
intervertebral disks 
Synovial Movable – complex joint 
structure determines extent 
of movement 
Diarthroses Many including: 
shoulder, hip, 
knee, elbow, ankle 
  
 Synovial joints  1.2
Synovial (diarthroidal) joints are those that allow relatively free movement around the joint, with 
the extent of the movement being dictated by the specific joint anatomy. In general, the bones 
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forming synovial joints (Figure 1-1A) are separated by a synovial fluid filled cavity and are 
completely encapsulated by a fibrous synovial capsule and the synovial membrane. Type B 
fibroblastic synoviocytes within the synovial membrane secrete hyaluronan and proteoglycan 4 
(lubricin/superficial zone protein) into the synovial fluid, around 1 mL of which typically fills the 
joint space in the knee3. The ends of the bones forming synovial joints are covered in a thin layer 
of articular cartilage which is essential to protect the bone surfaces. The joints may be further 
stabilised by the presence of supporting ligaments and muscles (Figure 1-1B). 
 
 
Figure 1-1. Synovial joint anatomy. (A) Typical features of a simplified synovial joint (knee). B) 
Supporting anatomical structures that may be necessary for joint stability. (Images adapted from OpenStax 
Anatomy and Physiology
4
.)  
Licensed by Rice University under a Creative Commons Attribution License (by 4.0). 
 
The articular, hyaline cartilage that overlays the bones provides both an extremely low friction 
gliding surface to allow free movement and acts to protect and cushion the bone, preventing 
damage from the high forces generated within joints5. It also protects the subchondral bone from 
fluid influx and fluid flow that can cause osteolysis and bone cysts6. The high degree of anisotropic 
structural organisation and specific ECM composition found within the thin (1-4 mm) layer of 
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hyaline cartilage confers the necessary biomechanical properties to ensure normal function for 
many years. 
 Articular cartilage 1.3
1.3.1 Embryonic articular cartilage development 
During embryonic development a cartilaginous precursor of the appendicular component of the 
human skeleton is produced. The majority of this template goes on to be replaced by mineralised 
bone tissue via the process of endochondral ossification7. The cartilaginous tissue template 
develops from early undifferentiated mesenchymal tissue originating from the mesodermal germ 
layer of the embryo. Knowledge of the events of limb patterning during embryogenesis are 
incomplete8; however, it appears that initially proliferation of undifferentiated cells is driven by 
the mitogenic influence of fibroblast growth factors (FGFs) secreted from the embryonic limb bud 
apical ectodermal ridge (AER), this proliferation continues; possibly as a result of reducing the 
proximity of the more distal cells to the AER the FGF mitotic influence is gradually reduced. As the 
morphogenetic gradients from several signalling centres influencing the cells change, cells begin 
the process of chondrogenic differentiation. Broadly, this proceeds via condensation of the tissue 
where mesenchymal cells become very closely associated, expressing a variety of cell adhesion 
molecules including N-Cadherin, neural-cell adhesion molecule 1 (NCAM1), thrombospondin-4, 
versican and tenascin-C9. Condensation is followed by cell differentiation and the onset of the 
synthesis of a cartilaginous ECM10. 
The molecular mechanisms driving the process of chondrogenesis and importantly the prevention 
of terminal differentiation and endochondral ossification are not yet fully characterised; 
nevertheless, some important signalling molecules including transforming growth factor beta 
(TGF-β), transcription factor SOX9, Wnt9a, Noggin and growth and differentiation factor 5 (GDF5) 
have been identified11. SOX9 is a key transcription factor expressed throughout chondrogenesis, 
directly controlling levels of cartilage ECM protein gene expression and negatively regulating 
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endochondral ossification promoting a long-term hyaline cartilage phenotype. The SOX9 gene is 
expressed in all chondrogenic cells but is down-regulated in hypertrophic chondrocytes12. SOX9 
acts both directly and in combination with the transcription factors SOX5 and SOX6 to promote 
the chondrogenic phenotype, including direct upregulation of type II collagen and aggrecan13. 
The early pre-cartilaginous mesenchymal blastema that forms the presumptive bone is 
continuous, with no defined joint positions; the joint positions become defined when an 
‘interzone’ develops at the prospective joint location (Figure 1-2). Mesenchymal cells in the 
interzone area form a thin layer of very closely associated cells distinguishable from the remaining 
blastema. It is believed that the interzone area then becomes a signalling centre controlling the 
subsequent joint development. Following interzone specification joint development continues 
with inhibition of cartilage promoting bone morphogenetic proteins (BMPs) by antagonists like 
Noggin and Chordin. The loss of this BMP inhibition is known to cause abnormal syntosis whereby 
the joint(s) fails to form and the bone remains completely fused14. The converse also appears to 
be the case with Noggin overexpression negatively impacting the process of osteogenesis15. 
Following the interzone development the cartilage anlagen separates or ‘cavitates’ to create the 
joint space16. Although the signals specifying the interzone have yet to be fully elucidated, the 
next stage of cavitation appears to be as a result of changes in the cluster of differentiation 
(CD)44 receptor expression and hyaluronan glycosaminoglycan (GAG) production and distribution 
in response to mechanical stimuli at the joint position17. 
It is likely that the articular cartilage develops from the cells located immediately adjacent to the 
interzone region16. A study of the gene expression of cells within the interzone region in a mouse 
model has demonstrated a variation in the expression of the cartilage matrix protein matrilin-118. 
The study confirmed that articular chondrocytes, known to lack the expression of matrilin-119, 
don’t express matrilin-1 at any stage of joint development in contrast to other chondrogenic cells 
destined to become other joint tissues18. As an exception to this, within osteoarthritic tissues 
matrilin-1 is expressed by articular chondrocytes prior to histological evidence of tissue 
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degeneration20. Studies such as these provide strong evidence that articular cartilage 
chondrocytes are distinct from chondrocytes that form cartilage destined for endochondral 
ossification and that these cells are specified at an extremely early stage of the joint formation 
process18. 
 
 
Figure 1-2. The major steps in synovial joint formation. A: Mesenchymal pre-chondrogenic 
condensations appearing in the early limb autopod exhibit no overt signs of joint formation and 
are thus interrupted. B: Unknown patterning mechanisms determine the exact location for joint 
initiation. C: The interzone forming at each prescribed joint site represents the first overt 
morphological sign of joint formation and is characterised by further gathering and condensation 
of cells. Mesenchymal cells constituting the bulk of the condensations differentiate into 
chondrocytes and establish the cartilaginous skeleton. D: The cavitation process begins and will 
eventually lead to a physical separation of the adjacent skeletal anlagen and formation of the 
synovial cavity. E: Morphogenetic processes begin to mould the opposing sides of the joint into 
reciprocal shapes and interlocking structures. F: Eventually, all the distinct components of a 
mature joint form and include articular cartilage, capsule and a full-fledged synovial cavity. Note 
that the above phases of joint development are continuous and are presented here as distinct 
events only for descriptive purposes. 
Reprinted from Pacifici et al, 2005
21
 with permission from John Wiley and Sons Inc.   
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1.3.2 Postnatal articular cartilage 
Following birth mammalian articular cartilage continues to act as a growth plate region for the 
epiphyseal bone contributing to its growth in all directions. At this stage of development the 
cartilage is thicker and much more isotropic in its organisation than it will later become. Structural 
changes in the articular cartilage of rabbits’ cartilage have been observed to occur mainly in the 
first 3 months following birth (Figure 1-3) which represents puberty/sexual maturity in these 
animals22. 
 
 
Figure 1-3. Light micrographs of articular cartilage. Tissue derived from the medial femoral condyle of 
New Zealand white rabbits 1 month (A), 2 months (B), 3 months (C) and 8 months (D) after birth. The 
images illustrate the transition from an isotropic cellular organization 1 month after birth (A) to a highly 
anisotropic one by the third postnatal month (C). At this latter stage, the architecture resembles that in the 
adult animal (D). The change in structural organization is accompanied by a decrease in the overall height of 
the articular cartilage layer. One-micrometre-thick sections stained with toluidine blue. Scale bars: 
A = 220 μm; B, C,D = 110 μm 
Reprinted from Hunziker et al, 2007
22
 with permission from Elsevier 
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These changes leading to the maturation of the cartilage appear to be as a result of the resorption 
of the cartilage and replacement with bone tissue by endochondral ossification whilst new 
articular cartilage is deposited in an appositional manner at the articular surface by a body of 
stem cells and transit amplifying cells residing and proliferating in the superficial and transitional 
zones22,23.  
1.3.3 Mature articular cartilage 
At skeletal maturity human articular cartilage has a very low cellularity with a relatively small 
number of chondrocytes (<5% wet weight or approximately 1.65% of the total tissue volume24) 
embedded within a dense, highly hydrated ECM. Tissue cellularity decreases with both depth 
from the articular surface, and age, continuing to change during adolescence. Cells, particularly in 
the deeper tissue layers, can frequently be found in pairs, clusters or columns rather than in 
isolation25 and in the mature tissue are post-mitotic13. The tissue is avascular, alymphatic and 
aneural throughout and relies upon diffusion gradients with the synovial fluid and subchondral 
bone for nutrient and waste exchange, a process that is assisted by tissue fluid flow induced by 
pressure changes within the joint. The poor nutrient and oxygen supply confer a lower metabolic 
activity to the cells and the paucity of cells ensures that the rate of tissue turnover is extremely 
low with the collagen II in the ECM having a half-life of 117 years in comparison with the collagen 
found in skin which has a half-life of 15 years when determined by the rate of accumulation of 
advanced glycation end products26. 
The ECM consists primarily of collagen fibres embedded in a proteoglycan rich ground substance 
at a ratio estimated to be between 10:2 to 10:3 by mass (1:2 to 1:3 considering only 
hydroxyproline content)27 and is highly hydrated varying from 65-80% with progression from the 
surface28. Through the tissue depth zones with varying composition and structural organisation 
can be noted within cartilage (Figure 1-4). With the progression from the articulating surface to 
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the sub-chondral bone they can be categorised as: i. superficial or tangential zone, ii. middle zone, 
iii. deep zone, iv. calcified zone. 
 
 
Figure 1-4. Classification of articular cartilage into zones. Cartilage is typically divided into four zones, 
from the surface: superficial zone, middle zone, deep zone and calcified zone separated from the cartilage 
by the tide mark. 
 
The superficial zone accounts for 10% of the total cartilage depth and effectively resists shear and 
tensile stresses. Within this layer thin collagen fibres are numerous and aligned parallel to the 
surface, chondrocytes are present in relatively high numbers and are flattened and found as single 
cells; compared to the deeper zones the proteoglycan concentration is relatively low29. The 
middle zone accounts for a further 40-60% of the cartilage thickness, collagen fibres are thicker 
and are aligned obliquely rather than horizontally with fewer chondrocytes adopting a more 
rounded morphology, they are also more commonly found in clusters rather than in isolation24. 
The middle zone is suited to resisting compressive forces. The deep zone, making up the 
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remaining 30% of the cartilage, also resists compressive forces; here the largest collagen fibres 
are found arranged perpendicularly to the articulating surface, as are columns of chondrocytes. 
These fibres act to anchor the cartilage to the bone as they continue through the deep zone into 
the calcified zone. The calcified zone is bordered by a ‘tide mark’ marking the onset of tissue that 
has progressed further through the process of endochondral ossification and has become 
mineralised sub-chondral bone tissue.  
There are further distinctions apparent within the matrix dependent upon the proximity to the 
embedded chondrocytes; immediately surrounding cells is the pericellular matrix with both cell(s) 
and the immediate pericellular matrix together forming the chondron30 (Figure 1-5), surrounding 
the chondron is the territorial matrix with the remaining ECM being classified as interterritorial 
matrix. The pericellular matrix components in direct contact with the chondrocytes influence their 
behaviour and chondrocytes enzymatically isolated from the surrounding pericellular matrix have 
been found to behave differently in vitro than intact chondrons that retain the pericellular 
matrix30. Cellular turnover of the matrix is believed to occur only in the immediate vicinity of the 
chondrocytes (within 8µm) of the cell membrane, in young tissue this means that much of the 
matrix is within this zone of potential remodelling, whereas in older, more hypocellular tissue this 
zone excludes a significant proportion of the matrix25. 
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Figure 1-5. Electron micrographs showing the ECM compartments of articular cartilage. Electron 
micrographs of chondrocytes within the radial zone of articular cartilage tissue derived from the medial 
femoral condyle of New Zealand white rabbits 1 month (A), 3 months (B) and 8 months (C) after birth. In 1-
month-old rabbits (A), the collagen fibrils are distributed randomly (isotropically) and homogeneously 
throughout the entire extracellular space. No distinct compartmentalisation of the matrix is apparent. In 3- 
(B) and 8-month-old rabbits (C), the extracellular space is organized into distinct pericellular (P), territorial 
(T) and interterritorial (I) compartments. The narrow pericellular matrix compartment is highly electron-
dense owing to the abundance of RHT-precipitated proteoglycans. Within the territorial compartment, the 
collagen fibrils are arranged in a typically basket-like fashion around the cells. Within the interterritorium, 
which constitutes the bulk of the extracellular space, the collagen fibrils are oriented parallel to each other 
and in a predominantly longitudinal direction. Scale bars: A = 10 μm; B, C = 5 μm. 
Reprinted from Hunziker et al, 2007
22
 with permission from Elsevier 
 
 The extracellular matrix 1.4
1.4.1 Collagen 
A key component of ECM throughout the body the collagens represent a family of proteins that 
typically assemble in a hierarchical manner allowing the formation of supra-molecular structures 
including fibrils/fibres and sheets. At the simplest level collagen consists of a triple helical 
structure of amino acid chains, referred to as α chains, forming the procollagen molecule31. 
Different combinations of identical or differing α chains constitute the different collagen types 
and this, along with interaction of the procollagen with other ECM constituents including other 
collagens, controls the higher level protein structure following procollagen processing32. 
Hyaline cartilage ECM contains abundant collagen (Table 1-2.) around 95% of which is type II 
fibrillar collagen; it provides the tensile strength that is required to give articular cartilage its 
resistance to loading. Types IX and XI, present at around 1% and 3%33, act to stabilise or direct the 
12 
 
crosslinking of the type II collagen and are therefore found distributed within the collagen fibres 
throughout cartilage34. Type VI collagen, present at 1-2%33, has a role in the attachment of the 
chondrocytes to their immediate ECM and is found at high concentrations in the pericellular 
region35. Collagen fibres in the pericellular region are also typically finer than those in the 
territorial and inter-territorial regions29. Type X collagen is found in the calcified, hypertrophic 
regions of the cartilage and can be considered a marker of hypertrophic chondrocytes36. Type I 
collagen is the primary collagenous component of bone tissue and fibrocartilage and is also 
considered a marker of inappropriate matrix production although type I collagen has also been 
found to be expressed by cells in freshly isolated, non-calcified cartilage tissue37. 
 
Table 1-2. Types of collagen and their role within articular hyaline cartilage.  (Adapted from data in 
Ross & Pawlina 2006 ch. 6
38
and Wu et al 2010
39
.)  
 Primary Role Polypeptide Chains 
Type II 
Fibrillar collagen, represents the bulk of the structural 
collagen in cartilage 
[α1(II)]3 
Type III 
Fibrillar collagen, also found in other tissues, in cartilage 
forms a mesh crosslinked with other type III fibres and type 
II fibres 
[α1(III)]3 
Type VI 
Pericellular fibrillar collagen (“chain and bead” structure), 
assists in attaching chondrocytes to ECM 
[α1(VI)]2 α2(VI)] or 
α1(VI) α2(VI) α3(VI) 
Type IX  
Fibril Associated Collagens with Interrupted Triple helices 
(FACIT) cartilage, associated with type II fibres, facilitates 
fibril interaction with proteoglycans 
α1(IX) α2(IX) α3(IX) 
Type X 
Organises collagen fibrils into three dimensional (3D) 
hexagonal lattice, typical of hypertrophic cartilage 
[α1(X)]3 
Type XI Regulates collagen fibril size 
[α1(XI)]2 α2(XI) or 
α1(XI) α2(XI) α3(XI) 
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1.4.2 Articular cartilage proteoglycans and glycosaminoglycans 
Proteoglycans consist of one or more GAGs covalently linked to protein cores forming highly 
negatively charged proteoglycans. In the articular cartilage ECM the major proteoglycan by mass 
is aggrecan, a large aggregating proteoglycan formed from numerous chondroitin sulphate and 
keratan sulphate GAG chains attached to an aggrecan specific protein core. These aggrecan 
monomers further attach via the hyaluronan binding domain of their protein core to the GAG 
hyaluronan, a connection that is stabilized by the presence of a link protein. These extremely 
large aggregates ensure that aggrecan is retained within the matrix and act to prevent the loss of 
smaller molecules40. The keratan and chondroitin sulphated (s)GAGs contain multiple negatively 
charged sulphate and carboxylate functional groups all of which repel each other creating a 
‘bottlebrush’ structure at both the individual aggrecan molecule (Figure 1-6) and the aggregate 
scale.  
 
 
Figure 1-6. Atomic force microscopy (AFM) height images of foetal epiphyseal aggrecan. Low and 
high resolution AFM images of an aggrecan monomer showing the attached GAGs. 
Reproduced from Ng et al, 2003
41
 with permission from Elsevier. 
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The accumulation of negative charge conferred by proteoglycans serves to attract cations which 
then cause water to enter the tissue to maintain the osmotic balance with the surrounding 
synovial fluid42. It is this hydrostatic pressure within the tissue that maintains the ECM collagen 
fibres in tension, particularly when the tissue bulk is under the influence of compressive forces 
and the pressure is further increased. There is significant resistance to fluid flow within the tissue 
when a force is rapidly applied such as that found during joint loading due to the low porosity of 
the tissue and the charge interactions between water and proteoglycans allowing the tissue to 
withstand extremely high forces as these are largely borne by the water component of the tissue. 
With aging the average molecular mass of aggrecan has been found to decrease resulting in an 
increase in its molar concentration. There is also an accumulation of non- or poorly glycosylated 
protein from the hyaluronan binding region of the protein core reflecting a change in synthesis or 
degradation rates40.  
A second large aggregating chondroitin sulphate proteoglycan – versican - has also been identified 
in cartilage. Typically having a wider tissue distribution than aggrecan, versican can also interact 
with hyaluronan and may have a role during joint development at the interzone, possibly by 
restricting innervation and vascularisation of the tissue43,44. 
1.4.3 Small leucine-rich repeat proteoglycans 
In addition to aggrecan articular cartilage contains the small leucine-rich repeat proteoglycans 
(SLRPs) decorin, biglycan, fibromodulin and lumican. These SLRPs represent only a small 
proportion of proteoglycan by mass; however, they are present in a comparable molar quantity to 
that of aggrecan. Decorin and biglycan contain the sGAG chondroitin/dermatan sulphate, lumican 
and fibromodulin both contain keratan sulphate. The SLRP proteoglycans decorin, fibromodulin 
and lumican are often found associated with collagen fibrils and are believed to have a regulatory 
role in fibril synthesis and matrix interaction, they are also known to interact with non-fibrillar 
collagens found in the ECM42.  
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The cartilage ECM structure and organisation ensures that the tissue meets the demands placed 
upon it by joint motion: however, the ECM serves more than a mechanical role, influencing 
cellular function. Proteoglycans in the matrix can sequester growth factors with the potential to 
maintain a reservoir of the factor in proximity to the cells, and to modulate their influence upon 
the cells. Decorin can bind TGF-β, a promoter of proteoglycan synthesis45, and in doing so can 
modulate its effects providing both a feedback mechanism and an ECM reservoir of growth factor 
to control proteoglycan synthesis and possibly cartilage remodelling42. Heparan sulphate binds 
numerous growth factors including basic fibroblast growth  factor (bFGF), acidic fibroblast growth 
factor (aFGF), granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) 
and interferon gamma (IFNγ)42. 
1.4.4 Glycosaminoglycans 
By far the most abundant sGAG within the articular cartilage is chondroitin sulphate, accounting 
for 80% of the sGAG present it is a polysaccharide consisting of repeating glucuronic acid (GlcA) 
and N-acetylgalactosamine (GalNAc) disaccharide units. The disaccharide can be sulphated at the 
GlcA C2 position, the GalNAc C4, GalNAc C6 or both GalNAc C4 and C6 with sulphation at C4 or C6 
being most common46. The chain length, terminal saccharide and extent and position of 
sulphation have been found to vary with age, with an overall decrease in C4 sulphation and an 
increase in sulphation at C6 from birth to 20 years46. Relatively lower sulphation has been found 
within the linkage region than the main body of the chain47. Zonal variations have also been noted 
corresponding to variation in tissue depth and topographical location46. Changes in sulphation 
have also been noted when cartilage is in a diseased state with reductions in the terminal residue 
sulphation from 60% to 30%48.  
A further 5-20% of the sGAG content is keratan sulphate, with repeating disaccharides of 
galactose (Gal) and N-acetylglucosamine (GlcNAc). Keratan sulphate can also be sulphated to 
varying degrees at the C6 position of one or both of the monosaccharide units and like 
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chondroitin sulphate has also been found to exhibit changes in chain length and the degree of 
sulphation with tissue age42, with an increase in the proportion of keratan sulphate with 
increasing age40. The extent and positioning of sulphation in both chondroitin and keratan 
sulphate confer different properties upon the GAGs affecting their interaction with chondrocytes 
and other matrix molecules. 
Hyaluronan is found in both the synovial fluid and in the articular cartilage and is a polysaccharide 
made up of repeating disaccharide sub-units of GlcA and GlcNAc. In synovial fluid it is present at 
approximately 3.1-4.1 mg/mL with a weight average molecular weight of 6-7 MDa3. In the 
articular cartilage hyaluronan represents 1-10% of the total GAG and it is present both as a free 
GAG and as the backbone for aggrecan aggregation where up to one hundred aggrecan molecules 
attach to a single hyaluronan chain49. There is evidence that the hyaluronan content becomes 
reduced with increasing age47 although this is in contrast to previous evidence that it increased to 
age 30 then remained largely static50. 
 Cartilage ageing, damage and degeneration 1.5
1.5.1 Ageing 
The structure of cartilage is not static throughout the lifetime of an individual; following tissue 
maturation there is constant activity by the chondrocytes to maintain the structure of the 
cartilage by interstitial growth and to replace cartilage that is degraded at the articulating surface 
despite the low co-efficient of friction. However, the level of ECM molecule synthesis declines 
with increasing age of the individual, possibly as a result of reduced responsiveness of 
chondrocytes to anabolic growth factors like insulin like growth factor 1 (IGF1)51, which along with 
a reduction in cellularity52 leads to a reduction in the chondroitin sulphate and aggrecan content 
of the cartilage and a concomitant reduction in the water content. Not only is there a reduction in 
the overall GAG content, there are changes in the GAG structures including the extent and 
position of sulphation. The collagen within the ECM becomes increasingly cross-linked, increasing 
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the cartilage stiffness52. These changes in the ECM reduce the ability of the cartilage to resist the 
forces placed upon it and this is reflected in a gradual degeneration of the cartilage structure. This 
frequently progresses to the degenerative disease state osteoarthritis.  
1.5.2 Damage and degeneration 
The avascular, aneural, and hypocellular nature of the cartilage tissue is detrimental when the 
tissue sustains physical damage, often due to sports related injuries. It was noted in 174353 based 
on observation and historical reports that once damaged the cartilage within joints was 
intractable to treatment, and this remains the case today. Damaged mature cartilage, particularly 
partial thickness chondral defects, will have a negligible healing response to injury although 
interestingly experimental animal models demonstrate that foetal cartilage will completely heal 
partial thickness defects with little to distinguish the healed tissue from the normal undamaged 
tissue54. There are few warning signs of early tissue damage as no pain is felt until the injury 
progresses to the subchondral bone with its associated nerves, and injuries are not generally 
repairable due to the low intrinsic metabolic rate and cellular and ECM turnover. 
Arthritic and rheumatic diseases, mainly osteoarthritis and rheumatoid arthritis, plus a number of 
much less common diseases that affect the joints, are the most common cause of disability in the 
United States55. Osteoarthritis is by far the most prevalent and is responsible for 80% of cases in 
the UK56, with US based estimates suggesting that symptomatic osteoarthritis affects 12% of 
individuals over the age of 24 increasing to 33% for those over 6057 and around 50% by 85. The 
risk further increases with an increase in body mass index58. 
Osteoarthritic joints (Figure 1-7) are characterised by thinning, fibrillation, damage, and loss of the 
hyaline cartilage. As a whole-joint disease, there is also formation of bony spurs called 
osteophytes at the joint periphery, bony sclerosis, and some inflammation affecting the 
synovium. Surrounding muscles may be weakened and ligaments may develop laxity59. The 
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aetiology of the disease or, in fact, whether there is a single disease process, is unclear and it is 
likely that the disease may be as a result of combined systemic and extrinsic causes.  
 
 
Figure 1-7. Pathology of osteoarthritis. The osteoarthritic joint is characterized by degradation and loss 
of the articular cartilage, thickening of the subchondral bone accompanied by formation of bone marrow 
lesions and cysts, osteophytes at the joint margins, variable degrees of synovitis with synovial hypertrophy, 
meniscal degeneration (knee), and thickening of the joint capsule. 
Reproduced from Loeser 2010
60
 with permission from Elsevier. 
 
The cartilage in osteoarthritic joints is subjected to increased enzymatic degradation by a number 
of different matrix degrading enzymes61 as a result of an imbalance of anabolic and catabolic 
processes (Figure 1-8) resulting in altered tissue properties. The disease causes chronic pain in 
affected joints and can lead to reduced mobility and a significantly impacted quality of life62.  
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Figure 1-8. Catabolic and anabolic factors that regulate chondrocyte function. A host of factors, 
produced locally by articular chondrocytes, regulate matrix synthesis and degradation in articular cartilage. 
As osteoarthritis develops, catabolic activators overwhelm anabolic factors resulting in an imbalance in 
matrix synthesis and degradation. Matrix degradation is mediated by MMPs, aggrecanase, and other 
proteases produced by the chondrocyte in response to the catabolic factors. A change in the chondrocyte 
phenotype to a hypertrophic phenotype also occurs, likely in response to one or more of the catabolic 
factors. 
Reproduced from Loeser 2010
60
 with permission from Elsevier. 
 
Other less common conditions can also lead to the formation of chondral or osteochondral lesions 
which may further cause osteoarthritis including osteochondritis dissecans where the damage is 
caused by an insufficient blood flow in the subchondral bone progressing to necrosis and cartilage 
delamination63. 
The treatment options for arthritic joints remain limited, the UK body NICE (National Institute for 
Health and Care Excellence) recommend exercise, oral or topical analgesia, in some cases 
arthroscopic lavage and debridement and finally a joint replacement64, with osteoarthritis alone 
being responsible for more than half of all replacements in the US61. In Europe this procedure is 
performed every 1.5 minutes, again mainly due to osteoarthritis65, with 15% of joint replacement 
surgeries being performed on those under 60 in the UK66. Whilst a joint replacement can be a 
good option for elderly patients, it is not suited to younger patients where the lifetime of the 
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artificial joint is inadequate leading to the need for a second replacement joint, a more difficult 
procedure, later in life.  
Alternative, more experimental treatment options whereby attempts are made to induce tissue 
regeneration or at the very least repair fall within the purview of the emerging field of 
regenerative medicine.  
 The role of regenerative medicine 1.6
Regenerative medicine, either through the replacement of tissue with an in vitro engineered 
alternative or a cell therapy to support in vivo cellular activity aims to reproduce tissue with the 
anatomy and physiology of the native tissue67. Regeneration rather than the formation of scar 
tissue is the desired outcome, returning full function to the tissue or organ in question.  
The limited treatment options along with an aging population and a higher incidence of injury 
within the younger population make articular cartilage tissue an ideal target for regenerative 
medicine therapies. To date progress in the area of musculoskeletal therapies has been relatively 
rapid in comparison to other body systems, with numerous clinical trials of treatments having 
been undertaken over the last thirty years, despite this long term outcomes remain uncertain.   
Early techniques to promote repair included damaging the subchondral bone surface, beginning in 
1959 with bone drilling68,69 and microfracture70 of the bone to induce bleeding and the formation 
of a fibrin clot in the defect. These procedures are believed to recruit stem cells from the 
underlying bone marrow. After 4-6 months the clot is replaced by a fibrocartilaginous tissue and 
the defect is filled71. Fibrocartilage tissue is more commonly associated with the menisci of the 
knees or the intervertebral discs49, rather than the hyaline articular cartilage, and is less suited to 
the mechanical demands placed upon it at the articulating surfaces. Alternative techniques aim to 
promote hyaline cartilage over fibrocartilage and include mosaicplasty also known as 
osteochondral autograft transplant system (OATS) whereby plugs of osteochondral tissue from a 
healthy non-lead bearing region of cartilage are transplanted to the lesion. This technique does 
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lead to functional improvement but the size of the defect to be treated may be limited by 
available donor tissue71. Allogeneic transplants of osteochondral tissue can also be performed, 
particularly for larger defects where there is insufficient autologous tissue, but have the 
additional risks of disease transmission and rejection of the transplant72.  
1.6.1 Autologous chondrocyte implantation 
Autologous chondrocyte implantation/transplantation (ACI/ACT) relies upon the implantation of 
in vitro expanded autologous chondrocytes to a cartilage lesion site which is covered with a patch 
to retain the cells (Figure 1-9). First performed in man by Brittberg et al73 in the early 1990s the 
procedure requires the acquisition of a small cartilage biopsy from a macroscopically healthy, 
non-load bearing region of the joint. The biopsy is subjected to enzymatic digestion to dissociate 
the cells from the ECM and the resulting cells are cultured in vitro for 10-20 days. Following this 
period of expansion the cells are re-implanted to the defect site under a suitable patch, originally 
periosteal tissue. The Brittberg patient cohort generally reported improvements in function and a 
reduction in pain in response to the treatment and all had tissue rich in type II collagen filling the 
defect. Despite this, the resultant tissue was not always well anchored, varied with the transplant 
location and the quality of the tissue determined by biopsy and histological assessment was 
variable with frequent incidences of fibrocartilage rather than hyaline cartilage73.  
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Figure 1-9. The steps involved in the ACI procedure. 
 
As with the Brittberg study many trials of ACI report the production of fibrocartilage alone or a 
hyaline/fibrocartilage mix at the defect site74. Other problems noted on follow-up have included 
limited cellular and matrix distribution and organisation, tissue overgrowth and delamination of 
the new tissue from the subchondral bone74. The use of the periosteum as the patch is also in 
question as it may contribute to hypertrophy at the tissue surface75. Alternative sealing patches, 
particularly of collagen (e.g. chondrogide), are now undergoing assessment with a reduction, 
although not a complete elimination, in tissue hypertrophy apparent when assessed 1-2 years 
post-operatively76. Studies frequently have only a small number of participants and a limited 
follow-up duration (commonly 1-5 years74) making a long-term assessment of the results to date 
difficult, there are also constraints in monitoring repair as only very limited numbers of biopsies 
are practicable77. In addition to the uncertain outcome, ACI has other associated disadvantages 
including the requirement for two surgical procedures and thus an increased risk of surgical 
complications including infection and the potential for donor site morbidity. 
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As well as modifying ACI with the use of a collagen membrane rather than periosteum further 
alterations of the ACI technique have been attempted to improve the outcome including the use 
of 3D spheroids78 that are entirely cell based and the introduction of biocompatible materials as 
carriers or scaffolds, seeded with cells prior to implantation to a defect site. Many of these are 
currently under investigation for commercial clinical application (Table 1-3)79. 
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Table 1-3. Biomaterials intended for use as cell carriers for cell implantation for cartilage repair. 
(From Marlovits et al, 200679 and Nehrer and Brix, 201480) 
Technique Product Company 
1st Generation -  Cell suspension 
with periosteum 
ACT-Biotissue BioTissue 
 Carticel Genzyme 
 ChondroCelect Tigenix 
 Chondrotransplant Codon 
 Novocart Tetec 
2nd Generation - Cell suspension 
with collagen membrane 
Artrocell Cellgenix/Geistlich/
Ormed 
 CACI Verigen 
3rd Generation - Cell-Biomaterial   
Hyaluronan polymer Hyalograft FAB 
 Hyaff-11-S Fidia, Anika 
Therapeutics 
Collagen gel CaReS-Collagen type 
I hydrogel 
Ars Arthro 
Collagen-membrane ArthroMatrix Arthrex/Orthogen 
 MACI Verigen/Genzyme 
 MACT Igor/André 
Polymer BioSeed-C – 
Fibrin/polygalactin
/polydioxanone 
BioTissue 
 
Matrix induced autologous chondrocyte implantation/transplantation (MACI/MACT) introduced in 
199981, is a third generation ACI technique, involves culturing the chondrocytes on a collagen 
membrane prior to implantation, addressing both problems with cell retention at the defect site 
and associated with the use of a periosteal patch82. The cells are obtained from a 200-400 mg 
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cartilage biopsy and cultured for 3 days on the membrane prior to being re-implanted to the 
defect site with the cultured cells apposed to the prepared defect site80. 
The substitution or a comparison of chondrocytes with MSCs is also increasingly common as bone 
marrow aspirate (BMA) harvest is relatively simple in comparison to obtaining a cartilage biopsy 
for chondrocyte expansion. Variations on this include the implantation of ‘activated’ of bone 
marrow aspirate concentrate (BMAC), with the advantage of requiring only a single surgery 
reducing patient risk and cost, the BMAC is pasted into the defect improving cell retention and 
can still be used with a scaffold material if desired. Early outcomes are similar to those of the 
MACI technique83. 
Many of these modified techniques appear promising, but again will require long-term follow up 
to determine overall efficacy. Furthermore although these interventions are a viable alternative 
for the treatment of focal defects they are less efficacious in patients with osteoarthritis, the 
major cause of joint problems84. 
 Cells with prospects for use in cell therapies 1.7
With the exception of microfracture techniques where cells are recruited from the sub-chondral 
bone the therapies described in the previous section rely upon an exogenous source of cells. This 
is largely as a result of the poor migratory capacity of cells within cartilage, which are in any case 
present in only limited numbers. There are several possible cell types which may be utilised each 
with differing properties.  
1.7.1 Autologous chondrocytes 
Despite the hypocellularity of hyaline cartilage autologous chondrocytes can usually be isolated 
and expanded to sufficient numbers for treatment as is currently the case for ACI and associated 
therapies. However, there are factors that may be deleterious to chondrocyte recovery and 
expansion. In particular, chondrocytes obtained from older donors may not express either a 
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sufficient quantity, or the correct mix of ECM molecules to reproduce the mature hyaline cartilage 
matrix that is necessary for tissue regeneration85.   
Primary chondrocytes are typically cultured in vitro in monolayer for expansion purposes; 
however, during monolayer culture cellular morphology digresses from the expected spherical cell 
to a more flattened appearance resembling a fibroblast. Associated with this change in cell 
morphology is a switch towards type I collagen production rather than type II and a tendency to 
produce increased amounts of smaller proteoglycans and reduced aggrecan86. This process is 
labelled as cell de-differentiation and has been an acknowledged issue with chondrocytes for 
decades87. Whilst 3D culture can restore some of the features of the chondrocytic phenotype it is 
also associated with a much slower rate of proliferation37 with the maximum size of the cellular 
aggregate limited by the need for sufficient nutrient diffusion to prevent cell death in the centre 
of the mass. Collagen type I which should be absent in hyaline cartilage is still also frequently 
expressed88.  
Additionally, as adult, committed lineage cells chondrocytes inherently have a limited proliferative 
capacity before the cells undergo senescence, a state that is associated with considerable changes 
in the cell phenotype and an absolute cessation of proliferation. Chondrocyte senescence is 
discussed further in section 1.8.  
1.7.2 Stem cells 
Stem cells are defined as those cells with the ability to self-renew and undergo asymmetric 
division, i.e. to maintain a population of undifferentiated progeny identical to themselves and, 
under the influence of the appropriate cues, to differentiate into multiple cell types89. The 
totipotent zygote is the only cell with the ability to differentiate into all cell types including the 
extra-embryonic cells of the trophoblast90. Stem cells resident in in vivo niches serve as a self-
renewing pool of cells for the regular replacement or repair of tissues as required91. Research is 
on-going using a variety of stem cells of different origin with variable proliferative and 
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differentiation capacities including hESCs, MSCs and tissue specific stem cells at both the 
fundamental and clinical application levels. 
1.7.2.1 Mesenchymal stem cells 
Whilst it is possible to use relatively mature autologous somatic cells in tissue engineering, for 
example, in ACI procedures, the cells may prove to be less than ideal due to potential donor site 
morbidity, poor proliferative potential and a loss of cell phenotype. This has led to the 
investigation of the use of adult MSCs as a cell source for regenerative medicine therapies. These 
cells have been shown to have a higher proliferative capacity in culture than somatic cells and to 
retain their differentiation potential over multiple passages; however, these features do not 
persist indefinitely92,93.  
The existence of fibroblastic cells in the bone marrow was suggested first in 1867 by Cohnheim94 
and later confirmed by the work of Friedenstein in the 1970s95. Specifically adult stem cells 
capable of producing tissues of the mesenchymal germ layer (i.e. mesenchymal stem cells) were 
found within the plastic adherent bone marrow cell population that formed ‘colony forming units-
fibroblasts’ and had the ability to proliferate extensively and to become a range of differentiated 
cell types95. Since then MSCs, or MSC-like cells, have been described in multiple tissue types 
including: peripheral blood96, muscle97, dermis98, dental pulp99, periosteum100/perichondrium101, 
adipose tissue102 and the various birth associated tissues including UCB103, Wharton’s jelly 
tissue104,105, amniotic fluid106, placenta107 and synovial membranes108.  
MSCs, alternatively described as bone marrow stromal cells (BMSCs), mesenchymal stromal cells 
or bone marrow stem cells, can be obtained with relative ease from aspirates of bone marrow, 
typically from the iliac crest38. Aspirated marrow consists of a heterogeneous mixture of 
haematopoietic and non-haematopoietic bone marrow cells, within the non-haematopoietic 
fraction is a mixture of cells including those with multi, tri, bi and unipotential 
characteristics109,110. Some cells have relative maturity and can form only a very limited range of 
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cell types for example those which appear to be committed osteoprogenitors, whilst others retain 
a more varied potentiality and can become a range of cell types including adipocytes, 
chondrocytes, osteoblasts and myoblasts in vitro when exposed to appropriate culture media 
and/or the application of physical forces111. MSCs have a well-established capacity for 
mesodermal differentiation pathways and additionally their differentiation to cells with features 
of other germ layers has also been described suggesting that the cells have trans-differentiation 
capacity or greater plasticity than first thought112. The fraction of bone marrow cells believed to 
be MSCs is low, reportedly 0.01 to 0.001%93,113. The isolation of MSCs from BMA can be achieved 
by simple plastic adherence to tissue culture plastic with the remaining non-adherent cells 
discarded during subsequent media changes. This simple approach appears to yield the greatest 
number of cells, although arguably a more heterogeneous cell population than the application of 
sorting techniques such as density, magnetic or flow cytometry based cell sorting114. 
Confirmation of the identity of the recovered cells as MSCs remains challenging due to their lack 
of unique characteristics. They are therefore identified on the basis of being plastic adherent, 
having multipotent differentiation capacity as a population and by the expression of a range of 
cell surface markers. Typically those used are as proposed by the Mesenchymal and Tissue Stem 
Cell Committee of the International Society for Cellular Therapy and are the positive expression of 
CD73, CD90 and CD105 and the absence of expression of CD45, CD34, CD14 or CD11b, CD79a or 
CD19 and HLA-DR115, see Table 1-4 for more information on these markers . Other surface 
markers have also been described for MSCs including CD44, CD106, CD146, CD166, CD271 and 
STRO-1116, see Table 1-5 for a more extensive list of MSC positive and negative markers.  
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Table 1-4. Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cellular Therapy recommended MSC markers.  
Marker Description Location Present(+)/absent 
(-) on MSCs 
CD14 55 kDa glycoprotein 
lipopolysaccharide (LPS, 
endotoxin) pattern recognition 
receptor (PRR)
117
 
Monocyte/macrophage 
lineage marker 
- 
CD19 Regulatory B cell antigen 
receptor
118
 
B lymphocyte marker - 
CD34 115 kDa transmembrane 
phosphoglycoprotein
119
 
Considered to be a 
haematopoietic cell marker, 
also present on other 
populations including early 
MSCs 
- 
CD45 Leukocyte common antigen 
transmembrane glycoproteins
120
 
Expressed on all nucleated cell 
of the haematopoietic lineage 
- 
HLA-DR MHC class II receptor
121
 Expressed on ‘professional’ 
antigen presenting cells 
(macrophages, dendritic cells) 
- 
CD73 Ecto-5-prime-nucleotidase 
involved in marrow stromal 
interactions
122
 
Expressed on MSCs + 
CD90 
 
25–30 kDa glycosyl-
phosphatidylinositol-linked 
membrane glycoprotein
123
 
Expressed on MSCs + 
CD105 Endoglin - TGF-beta receptor 
III
122,124
 
Expressed on MSCs + 
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Table 1-5. Expression of a range of markers in hMSCs. Adapted from Batsali et al, 2013125 with 
additional markers from *Niehage et al 2011
126
. N.B. some markers are not universally positive. 
Marker -/+ expression 
CD11b Integrin αM - 
CD31 Platelet endothelial adhesion molecule 1 (PECAM1) - 
CD33 Sialic acid binding Ig-like lectin 3 - 
CD38 Adenosine diphosphate (ADP)-ribosyl cyclase-1 - 
CD49d Integrin α3 - 
CD50 Intercellular adhesion molecule 3 (ICAM3) - 
CD53 Tetraspanin-25 - 
CD56 NCAM1 - 
CD80 CD28 ligand - 
CD86 Activation B7-2 antigen - 
CD117 C-kit receptor - 
CD133 AC133 (prominin) - 
CD144 VE-cadherin - 
CD235α Glycophorin - 
SOX2 Transciption factor SOX2 - 
CD10 Neutral endopeptidase + 
CD13 Aminopeptidase N + 
CD26 Dipeptidylpeptidase 4 + 
CD29 Integrin β1 + 
CD40 Tumour-necrosis factor receptor superfamily 5 + 
CD44 Hyaluronan receptor + 
CD49a Integrin α1 + 
CD49b Integrin α2 + 
CD49c Integrin α4 + 
CD49e Integrin α5 + 
CD51 Integrin αV + 
CD54 ICAM1 + 
CD58 Lymphocyte function associated antigen 3 (LFA3) + 
CD71 Transferrin receptor + 
CD106 Vascular cell adhesion molecule 1 (VCAM1) + 
CD140α Platelet-derived growth factor receptor α (PDGFRα) + 
CD140β PDGF-Rβ + 
CD146 Melanoma-cell adhesion molecule (MelCAM) + 
CD166 Activated lymphocyte cell adhesion molecule (ALCAM) + 
CD325 N-cadherin + 
HLA-I Human leukocyte antigen I (A, B, C, G) + 
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STRO-1 STRO-1 cell surface antigen + 
SSEA4 Stage-specific embryonic antigen 4 + 
α-SMA α-smooth muscle actin + 
NANOG Transcription factor + 
OCT4 Octamer-binding transcription factor 4 + 
GD2 Ganglioside + 
CD9 Tetraspanin-29 +* 
CD46 Membrane co-factor protein +* 
CD47 Leukocyte surface antigen +* 
CD59 Protectin +* 
CD61 Integrin β3 +* 
CD63 Lysosomal associated membrane protein(LAMP)-3 +* 
CD81 Tetraspanin-28 +* 
CD95 Fas antigen +* 
CD97 Leukocyte antigen 97 +* 
CD98 Solute carrier family 3 +* 
CD99 E2 antigen +* 
CD109 Platelet-specific Gov antigen +* 
CD112 Polio virus receptor related 2 protein +* 
CD147 Basigin +* 
CD151 Tetraspanin-24 +* 
CD155 Polio virus receptor +* 
CD172a Signal regulatory protein alpha +* 
CD239 Basal cell adhesion molecule (BCAM) +* 
CD248 Endosialin +* 
CD276 B7 homolog 3 +* 
CD304 Neuropilin-1 +* 
CD316 Ig superfamily member 8 +* 
CD325 Cadherin 2 +* 
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Under the influence of the TGF-β growth factors MSCs can be readily induced to produce markers 
of chondrogenesis in vitro including collagen type II and aggrecan127. Culture of the MSCs in the 
form of micromass pellets to allow 3D interactions leads to a phenotype more typical of the in 
vivo chondrocyte128; however, this approach may not be practical for cell therapy purposes. 
Unsurprisingly, given the results of treatments like microfracture that result in fibrocartilaginous 
matrix, MSCs, even in pellet culture progress to a hypertrophic phenotype, producing copious 
amounts of type I and type X collagen in addition to the desired type II collagen128. 
Whilst MSCs have a well-documented ability to differentiate into chondrocytes the mechanism by 
which they achieve improvements in clinical applications is unclear. Improvements may be a 
result of direct differentiation of cells; alternatively MSCs are believed to secrete trophic factors 
(bioactive molecules) contributing to changes mediated by cells in situ91,129. It is through this 
mechanism that haematopoiesis is supported in the bone marrow via the secretion of 
haematopoietic growth factors and cytokines91. MSCs can also respond to inflammatory signals 
secreted during tissue damage and migrate to the damaged area. It may be that both 
differentiation and trophic factors combined are necessary to achieve regeneration. 
In addition to their utility based upon their differentiation capacity and the secretion of trophic 
factors MSCs can also modulate the immune response130 greatly reducing the T-cell response to 
their, and other allogeneic cells’ presence131. The immune modulation capabilities in vitro and in 
vivo are not yet well characterised and to assist with this attempts are underway to standardise 
experiments investigating these features of MSCs132. Alongside cartilage’s somewhat immune-
privileged status133 due to its avascular nature these immunomodulatory effects may make MSCs 
a suitable source for an allogeneic treatment. An equine trial of injections of allogeneic MSC into 
articular cartilage resulted in some inflammatory response; however, this was no different than 
the response promoted by autologous injection134.  
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Unfortunately, the incidence and recovery of MSCs from bone marrow decreases with the age of 
the donor; this depletion in MSCs in bone marrow being responsible for the increased healing 
time of bone fractures in the elderly131. With increased time in culture the cells may also lose 
some of their differentiation potential beginning with a loss of adipogenic, then chondrogenic and 
lastly osteogenic differentiation capacity135. The term stem cell may also be a misnomer as so far 
the cells have not conclusively been shown to renew indefinitely in culture, becoming senescent 
probably due to their lack of telomerase activity136.  
Interestingly MSCs have also been identified, by co-expression of two MSC markers: CD105 and 
CD166, in adult articular cartilage in both a normal and osteoarthritic state. Predictably, the 
expression of CD105 (endoglin), a TGF-β receptor, was widespread within the cartilage; however, 
CD166 and co-expression of CD105 and CD166 was limited to smaller sub-populations of cells. The 
CD105/CD166 positive cells were found to be multipotent and demonstrated adipogenic, 
osteogenic and chondrogenic differentiation capacity. The presence of CD166 on perichondrial 
cells also appears to be a marker for a multipotent progenitor population137. Distribution of the 
cells throughout the cartilage is not uniform and they are predominantly located in the superficial 
and upper transitional zones138. The presence of these progenitor cells in adult cartilage may 
confer a much greater capacity for regeneration than that appreciated to date; however, it is clear 
from the inadequate tissue response that this cannot be exploited effectively during the natural 
response to injury. The incidence of CD105/CD166 positive cells was also found to be higher in 
osteoarthritic tissue than normal tissue137 so the use of these cells, as with all MSCs due to their 
multilineage potential, must be approached with caution as it is likely that careful regulation of 
their activity is necessary to produce the required hyaline tissue. 
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1.7.2.2 Umbilical cord blood stem cells   
The original source of MSCs as previously discussed is the bone marrow, and this remains the 
most commonly used; however, alternative sources may have benefits, including somewhat 
different proliferation and differentiation capacities, and a greatly increased ease of access. 
Isolation of MSCs from bone marrow is reliable with several well supported methods relying on 
simple plastic adherence, either alone or in conjunction with density separation of mononuclear 
cells (MNCs), described in the literature; nevertheless, there are significant drawbacks associated 
with bone marrow aspiration. Typically marrow is aspirated from the iliac crest of the pelvic bone, 
with donor pain and donor site morbidity being of particular concern. Recovery and quality of the 
cells recovered from marrow have also been found to vary with donor age135. As such, postnatal 
tissues from even a fraction of the approximately 700,000 births annually in the UK alone139, and 
that would otherwise be considered as waste and discarded, represents a desirable and under-
utilised pool of stem cell donor material. 
Since the first report in 2000140, which detailed the recovery of MSC-like cells in 24% of the UCB 
samples tested, MSCs have been successfully isolated from UCB using methods similar to those 
described for bone marrow recovery. However, across many studies the rates of successful 
recovery of MSCs from UCB have generally been found to be much lower (e.g. 29%141, 34%142, 
43%143) than with bone marrow, which rarely fails to yield MSCs. Rapid recovery (<2 hours), and a 
volume of blood in excess of 90 mL has been associated with a reported success rate increased to 
90%144 which compared to other reports to date is unusually high. UCB-MSCs have similar 
morphology, greater proliferative capacity than bone marrow-derived MSCs and surface marker 
analysis yields similar, although not identical, results. Cells from either source have been shown to 
be negative for the haematopoietic markers CD14, CD34, and CD133 and positive for CD29, CD44, 
and CD73. However, UCB-MSCs have 30% lower CD105 expression and 30% higher CD166 
expression. CD90 expression also varied with most (≥95%) cells from either source positive for the 
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marker but at a lower fluorescence intensity in UCB-MSCs103. The greater proliferative capacity of 
UCB-MSCs may be attributed to longer telomeres in UCB-MSCs compared to bone marrow 
MSCs143, this characteristic could potentially support further scale up, therefore larger numbers of 
cells, before they are no longer clinically useful. The immune system modulatory effects may also 
be greater in MSCs isolated from neonatal tissues145 making the cells a more suitable source for 
allogeneic transplants. 
Differentiation of UCB-MSCs following typical protocols has shown good osteogenic and 
chondrogenic differentiation capacity; however, UCB-MSCs have frequently been found to have 
limited capacity to differentiate into adipocytes with little to no lipid accumulation even with 
extended culture103. Contrastingly some authors have reported that UCB- MSCs represent cells 
with a less restricted differentiation capacity with the potential for differentiation down 
endodermal or ectodermal pathways143. Conflicting reports of varying degrees of success when 
attempting to isolate and differentiate UCB-MSCs indicate that the ideal isolation and in vitro 
conditions may not yet have been elucidated. This is further supported by reports of similar gene 
expression profiles from different donors isolated in the same conditions, compared to the same 
donor isolated in differing culture conditions142.  
Interestingly there is evidence of a small population of primitive cells that express ESC markers 
and support both haematopoietic and non-haematopoietic therapies. These cells are reside 
within the lineage negative population (CD45-, CD33-, CD7-, glycophorin A146) or more simply the 
CD133+ population of UCB MNCs.  
As a readily available cell source with an established banking system resulting in over 600,000 
units of UCB stored in public banks147 and more than 780,000privately stored units148 UCB-MSCs 
may have advantages over bone marrow MSCs including wider differentiation capacity, greater 
proliferation and reduced immune response that would make these cells an ideal choice for 
regenerative medicine therapies.  
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1.7.2.3 Embryonic stem cells and their derivatives 
Beyond the four-cell stage of embryonic development the ability of isolated cells to form a 
complete organism, i.e. totipotency, is lost. Cells become specified to either the extra-embryonic 
tissues, or the inner cell mass that will continue to develop into the embryo. The cells of the inner 
cell mass retain the capacity to form all the cell types required to form a complete organism but 
can no longer support implantation and development90. This capacity to form endoderm, 
ectoderm and mesoderm is pluripotency and is a defining feature of embryonic stem cells (ESCs). 
ESCs, cells essentially halted at the pluripotent stage of embryonic development, were isolated 
from mice in 1981149,150 and subsequently from non-human primates151,152. hESCs were first 
isolated from the inner cell mass of a surplus in vitro fertilisation (IVF) blastocyst and successfully 
cultured in vitro by Thompson et al in 1998153. Under the proper in vitro conditions these cells 
appear capable of indefinite self-renewal and retain their pluripotency as evidenced by the 
formation of teratomas when cells are transplanted to immune compromised mice153. Combined, 
the properties of pluripotency and unlimited expansion make hESCs a tool with exceptional 
potential in the study of developmental biology and for regenerative medicine therapies.  
As expected of pluripotent cells, hESCs will differentiate down the chondrogenic lineage; during 
the formation of in vivo teratomas or via the production in suspension culture of embryoid bodies 
a cartilage like tissue can be observed, in conjunction with other tissue types154. hESC 
chondrogenic differentiation has been induced by a variety of factors often used in a complex 
cocktails and at different time points including TGF-β, activin A, BMA4, bFGF, BMP receptor 
inhibitor dorsomorphin, Wnt3a, follistatin, GDF5, neurotrophin 4, chondrocyte conditioned 
media, and hypoxic pre-conditioning155–159. In an attempt to avoid the formation of multiple 
contaminating cell types, a major barrier to the therapeutic use of hESCs, a stepwise 
differentiation of hESCs may be favoured with the formation and selection of more lineage 
restricted MSC-like cells followed by chondrogenic differentiation, with selection being based 
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upon the previously identified MSC markers160,161. In vivo studies using hESCs for chondrogenesis 
have only resulted in partial success with reports of heterogeneous cartilage, insufficient cartilage 
and teratoma formation161. To successfully produce only chondrogenic cells in sufficient numbers 
protocols are likely to be extremely complex and require rigorous selection procedures. 
Despite the potential evidenced by hESCs, and the cells derived from them, exploiting them 
remains challenging. Issues of practicality, ethical concerns associated with the destruction of 
viable embryos and safety concerns with respect to teratogenesis persist. Despite these issues 
clinical trials have been initiated using two hESC derived cell types. The first, a clinical trial by the 
biopharmaceutical company Geron Corporation for the treatment of spinal cord injury using 
oligodendrocyte progenitor cells derived from hESCs162 has since been halted due to cost 
considerations163. However, Advanced Cell Technology continue trialling the use of derived retinal 
pigmented epithelial cells for degenerative eye conditions164,165. 
1.7.2.4 Induced pluripotent stem cells 
A major advancement in hESC technology was the development of the technique inducing 
pluripotency in previously differentiated somatic cell types to create induced pluripotent stem 
cells (iPSCs). The conversion of adult somatic cells to iPSCs involves the transfection of cells with a 
number of key genes that re-programme the cell phenotype so that it resembles that of ESCs. This 
was first achieved in mice in 2006 by Takahashi et al166 who, following reductionist screening of 24 
candidate genes by transduction, identified the inductive gene combination of Oct3/4, Sox2, c-
Myc, and Klf4166. This was quickly followed in 2007 by successful reprogramming of human cells 
by both Takahashi et al using the same 4 defined factors167 and by Yu et al with the Thomson 
group again using OCT3/4, and SOX2 but in combination with NANOG and LIN28168. The 
elimination of C-MYC  from the protocol is an important improvement as the gene is oncogenic 
and Takahashi et al followed their publication soon after with a modification which excluded the 
C-MYC gene completely without replacement, they were still able to generate iPSC colonies, albeit 
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with reduced speed and efficiency169. In all of the protocols the resulting cells were found to 
strongly resemble hESCs. 
The potential to use iPSCs rather than hESCs circumvents two established issues of hESCs. Firstly, 
the immunogenicity of allogeneic hESCs derived cells, as no hESCs are available from autologous 
sources, and secondly bypass of the ethical concerns surrounding the destruction of human 
embryos for hESC production. There is also the possibility of generating iPSCs from abnormal cells 
with the possibility of studying those disease causing cells and using them in disease models for 
therapy screening. Combining iPSC technology with protocols for differentiation towards specific 
tissue types raises the prospect of therapies where practically unlimited numbers of cells can be 
generated which can then thereafter can be used for numerous autologous therapies in any 
individual with no ethical concerns. As with hESCs, iPSCs can be differentiated into MSC-like cells 
that gain an MSC immunophenotype and differentiation capacity although this is altered 
compared to bone marrow MSCs, particularly with regard to adipogenesis170. Chondrogenesis in 
these cells has also now been demonstrated171,172. 
The plasticity of hESCs and iPSCs in extensive; however, they cannot be used alone to re-create a 
whole organism due to the lack of differentiation to extra-embryonic tissues that arise from the 
trophectoderm, i.e. they are not totipotent. Recent research with mouse cells suggests that cell 
differentiation state can be further reversed to the totipotent stage and this may lead to cells with 
an even more naïve phenotype and further improved plasticity173.  
 Cell Senescence 1.8
The onset of cellular senescence where cells irreversibly cease proliferation and undergo a 
number of phenotype changes is a major barrier to their in vitro study, meaning only limited 
numbers of investigations can be performed on a relatively small scale before the finite cell supply 
is exhausted.  
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1.8.1 Replicative senescence 
From 1910 onwards Alexis Carrel and colleagues published work asserting that normal vertebrate 
somatic cells were capable of undergoing an infinite number of cell divisions and were therefore 
immortal in culture, maintaining that they had established an immortal culture of chick embryonic 
heart cells and later alleging that this culture was grown continuously for 34 years. The failure of 
other researchers to successfully grow normal cells indefinitely was ascribed entirely to 
inadequate culture conditions174. This remained the prevailing opinion until 1961 with the 
publication of work by Leonard Hayflick demonstrating that, unless they were genetically 
abnormal, cells in vitro could be cultured only for a limited number of divisions and that this was 
an intrinsic property of the cells175,176. This phenomenon of replicative senescence whereby cells 
are only able to undergo a finite number of mitotic divisions before replicative potential is 
exhausted and proliferation ceases has since been termed the ‘Hayflick limit’. It is now believed 
that cells undergo replicative senescence when, due to a gradual loss with each cell division, their 
telomeres are shortened beyond a critical minimum length required for DNA replication both in 
vitro and in vivo177–179.  
The presence of telomeres was identified at the end of the 1930s when it was determined that 
chromosome termini had specialised structures that were key to successful separation of 
chromatids during cell division without fusion events180. Building on the subsequent discoveries of 
DNA structure181 and DNA polymerase182 Olovnikov recognised that incomplete synthesis of DNA 
during replication would lead to residual single stranded DNA at the ends of chromosomes which 
would shorten with each replication cycle (the ‘end replication problem’), and  that this may be 
the cause of the limited in vitro lifespan of somatic cells183. Human telomeres consist of 
approximately 5-15 kb of repeats of the nucleotide hexamer TTAGGG184 the 3’ terminal telomere 
ends have a single stranded overhang of between 100 to 300 bases , this overhang in association 
with various telomere binding proteins (Shelterin complex) form a protective T-loop structure 
believed to prevent the activation of the DNA damage response185,186. The progressive loss of the 
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telomere overhang region that enables the formation of the T-loop and the resultant 
chromosomal capping may be the key structure controlling the onset of senescence rather than 
the overall telomere length187. The senescence response acts as an essential mechanism to the 
uncontrolled proliferation of abnormal cells thereby preventing cancerous growths. This is 
increasingly apparent from the close relationship between tumour suppressor genes, senescence 
and cancer188. 
The defining feature of senescence is irreversible growth arrest; however, senescent cells in vitro 
frequently also undergo changes in morphology, in particular becoming larger and flatter; 
additionally there are other markers of senescence including the accumulation of senescence 
associated β-galactosidase (SAβGal)189. This enzyme accumulates in the lysosomes of cells 
presumed to be undergoing senescence190 and as such is used as an in vitro marker of cell 
senescence. SAβGal is also detectable in cells in tissues where there is a correlation between 
increasing age and increased amounts of SAβGal191,192. 
Senescence can also be induced in cells by alternative mechanisms that are generally not 
intrinsically linked to the Hayflick limit but rather are environmental193. These environmental 
stressors can also be linked in chondrocytes with reduced synthesis of the vital ECM components 
type II collagen and aggrecan and a reduced response to growth factors including insulin-like 
growth factor191 TGFβ1, bFGF and platelet-derived growth factor ββ (PDGFββ)85, and epidermal 
growth factor (EGF)194. Other changes in cell secretion also occur during senescence that are 
collectively described as the senescence-associated secretory phenotype (SASP) which leads to a 
chronic pro-inflammatory state195. In chondrocytes the acquisition of a SASP results in changes 
that may lead to the onset of, or contribute to osteoarthritis196–198. 
Whatever the causative mechanism involved, chondrocyte senescence is highly likely to impact 
upon the tissue’s ability to regenerate with increased age and may play a significant role in the 
development of degenerative disease as evidenced by a report that cells with a higher SAβGal 
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content have been found to be concentrated in areas in closer proximity to osteoarthritic damage 
whilst cells further from lesions have a lower SAβGal content199. 
1.8.2 Telomerase enzyme 
In a limited number of cell types telomere shortening and therefore replicative senescence is 
innately avoided by the maintenance of telomere length by via the actions of the 
ribonucleoprotein telomerase reverse transcriptase. Restricted to only a few cell types with a 
rapid turnover, some stem cells and cancer cells200 the enzyme consists of an RNA template 
component TERC, the catalytic component TERT and telomerase associated protein-1 (TEP1)201 
with both TERC and TEP1 expressed constitutively202,203. Following fertilisation telomerase is active 
throughout the human embryo through the first trimester of development and is gradually lost 
from various tissue compartments thereafter200.  
The canonical role of the telomerase enzyme is the maintenance or extension of telomeres via the 
synthesis of new telomere repeats extending the overall telomere length; however, the enzyme 
has additional non-telomere related functions. The TERT component of the telomerase complex 
acts in canonical Wnt transcriptional regulation via complexation with β-catenin and NF-κB 
signalling by binding with p65204, post-transcriptional gene silencing via the production of siRNA 
that can modulate cell proliferation and regulation of apoptosis via mechanisms that are unclear 
but are mitochondrial rather than nuclear responses205. It is also involved in the DNA damage 
response again by unknown mechanisms (reviewed in206). 
It has been demonstrated that in vitro replicative senescence can be avoided, despite extensive 
proliferation, by the re-expression and activity of hTERT200,207,208. In several cell types this strategy 
has supported the maintenance of telomere length and enhanced proliferation, or even resulted 
in immortalisation, whilst also preserving or potentially enhancing cell function209. This strategy of 
telomerase re-introduction or re-expression may be a valuable tool for increasing the availability 
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of cells that would otherwise only be available in limited numbers and would particularly enable 
much more extensive studies.  
 Hypoxic culture 1.9
The three primary cell types under investigation in this thesis have previously been investigated 
for chondrogenic potential in both standard 21% O2 culture and in reduced oxygen culture at 2% 
and 0.2% O2 with some benefits described at the lower 2% O2 level
210,211. As such, the work 
described herein is predominantly carried out in a 2% O2 environment. The in vitro culture of cells 
in an environmental oxygen level that is below the ambient 21% level is often referred to as 
hypoxia; however, with bone marrow oxygen tensions reportedly as low as 1-2%212, the 
mammalian reproductive tract ranging from 1.5-8%, foetal circulation at approximately 5%213 a 
mean arterial level of 12% and a mean tissue level of 3%214 culture of cells under standard in vitro 
conditions at atmospheric oxygen levels (21% O2) exposes them to greatly increased amounts of 
oxygen compared to physiological norms. This is particularly relevant to articular cartilage which 
has been reported to have an oxygen tension of <1% due to its avascular nature215.  
Oxygen functions as both a metabolite for energy production and as a signalling molecule, thus 
oxygen tensions can have wide ranging effects upon cell behaviour including at the transcriptional 
level. At low O2 levels hypoxia inducible factor (HIF), usually rapidly degraded when oxygen is 
abundant, accumulates within cell nuclei activating those genes that have hypoxia response 
elements (HREs)216. These changes in gene expression in low O2, often referred to as the hypoxic 
response, are important during periods of O2 deprivation that lead to pathological changes but 
also have a significant non-pathological role in tissues where lower O2 levels are the physiological 
norm. During early embryonic development the lack of vasculature within the embryo severely 
limits the available oxygen and following the establishment of early vasculature significant regions 
of hypoxia remain. Evolution in the presence of this non-pathological hypoxia has resulted in a 
significant regulatory role for oxygen level during embryonic morphogenesis. Hypoxia is 
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implicated in the formation of mesenchymal condensations, the earliest stage of joint formation, 
and the switch from chondrocyte proliferation to hypertrophy. A number of genes well known for 
their role in chondrogenesis and endochondral ossification are regulated via a HIF pathway 
including SOX9 and VEGF by direct activation and RUNX2, required for bone formation, subjected 
to inhibition by SOX9217. 
Culture of cells in hypoxic (i.e. oxygen levels below the 21% O2 found in ambient air) conditions 
has generally been reported to be beneficial to cell recovery and proliferation, differentiation 
status and matrix production depending upon cell type218–223. This improvement in recovered cell 
numbers, proliferation and maintenance of a stem cell state has been noted in hESCs, bone 
marrow MSCs and MSCs recovered from birth associated tissues, e.g. UC tissue/Wharton’s jelly 
MSCs cultured in 2% O2 displayed more rapid population doubling times and greater proliferative 
capacity whilst retaining their immunophenotype and differentiation potency213,224. Although the 
balance of the evidence is generally in favour of hypoxic culture there are conflicting reports225. 
These variations in results may be due, at least in part to the wide variation in the conditions of 
culture. 
Chondrocytes that could be considered to be de-differentiated after expansion in monolayer 
culture that were then cultured in 3D culture systems at reduced O2 tensions demonstrated an 
increase in cell numbers, along with significantly increased collagen deposition and GAG content 
over 20% O2 controls
86,226. The improved chondrocytic phenotype achieved in studies like these by 
the use of a 3D culture system were greatly enhanced by the use of reduced O2 levels and 
appeared to be regulated at least in part by hypoxic modulation of the transcription factor SOX986. 
Gene expression analysis of chondrocyte samples using microarray has demonstrated that all of 
the common cartilage ECM molecules are upregulated in response to hypoxic conditions. The 
mode of action of hypoxia in maintaining the desired phenotype appears to involve both SOX9 
mediated pathways and SOX9 independent pathways and also extend to down–regulation of the 
genes associated with hypertrophy155,227,228.  
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 Summary and hypotheses 1.10
The poor healing capacity and limited treatment options available for cartilage damage and 
degeneration results in an opportunity to resolve these issues using strategies arising from the 
emerging field of regenerative medicine, with potential contributions from tissue engineering and 
cell therapies. Strategies employed to date have largely involved the transplantation of 
autologous cells, particularly chondrocytes and MSCs, to damaged areas and have resulted in 
significant improvements in patient quality of life. Nevertheless, despite this success more 
detailed examination of the repair tissue reveals sub-optimal fibrocartilage tissue rather than the 
desired hyaline cartilage tissue. It is possible that these inferior results are due to the application 
of an unsuitable cell type or a lack of understanding of chondrogenesis and joint development 
processes. Further study is clearly warranted; however, extensive in vitro investigation is 
hampered by the process of replicative senescence and the accompanying changes that cells 
inevitably undergo due to their inherent lack of the telomerase enzyme.    
The work described in this thesis employs several strategies, namely the use of a more 
physiologically relevant O2 environment to compare chondrogenesis in three different cell types 
with potential for application in cartilage repair strategies. This is further extended to attempt to 
resolve the issues encountered with extensive in vitro cell expansion by using a strategy of re-
introduction of the hTERT gene, with changes in the cell phenotype of the resulting progeny 
following considerable expansion assessed. The potential of using an alternative source of tissue 
in the form of UCB rather than bone marrow to recover MSCs was also considered with an 
emphasis on the use of physiological hypoxia to improve cell recovery.  
 
These strategies tested two key hypotheses: 
 The application of a physiologically relevant 2% O2 environment improves the numbers of 
colonies and MSC cells recovered from UCB (Chapter 3). 
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 Re-expression of hTERT in cells with relevance to cartilage tissue engineering 
(chondrocytes, MSCs and ESC-derived cells) is sufficient to extend the proliferative 
capacity of the cells whilst concomitantly maintaining the primary cell phenotype and the 
chondrogenic differentiation capacity (Chapters 4-6). 
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Chapter 2 
 
Materials and methods 
2 Materials and methods  
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 Materials 2.1
Unless otherwise indicated materials were sourced from the manufacturer or their distributor 
within the United Kingdom. 
 
Table 2-1. List of materials, catalogue numbers and suppliers. 
 
Catalogue 
number 
Supplier 
3,3’-Diaminobenzidine (DAB) D8001 Sigma-Aldrich 
3-aminopropyltriethoxysilane (APES) A3648-100mL Sigma-Aldrich 
3-isobutyl-1-methylxanthine (IBMX) I7018 Sigma-Aldrich 
ABC immunoperoxidase staining system: anti-mouse 
                                                                          anti-goat 
                                                                          anti-rabbit 
SC-2017 
SC-2023 
SC-2018 
Santa Cruz Biotechnology 
Acetic acid A6283 Sigma-Aldrich 
Acetone A/0560/17 Fisher Scientific 
Agarose BP1356-500 Fisher Scientific 
Alcian blue A3157 Sigma-Aldrich 
Alizarin red S A5533 Sigma-Aldrich 
Ammonium acetate A2706 Sigma-Aldrich 
Ascorbic acid phosphate A8960 Sigma-Aldrich 
Basic Fibroblast growth factor (bFGF) 100-18B Peprotech 
Bovine serum albumin (BSA) BP9703-100 Fisher Scientific 
CD45 coated microbeads 130-045-801 Miltenyi Biotec 
Citric acid C0759 Sigma-Aldrich 
Cryopreserved human bone marrow mononuclear cells 
(MNCs)(isolated from human bone marrow aspirate) 
2M-125B Lonza 
4′,6-Diamidino-2-phenylindole (DAPI) D9542 Sigma-Aldrich 
Dexamethasone D2915 Sigma-Aldrich 
Dimethyl methylene blue (DMMB) 341088 Sigma-Aldrich 
DirectLoad Wide Range DNA Marker D7058 Sigma-Aldrich 
Dimethylsulphoxide (DMSO) D2650 Sigma-Aldrich 
DPX mounting medium 360294H Analar 
Dulbecco’s Modified Eagle Medium (DMEM) – 4.5 g/L 
glucose 
BE12-709F Lonza 
Eosin SLBJ6425V Sigma-Aldrich 
Ethanol (absolute) E0650/17 Fisher Scientific 
Ethidium bromide E1510 Sigma-Aldrich 
Ethylene diaminetetraacetic acid (EDTA) BP2482-1 Fisher Scientific 
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FBS (foetal bovine serum)  
DE14-801F 
(Lot#1SB020) 
FB-1001G/500 
(Lot#11484) 
Lonza 
 
Biosera 
Fibronectin F0895  Sigma-Aldrich 
Ficoll-Paque Premium (1.077 ± 0.001 g/mL at 20 °C) 17-5442-02 GE Healthcare 
Fresh human bone marrow aspirate (BMA)13 1M-125 Lonza, US 
FuGENE 6 Transfection reagent E2691 Roche 
G418 G418-RO Sigma-Aldrich 
Gel Loading Buffer (0.05% bromophenol blue, 40% 
sucrose, 0.1 M EDTA, 0.5% SDS)  
G2526 Sigma-Aldrich 
Glucose G7021 Sigma-Aldrich 
Glycine 50046 Sigma-Aldrich 
Haematoxylin (Gill’s Number 2) GHS216 Sigma-Aldrich 
Human chondrocytes (OK3) C12710 Promocell 
Hydrochloric acid (HCl) 320331 Sigma-Aldrich 
Hydrogen peroxide BPE2633-500 Fisher Scientific 
Immunohistochemistry antibodies: Collagen I 
                                                                 Collagen II 
                                                                 Collagen VI 
                                                                 Collagen X 
                                                                 Aggrecan 
AB90395 
AB3092 
AB6588 
AB49945 
AF1220 
Abcam 
Abcam 
Abcam 
Abcam 
R&D Systems 
Indomethacin I7378 Sigma-Aldrich 
Industrial methylated spirits (99%) I99050 Genta Medical 
Insulin I9278 Sigma-Aldrich 
Insulin, Transferrin, Selenium (ITS) I3146 Sigma-Aldrich 
Isopropanol P/7500/17 Fisher Scientific 
Knockout DMEM 10389172 Fisher Scientific 
Knockout serum replacement 10828-028 Fisher Scientific 
LD MACS columns 130-042-901 Miltenyi Biotec 
L-Glutamine BE17-605E Lonza 
L-Proline P5607 Sigma-Aldrich 
Magnesium sulphate M2773 Sigma-Aldrich 
Matrigel 354234 SLS/BD Biosciences 
Methanol M/3900/17 Fisher Scientific 
Non-essential amino acids  BE13-114E Lonza 
Oil Red O O0625 Sigma-Aldrich 
Paraffin-Histoplast 6774060 Thermo Scientific 
Paraformaldehyde P/0840/53 Fisher Scientific 
Penicillin, streptomycin, amphotericin B  BE17-745E Lonza 
Phosphate buffered saline (Mg
2+
 and Ca
2+
 free) BE17-516F Lonza 
Phycoerythrin conjugated antibodies: CD14 
                                                                     CD19 
                                                                     CD34 
130-098-167 
130-098-168 
130-098-140 
 
 
 
49 
 
                                                                     CD45 
                                                                     HLA-DR 
                                                                     CD73 
                                                                     CD90 
                                                                     CD105 
                                                                     IgG1 
                                                                     IgG2a 
130-098-141 
130-098-177 
130-097-943 
130-097-932 
130-098-906 
130-098-845 
130-098-849 
 
Miltenyi Biotec 
PicoGreen double stranded DNA assay P11496 Fisher Scientific 
Picric acid P6744 Sigma-Aldrich 
Polybrene (Hexadimethrine bromide) H9268 Sigma-Aldrich 
Proteinase K P2308 Sigma-Aldrich 
QIAshredder minispin columns 79656 Qiagen 
RNase Zap R2020 Sigma-Aldrich 
RNeasy mini kit 74104 Qiagen 
Senescent cells histochemical staining kit CS0030 Sigma-Aldrich 
Silver nitrate S/1280/46 Fisher Scientific 
Sirius red/Direct red 80 365548 Sigma-Aldrich 
Sodium bicarbonate 10247 Analar 
Sodium chloride S7653 Sigma-Aldrich 
Sodium citrate S4641 Sigma-Aldrich 
Sodium hydroxide 301677P Analar 
Sodium pyruvate S8636 Sigma-Aldrich 
SuperScript III One-Step RT-PCR System with Platinum 
Taq High Fidelity DNA Polymerase kit 
12574030 
Life Technologies/ Fisher 
Scientific 
SuperScript III Platinum SYBR Green One-Step qPCR Kit 11588656 
Life Technologies/ Fisher 
Scientific 
Toluidine blue 10506271 Fisher Scientific 
Transforming growth factor β3 (TGF β3) 100-36E Peprotech 
Tris-Acetate-EDTA (TAE) buffer (50X) (2 M Tris Acetate, 
100 mM Na2EDTA) 
EC-872 National Diagnostics 
Tris-HCl T5941 Sigma-Aldrich 
Trypan blue T8154 Sigma-Aldrich 
Trypsin 15090 Life Technologies 
Trypsin/Versene (EDTA) BE02-007E Lonza 
Tween 20 66368 Analar 
Ultrapure distilled water DNAse RNAse free 10977-035 Gibco 
Xylene X/0250/17 Fisher Scientific 
β-glycerophosphate G5422 Sigma-Aldrich 
β-mercaptoethanol 10368072 Fisher Scientific 
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 General cell culture techniques  2.2
To maintain sterility all cell culture procedures were carried out in a class II microbiological safety 
cabinet using disposable sterile plastic consumables. Except where indicated all cells and pellets 
were cultured in humidified, 2% oxygen, tri-gas controlled incubators with 5% CO2 and 93% N2 as 
we have previously demonstrated that this is beneficial to all of our cells during recovery, 
expansion or chondrogenesis210,221,229,230.  
2.2.1 Enzymatic sub-culture with trypsin 
As necessary cells were sub-cultured enzymatically at confluence using 0.05% (w/v) trypsin/0.02% 
(w/v) ethylenediaminetetraacetic acid (EDTA) (5 g/L trypsin and 2 g/L EDTA diluted 1 in 10 in 
calcium and magnesium free PBS). To trypsinise to a single cell suspension media was aspirated 
from cells and the monolayer washed thoroughly with PBS until all traces of culture media were 
removed. Sufficient trypsin/EDTA was added to cover cells and culture vessels were incubated at 
37 °C until cells began to detach. Flasks were tapped to encourage cell detachment and once this 
was complete, approximately 3 volumes of the cell-relevant maintenance media (MM) added to 
halt the trypsin activity. Cell suspensions were then transferred to an appropriately sized 
centrifuge tube and pelleted at 250 g. The supernatant was aspirated and cells re-suspended in 
media in preparation for seeding. 
2.2.2 Haemocytometer cell counting 
Cells to be counted were trypsinised as described in 2.2.1 to obtain a uniform, single cell 
suspension, if trypan blue viability was to be ascertained a small aliquot of the suspension was 
diluted and mixed 1 in 2 with trypan blue. A Neubauer haemocytometer was prepared by exhaling 
on the haemocytometer and using gentle pressure to adhere the haemocytometer coverslip to 
the resulting condensate. Approximately 10 µL of suspension was introduced by capillary action 
under the adhered coverslip of the Neubauer haemocytometer, cells were then counted under a 
microscope. A mean count was determined from the 4, 1 mm2 corner regions to give the number 
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of cells per 0.1 µL. To determine the number of cells/mL and the total cells the mean number of 
cells/0.1 µL was multiplied by 104 and the total number of mL of cell suspension respectively. If 
trypan blue was used the dilution factor was also taken into account in the calculation.  
2.2.3 Cryopreservation of cells  
For long term storage, as necessary, cells were detached from flasks with trypsin/EDTA as 
described in 2.2.1, re-suspended in FBS supplemented with 10% (v/v) dimethyl sulphoxide 
(DMSO) and immediately transferred to cryovials and placed in an isopropanol filled Mr Frosty 
freezing container for controlled cooling to -80 °C before being transferred to liquid nitrogen 
storage dewars. 
2.2.4 Cell counting using the Millipore Scepter cell counter 
The Millipore Scepter hand-held cell counter (Figure 2-1) uses the principle of Coulter counting to 
determine cell count and cell size, producing a cell distribution histogram that can be gated by cell 
diameter or volume231. To count, cells were re-suspended in PBS or if already suspended in media, 
diluted in PBS to a volume of 200 µm. The ideal working concentration range for the Cell Scepter 
lies between approximately 1x104 to 5x105 cells/mL, when the cell concentration is above the 
working range this is indicated on the Cell Scepter and the count is void. On any occasion that this 
was the case a more dilute sample was re-counted. To use the counter a single use cartridge was 
inserted into the Cell Scepter and then submerged in the cell suspension. The plunger of the 
counter was depressed and released to sample the suspension after which the cell count was 
displayed on the Scepter screen and was gated by cell size as required. For analysis data was 
downloaded from the Cell Scepter and analysed using the proprietary software package Scepter 
Software Pro. 
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Figure 2-1. Hand held Cell Scepter counter. The hand held Cell Scepter (A), single use, disposable 
counting cartridges (B) and (C) and a cartridge loaded into the Scepter (D). 
 
 Isolation and culture of cells  2.3
2.3.1 Isolation and culture of bone marrow mesenchymal stem cells from bone marrow 
aspirate 
MSCs were isolated from whole BMA by a modification of the plastic adherence technique 
described by D’Ippolito et al232 and as refined in Kay et al230. 
Commercially sourced whole human BMA, retrieved from the bilateral iliac crests of healthy 
consenting donors and supplemented with approximately 100 U of heparin/mL bone marrow, was 
seeded within 48 hours of aspiration at a density of 1x105 MNCs/cm2 in 75 cm2 tissue culture 
flasks according to the MNC count provided with the aspirate by the supplier. Culture flasks were 
pre-coated with 10 ng/ml fibronectin diluted in PBS for a minimum of one hour at room 
temperature after which the fibronectin solution was aspirated and the BMA seeded in coated 
flasks in Dulbecco’s Modified Eagle Medium (DMEM) (4.5 g/L glucose) supplemented with 5% 
(v/v) FBS, 2 mM L-Glutamine (L-Glut), 1% (v/v) non-essential amino acids (NEAA) and 1% (v/v) 
penicillin, streptomycin, amphotericin B (PSA) (100 U/mL penicillin, 100 µg/mL streptomycin, 
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0.25 µg/mL amphotericin B) and cultured for one week. A 50% media change was then performed 
and cells incubated for a further week after which a 100% media change was performed removing 
the majority of the remaining non-adherent leukocytes and erythrocytes.  
Following isolation prophylactic antibiotic/antimycotic treatment with PSA was ceased and 
routine media changes were carried out twice weekly with maintenance media (MM) consisting 
of DMEM supplemented with 10% (v/v) FBS, 2 mM L-Glut, 1% (v/v) NEAA and 4 ng/mL bFGF to 
enhance cell proliferation233. The isolated adherent cells were designated BMA13. As an accurate 
population doubling (PD) was not determined during recovery, starting PD was designated as PD1 
at passage 1.  
2.3.2 Isolation and culture of bone marrow mesenchymal stem cells from bone marrow 
mononuclear cell preparations 
Vials of commercially available, density separated, cryopreserved, human bone marrow MNCs 
were stored in liquid nitrogen until required for MSC isolation. When required, vials of cells were 
transferred from liquid nitrogen to a 37 °C water bath and submerged until almost thawed. Cells 
and freezing media were then transferred to a centrifuge tube of complete media (as for hMSC 
isolation from bone marrow, 2.3.1) and centrifuged for 3 minutes at 250 g. The supernatant was 
then aspirated and cells re-suspended in complete media. Cells were then plated at 
1x105 MNCs/cm2 and treated as for human BMA, 2.3.1. 
2.3.3 Culture of human chondrocytes 
Commercially available primary human articular (knee) chondrocytes OK3 (Promocell) originally 
from a 71 year old female donor a were routinely cultured in a MM of DMEM (4.5 g/L glucose) 
supplemented with 10% (v/v) FBS, 2 mM L-Glut, 1% (v/v) NEAA and 4 ng/mL bFGF. Cells were 
supplied cryopreserved at P2 and banked at P4, this was designated PD4 as earlier PD could not 
be accurately determined and future PD were determined from that point. During culture a 
54 
 
complete media change was performed twice weekly and cells were sub-cultured enzymatically at 
confluence using trypsin/EDTA as described in 2.2.1. 
2.3.4 Culture of embryonic stem cell derived progenitor cells 
hESC clonally derived progenitor cells 9C12H and 1C6 were previously clonally isolated and 
expanded from the H9 or H1 ESC lines respectively, as described by Forsyth et al234. PD was 
previously determined and was continued from the previously calculated point. Cells were 
routinely cultured in MM consisting of Knockout DMEM (KO-DMEM) supplemented with 10% 
(v/v) FBS, 2 mM L-Glut, 1% (v/v) NEAA, 4 ng/mL bFGF and 100 nM dexamethasone. A complete 
media change was performed twice weekly and cells were sub-cultured enzymatically at 
confluence using trypsin/EDTA as per section 2.2.1.  
2.3.5 Culture of human embryonic stem cell line H1 
H1 hESCs were cultured using mouse embryonic fibroblast (MEF) conditioned media on a Matrigel 
coated substrate. Cells were enzymatically sub-cultured with trypsin/EDTA as necessary. 
2.3.5.1 Conditioning of media on mouse embryonic fibroblasts 
CBA and C57BL/6 mice were mated and the females sacrificed by cervical dislocation twelve days 
after the observation of a vaginal plug. To retrieve embryos, the mouse abdomen was thoroughly 
swabbed with alcohol and opened with sterile scissors. If pregnant, the embryonic horns were 
removed from the mouse and the placental sacks opened. The embryo heads’ were removed to 
ensure that they were euthanized and to remove neural tissue and the remaining tissue 
transferred to a 50 mL centrifuge tube containing 1% (v/v) PSA in PBS. Samples were then 
transferred to a biological safety cabinet for processing. 
Any visible vascular tissue was removed and the tissue minced before being transferred to 0.05% 
(w/v) trypsin/0.02% (w/v) EDTA and placed in an incubator at 37 °C for 15-20 minutes with 
vortexing every 5 minutes. Larger tissue fragments were then allowed to settle and the 
55 
 
supernatant removed and added to complete culture media (DMEM (4.5 g/L), 10% (v/v) FBS, 
2 mM L-Glut, 1% (v/v) NEAA and 1% (v/v) PSA) and distributed across an appropriate number of 
tissue culture flasks and placed in a humidified incubator at 37 °C, 5% CO2, ambient oxygen levels. 
When approaching 100% confluency MEFs were either sub-cultured enzymatically or 
cryopreserved as per section 2.2.1 or 2.2.3. Following the initial isolation cells were subsequently 
cultured in the absence of prophylactic antibiotics and antimycotics. 
To produce conditioned media cells were expanded until approximately 70% confluency before 
their culture media was removed, cells washed with PBS and unconditioned hESC media added. 
This media consisted of KO-DMEM, 20% (v/v) Knockout serum replacement, 2 mM L-Glut, 1% 
(v/v) NEAA, 4 ng/mL bFGF, 0.1 mM β-mercaptoethanol. After conditioning overnight, media was 
removed to sterile bottles and frozen until required. As needed, media was thawed and filtered 
through a 0.2 µm filter before being supplemented with a further 4 ng/mL bFGF and stored at 
4 °C.   
2.3.5.2 Matrigel coating of tissue culture flasks 
As required one 0.5 mL aliquot of Matrigel was thawed at 4 °C and diluted 1 in 50 in chilled KO-
DMEM. Diluted Matrigel was used to cover the growth surface of tissue culture flasks for a 
minimum of 1 hour at room temperature. Any flasks that were not to be used immediately were 
stored at 4 °C. Immediately prior to use the Matrigel solution was aspirated from the flasks. 
 Umbilical cord blood collection 2.4
Ethical approval was obtained for a pilot study to collect UCB from 12 elective caesarean section 
patients, REC reference number 13/NE/0045. This study was performed in collaboration with the 
Royal Stoke University Hospital, University Hospital of North Midlands NHS Trust (previously 
University Hospital of North Staffordshire) and approval was also obtained from Keele University, 
and the Trust Research and Development Office as required. Patients were considered eligible for 
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the study if they were due to undergo non-emergency elective caesarean sections at >37 weeks 
gestation, were over the age of 18 and deemed capable of giving informed consent. 
UCB was collected following informed consent, babies were delivered by the obstetrician as per 
usual practice and the umbilical cord (UC) clamped and cut. Following delivery venous and arterial 
samples were taken routinely by medical staff to determine cord blood gas saturation values after 
which the placenta and cord were available for cord blood collection.  
Initially it was intended that samples would be obtained under gravity; however, the requirement 
to clamp the cord, deliver the placenta and take blood gases delayed access for around 10 
minutes, sometimes longer. As such, clotting was already beginning, leading to poor drainage of 
blood from the cord. Therefore, blood was aspirated using a needle and syringe, firstly from the 
cord and then from the large visible blood vessels in the placenta (Figure 2-2) above the 
uppermost clamp. Collected blood was transferred to sterile 50 mL centrifuge tubes with sterile 
acid citrate dextrose (ACD) anticoagulant (85 mM sodium citrate, 78 mM citric acid, 111 mM 
glucose) at an approximate ratio of 5 mL per 30 mL blood. Collected blood was transferred to the 
Guy Hilton Research Centre for processing in sterile conditions; all UCB samples were processed 
immediately after collection. 
 Density separation of cord blood 2.5
MNCs were isolated from some cord blood samples using density gradient separation (Figure 2-3). 
Prior to blood collection Ficoll-Paque was transferred from 4 °C to room temperature to 
equilibrate.  
15 mL of Ficoll-Paque was pipetted to 50 mL centrifuge tubes and the cord blood, diluted 1 in 4 in 
PBS supplemented with ACD, layered carefully above the Ficoll. Tubes were then centrifuged for 
40 minutes at 400 g with the centrifuge brake set to minimal levels. 
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Around 80% of the upper layer (plasma) was aspirated and interface layer containing MNCs 
transferred to fresh tubes. Cells were then washed twice with PBS centrifuging for 15 minutes at 
200 g after each wash. Isolated cells were then either plated on 10 ng/mL fibronectin coated 
flasks in both 2% and 21% oxygen, or separated using MACS cell separation followed by plating, 
and treated as per bone marrow MSC isolation (section 2.3.1). 
  
 
Figure 2-2. Cord and placental blood collection. (A) Placenta and UC, a and b show positions of crushing clamps applied during delivery, note the damage evident at 
position b, on this occasion no clamp had been applied at position a. (B) Crushing clamp still applied to the UC. (C) Close-up view of placental vessels used to maximise 
blood collection (vessels are drained in this image and are more prominent prior to this).  
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Figure 2-3. Density gradient separation of blood. (A) Blood is carefully layered over Ficoll-Paque 
(density of 1.077 g/mL) and centrifuged for 40 minutes at 400 g leading to (B) separation of the components 
of blood into layers isolating the MNCs. 
 
 MACS cell separation 2.6
Magnetic separation of CD45+ cells was carried out using Miltenyi Biotec’s MACS system with anti 
CD45 magnetic micro beads. 
2.6.1 Labelling cells with beads 
Prior to cell isolation a buffer of PBS with 0.5% bovine serum albumin (BSA) and 2 mM EDTA was 
prepared, sterile filtered and stored at 4 °C. Following MNC isolation cells were counted using a 
Millipore Scepter cell counter and cells re-suspended in 80 µL of buffer/107 cells. 20 µL of CD45 
beads were added, mixed with gentle flicking and cells were incubated for 15 minutes at 4 °C. 
Following incubation cells were washed with approximately 2 mL buffer/107 cells and centrifuged 
at 300 g for 10 minutes, the supernatant removed and cells re-suspended in 0.5 mL buffer. 
2.6.2 Separating cells  
Cells were separated using LD columns. The column was removed from the packaging and 
inserted into a magnetic separator. Prior to the addition of labelled cells 2  mL of buffer 
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(described in 2.6.1) was added to the column and allowed to run through. A fresh collection tube 
was then placed below the column and the labelled cells added and allowed to run through 
before washing through with 2 x 1 mL aliquots of buffer. This fraction contained any un-labelled 
cells which were plated in two 10 ng/mL fibronectin coated T25 flasks, 1 in 2% O2 and 1 in 21% O2.  
The labelled cell fraction was then collected separately by removing the column from the magnet 
and flushing the contents out with 2 x 3 mL of buffer using the supplied plunger. This cell fraction 
was plated in 2 x T150 fibronectin coated flasks, 1 in 2% O2 and 1 in 21% O2. Both fractions were 
then treated as per bone marrow MSC isolation section 2.3.1 excepting an increase in FBS to 10% 
(v/v). 
 Retroviral transduction of cells with hTERT 2.7
Retroviral transduction was performed using the Phoenix-A (Amphotropic) system. Target cells for 
the transduction were BMA13, OK3 and 1C6. BMA13 and OK3 cells were seeded at 5x104 
cells/well and 1C6 at 2.5x104 cells/well in 6-well culture plates and cultured for 48 hours prior to 
retroviral infection.  
The Phoenix system is available as both an ecotropic (only capable of infecting murine or rat cells) 
and an amphotropic variant (capable of infecting most mammalian cells). As human cells were 
being infected the Phoenix-A variant was used. See Figure 2-4 for an explanation of the Phoenix-A 
system and Figure 2-5 for a summary of the transduction protocol. As the use of an amphotopic 
vector incorporating hTERT represents a potential biological genetically modified organism (GMO) 
safety risk all transduction work was performed at the Blizard Institute, Barts and The London 
School of Medicine and Dentistry, using their Class II GMO laboratory facility. 
The Phoenix-A system utilises a readily transfectable human embryonic kidney (HEK) 293T-based 
packaging cell line that has been stably transfected with the Moloney murine leukaemia virus 
(MMLV) gag, pol polyprotein genes under the influence of the human respiratory syncytial virus 
(RSV) promoter, and separately with the env gene under the influence of a cytomegalovirus 
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promoter (CMV). Thus these cells can produce the proteins required for retroviral packaging. 
Following the transient transfection of a gene of interest flanked by the MMLV LTR promoter, and 
under the influence of the cis-acting RNA packaging signal Ψ235, proteins produced by the 
packaging cell are used to package the gene of interest to produce complete virions capable of 
infecting and stably transducing cells. These virions themselves are still lacking the gag, pol and 
env genes so are not replication competent.  
 
 
Figure 2-4. The Phoenix-A system for retroviral vector production. Phoenix-A HEK packaging cells, 
containing viral packaging genes on two different constructs, can be transfected with a further construct 
containing the gene(s) of interest flanked by long terminal repeats. The gene of interest is then packaged 
under the influence of the cis-acting regulatory element Ψ, using proteins produced by the packaging cells. 
These virions are then capable of transducing most mammalian cells with the gene of interest but are not 
themselves replication competent. 
  
Ψ 
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Phoenix-A packaging cells were seeded in 10 cm culture dishes at a density of 2.5x105 cells/cm2 
and cultured for 24 hours in DMEM supplemented with 10% FBS, 1% NEAA, 1% L-Glut and 1% 
PSA. After 24 hours, for each dish of cells, 25 µL of Fugene was added dropwise to 550 µL of 
serum free DMEM and mixed gently before being incubated at room temperature for 5 minutes, 
after which 10 µg of DNA with hTERT/G418 (pBABE-hTERT) resistance, G418 resistance alone 
(pBABE) (provided by Professor E. K. Parkinson, Blizard Institute, QMUL) was added to the 
Fugene/DMEM, mixed gently and incubated at room temperature for 20 minutes. This was then 
added dropwise to the Phoenix-A cell dishes with gentle swirling to mix and cells incubated for a 
further 24 hours. Phoenix-A medium was then replaced with medium suitable for the target cell 
transduction and cells incubated for 24 hours at 32°C for optimal virus production. 
Supernatants containing virus were collected with a syringe and filtered with a 0.45 µm syringe 
filter, fresh medium was added to the Phoenix-A dishes for further viral supernatant collection 
and cells returned to an incubator at 32 °C. The collected supernatant was divided to 1 mL 
aliquots and kept on ice. To prepare target cells for infection media was removed and replaced 
with 1  mL of media supplemented with polybrene at 5 µg/mL and cells incubated at 37 °C for 15 
minutes.  For the infection of target cells a mixture of 1 mL of viral loaded supernatant and 1 mL 
of culture medium supplemented with polybrene at 5 µg/mL was prepared for each well and 
added as appropriate. Control plates that received no DNA were also prepared. Plates were then 
sealed with parafilm and centrifuged at 300 rpm for 1 hour before being returned to the 
incubator. After 6 hours the infection process was repeated with fresh viral supernatant. 
Selection of successfully transduced cells was begun 24 hours after infection with medium 
supplemented with G418 at 1 mg/mL and continued for 2 weeks, cells were sub-cultured once 
during selection. Following selection surviving resistant cells were trypsinised and cryopreserved. 
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Figure 2-5. Summary of the protocol for Phoenix-A transduction of target cells. 
 
 Longitudinal proliferation study 2.8
The ability of ectopic hTERT expression to prevent functional replicative senescence was 
determined by monitoring the proliferation of transduced cells in comparison to non-transduced 
cells. Cells were maintained in continuous culture following transduction in parallel with non-
transduced cells, all cells were enzymatically sub-cultured at confluence with the split ratio used 
to maintain approximately one sub-culture per week. Population doublings (PD) of cells were 
estimated based upon the split ratio of cells at sub-culture (i.e. 1:2 equals 1 PD, 1:4 equals 2 PD, 
1:8 equals 3 PD etc.175,176), cells were assumed to be senescent when the cumulative PD 
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plateaued. Cell counts were also performed at sub-culture using a haemocytometer to determine 
the number of cells/cm2 at confluence. 
 Senescence associated β-Galactosidase staining 2.9
Cells were expanded to the limit of their proliferative capacity, when cells were no longer actively 
proliferating or, in the case of transduced cells, had greatly exceeded the capacity of control cells 
senescence was confirmed by SAβGal staining190 using a SAβGal histochemical staining kit. If β 
galactosidase is present in the cells the enzyme cleaves the glycosidic bond present in X-Gal (5-
bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) to yield galactose and 5-bromo-4-chloro-3-
hydroxyindole which then dimerises to form an insoluble blue precipitate236. 
To detect SAβGal media was aspirated and cells washed twice with PBS before being fixed using 
the formaldehyde based fixation buffer supplied with the kit (2% formaldehyde, 0.2% 
glutaraldehyde, 0.704 mM Na2PO4, 0.147 mM KH2PO4, 0.137 M NaCl, 0.268  mM KCl) for 10 
minutes at room temperature. Fixed cells were then either stored under PBS at 4 °C or stained 
immediately. To prepare the staining mixture solution, reagent B (400 mM Potassium 
ferricyanide), reagent C (400 mM Potassium ferrocyanide), X-Gal solution (40 mg/mL), and 
ultrapure water (final ratio 1:0.125:0.125:0.25:8.5) was prepared and filtered with a 0.22 µm 
syringe filter. PBS was removed and a sufficient volume of staining mixture added to each well to 
cover the cells. Plates were then incubated at 37 °C with atmospheric CO2 levels for 16 hours. The 
reaction must be maintained at pH6 therefore incubation must not be carried out in an incubator 
with increased CO2 levels. 
The staining mixture was then removed and the cells washed with PBS.  
SAβGal stained cells were counterstained with haematoxylin for 10 minutes followed by washing 
in tap water. A final wash in acetic acid acidified water was carried out to ensure that 
haematoxylin remained red rather than blue for good contrast. Photomicrographs were then 
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obtained under brightfield. Total cells and SAβGal positive cells from 4 different fields were 
manually quantified using the Fiji distribution of ImageJ237.  
 Tri-lineage differentiation  2.10
To determine differentiation potential cells were seeded at 5x104/cm2 in standard proliferation 
media overnight to allow attachment after which media were changed to differentiation media. 
Cells were then cultured in the appropriate differentiation media for 20 days with media changes 
twice weekly. 
2.10.1   Chondrogenic differentiation 
Chondrogenic differentiation was induced in monolayer and in pellets using pro-chondrogenic 
media (PChM) which consisted of basal media with reduced FBS (1% (v/v)) further supplemented 
with, 1% (v/v) ITS, 1% (v/v) sodium pyruvate, 0.1 µM dexamethasone, 50 µM ascorbic acid 
phosphate, 40 µg/mL L-proline (Sigma-Aldrich) and 10 ng/mL TGF-β3. Cells for staining in 
monolayer were fixed with 95% methanol for 10 minutes, washed with PBS and stored at 4 °C 
under PBS until staining with alcian blue, section 2.11.1. Cells for glycosaminoglycan and DNA 
quantification were not fixed and were processed as described in section 2.14. 
2.10.2   Osteogenic differentiation 
Osteogenesis was induced in cells using media supplemented with 50 µM ascorbic acid 
phosphate, 10 mM β-glycerophosphate and 0.1 µM dexamethasone for 20 days before 
monolayers were fixed with 95% methanol for 10 minutes, washed with PBS and stored at 4 °C 
under PBS until staining with alizarin red S for calcium deposits as per section 2.11.2. 
2.10.3   Adipogenic differentiation 
Adipogenesis was induced with 0.5 µM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, 
10 µg/mL insulin and 0.1 mM indomethacin. Cells were fixed with 4% (w/v) paraformaldehyde in 
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PBS for approximately 20 minutes, washed with PBS and stored at 4 °C under PBS until staining 
with Oil Red O for intracellular lipid droplets as described in 2.11.3. 
 Histological staining of differentiated monolayers 2.11
2.11.1 Alcian blue monolayer staining 
Fixed monolayers were stained with Alcian blue to detect sulphated glycosaminoglycans. 1% (w/v) 
alcian blue was prepared in 0.1 M aqueous HCl and paper filtered. This results in a stain with a pH 
of 1.0, which has improved specificity for sGAGs over preparations made in acetic acid, as the 
higher pH results in more weakly acidic groups (e.g. carboxylated residues) remaining protonated 
and therefore un-stained. To stain monolayers the PBS under which monolayers were stored were 
removed and the cells washed before being covered with the Alcian blue stain overnight. The 
stain was then removed and the well washed gently under running tap water until clear. Stained 
monolayers were imaged as soon as possible thereafter. 
2.11.2 Alizarin red S monolayer staining 
Fixed monolayers were stained with alizarin red S to detect mineralised calcium nodules. An 
aqueous solution of 2% (w/v) of alizarin red S was prepared in distilled water (dH2O) and paper 
filtered. To stain monolayers PBS was removed and the cells washed before being covered with 
alizarin red S solution for 10 minutes. Stain was then removed and monolayers washed gently 
under running tap water until clear. Wells were then allowed to dry before image acquisition. 
2.11.3 Oil Red O monolayer staining 
Fixed monolayers were stained with Oil Red O for intracellular lipid droplets. An Oil Red O stock 
solution was prepared as a saturated solution using 300 mg of Oil Red O in 100 mL of 99% (v/v) 
isopropanol, to ensure maximum saturation of the solution it was left at least overnight before 
being used. The working solution was prepared fresh immediately prior to staining; to prepare, a 
small volume of stock solution was diluted to 60% (v/v) in dH2O and the resultant solution filtered 
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using a 0.22  µm syringe filter. PBS covering the wells was removed and the cell monolayer 
washed rapidly with a small amount of 60% isopropanol and covered with the filtered Oil Red O 
working solution for 5 minutes after which the stain was removed, the well rapidly washed once 
with 60% isopropanol before imaging immediately. 
 Flow cytometry 2.12
Cells were trypsinised, counted and re-suspended in flow cytometry buffer (PBS with 0.5% (w/v) 
BSA and 2  mM EDTA) for 15 minutes and approximately 1x105 cells aliquoted into 1.5 mL 
microcentrifuge tubes, centrifuged at 300 g for 10 minutes and the supernatant discarded. 
Phycoerythrin conjugated antibodies  (CD14, CD19, CD34, CD45, CD73, CD90 and CD105, HLA-DR, 
IgG1 and IgG2a isotype controls) diluted in flow cytometry buffer were used to re-suspend cell 
pellets followed by incubation in the dark at 4 °C for 10 minutes. Buffer was added to stained cells 
to a volume of approximately 1 mL and cells centrifuged at 300 g for 10 minutes, supernatant 
discarded and the cells re-suspended in 300 µL of flow cytometry buffer. At least 50,000 events 
were acquired on a Beckton Dickinson FC500 flow cytometer. Data were analysed using the freely 
available Flowing Software (version 2.1) supported by Flow Explorer 4 to produce coloured 
density plots of forward and side scatter. Percentage positive events were determined using gates 
to exclude 99% of the appropriate isotype control events. (IgG1: CD19, CD73, CD90 and CD105, 
IgG2a: CD14, CD34, CD45, HLA-DR.) 
 Preparation of monolayer samples for DMMB and PicoGreen analysis 2.13
2.13.1 Preparation of cell monolayers 
Chondrogenic differentiation was induced using PChM as described in section 2.10.1.  
Cells were seeded in MM at approximately 5x104/cm2 in 24 well tissue culture plates in triplicate 
wells for control and pro-chondrogenic condition assessment at days 0, 5, 10 and 20 and 
incubated overnight to allow attachment. Media was then replaced with either fresh MM or 
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PChM as appropriate and changed regularly throughout the experiment; all media were collected 
for DMMB sGAG analysis. 
At days 0, 5, 10 and 20 the media was removed and cells covered with 125 µg of proteinase K in 
100 µL of 100 mM ammonium acetate. After approximately 5 minutes the contents of the well 
were repeatedly pipetted to dislodge all cells and the contents transferred to a 1.5 mL 
microcentrifuge tube. Wells were washed with a second aliquot of 100 µL of proteinase K solution 
and this was added to the initial material. Tubes were capped and incubated overnight at 60 °C; 
all samples were vortexed at least twice during incubation. 
Following digestion 1 mL of ice cold absolute ethanol was added to each digest and samples were 
left to precipitate at -20 °C overnight, centrifuged at 17,000 g to pellet the precipitate and the 
ethanol supernatant discarded. Pellets were dried by speed-vac for ten minutes then re-dissolved 
in 125 µL of 100 mM ammonium acetate for PicoGreen and DMMB analysis, dissolution was slow 
so samples were left overnight at 4 °C to maximise this.  
2.13.2 Preparation of media 
Due to evaporation of media from wells during cell culture collected media volumes had to be 
restored to the correct volumes with dH2O, volumes for correction were determined by mass. 
Following volume adjustment where necessary, aliquots of 333 µL of collected spent media were 
aliquoted and treated with 25 µL of 2.5 mg/mL proteinase K at 60 °C overnight. Samples were 
cooled, 1 mL of ice-cold ethanol was added and samples precipitated at -20 °C overnight. The 
precipitate was pelleted by centrifugation at 17,000  g for 15 minutes and the ethanol 
supernatant discarded before the pellet was dried and re-dissolved in 125 µL of 100 mM 
ammonium acetate for DMMB analysis. Aliquots of all media types were also processed and 
prepared to correct media DMMB reading as media, particularly MM with 10% FBS, gave 
significant positive values. 
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 DMMB sulphated GAG quantification 2.14
Samples dissolved in 100 mM ammonium acetate were used for DMMB sGAG quantification, 
50 µL of each sample was aliquoted in duplicate to a 96 well microplate; plates were then 
transferred to a Synergy 2 plate reader. An automated dispense unit was used to dispense 200 µL 
of DMMB solution (16 mg DMMB, 0.76 g glycine, 0.595 g NaCl, 23.75 mL 0.1 M HCl, dH2O to 
250 mL) to a single well followed by determination of the absorption at 530 nm. All wells were 
processed in this manner to maximise reproducibility and minimise the potential for precipitation 
of the DMMB-GAG complex. 
 PicoGreen double stranded DNA assay 2.15
The Quant-iT PicoGreen double stranded DNA assay was carried out on ethanol precipitated cell 
digests re-dissolved in 125 µL of 100 mM ammonium acetate according to the manufacturer’s 
protocol. Double stranded DNA standards were prepared from the kit Lambda DNA standard at 
concentrations of 20, 10, 5, 2.5 and 1.25 µg/mL in 100 mM ammonium acetate. Duplicate sample 
aliquots and standards (10 µL) were diluted 1 in 10 in TE buffer in a 96 well microplate. PicoGreen 
working solution was prepared by diluting 1 in 200 in TE buffer immediately before use; 100 µL of 
the working solution was added to each sample or standard and incubated for two minutes 
before being read using a Synergy 2 plate reader (excitation 480 nm, emission 520 nm). 
Concentrations were determined using a calibration curve with linear regression; samples were 
normalised using 10 mM ammonium acetate in TE buffer.  
 Cell pellet creation  2.16
For each set of pellets created cells were trypsinised and counted to determine the total number 
of cells and therefore pellets that could be formed. The total cell suspension was divided in to two 
to allow the creation of pellets in both MM and PChM. The cell suspensions were then 
centrifuged at 250 g for 3 minutes to pellet cells and the trypsin/media supernatant removed. 
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Cells were re-suspended in either MM or PChM to a concentration of 2.5x105 cells/mL. 1 mL of 
cell suspension then pipetted to the requisite number of 1.5 mL microcentrifuge tubes. Tubes 
were capped and centrifuged at 300 g for 3 minutes before being transferred to an incubator.  
Cell pellets for day 0 DMMB and PicoGreen analysis had the media removed from the pellet and 
transferred to an additional microcentrifuge tube and both cells and media were stored at -20 °C 
until needed. Cell pellets for day 1 histology were cultured overnight before the media was 
removed and approximately 0.5 mL 4% buffered paraformaldehyde added for 24 hours at room 
temperature. The paraformaldehyde was then removed and replaced with PBS before storing at 
4 °C until required. Day 20 cell pellets continued to receive media changes twice weekly with the 
appropriate medium type and were then frozen or fixed as described. 
 Pellet size 2.17
Fixed cells were imaged and photomicrographs used for pellet size determination in ImageJ. 
Pellets were measured in ImageJ with the pixel/mm ratio determined using a stage micrometer. 
Pellets were generally spheroidal; however, as some were more ellipsoidal a measurement of 
diameter was taken on both the long and short axis. A volume for each pellet was then estimated 
using the equation for the volume of an ellipsoid: 
 
=1/6π*(a*b*c) 
 
 
As the measurements are taken from a two dimensional image b and c are assumed to be equal. 
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 Micro computed tomography 2.18
2.18.1 Sample scanning 
Samples were stored in PBS prior to scanning. To scan samples were blotted briefly to remove 
excess liquid and placed on polystyrene packed into a 0.5 mL microcentrifuge tube. The 
microcentrifuge tube was then slotted into the smallest sample holder provided with the µCT 40 
(Scanco Medical) µCT scanner before being sealed with Parafilm. The sample holder was then 
slotted into position in the µCT scanner and the door sealed (Figure 2-6). 
 
 
Figure 2-6. Scanco Medical µCT 40 scanner. External view of scanner (A), sample holder used for all 
samples (B) and internal mount for samples (C). 
 
A ‘Scout-view’ scan was performed to locate the samples and specify the region to be scanned; 
reducing this to the minimum required reduces the total scanning time. All scans were performed 
with µCt settings of 45 kVp/176 µA. Following scan acquisition samples were immediately 
removed and returned to PBS. Porcine cartilage was also scanned for comparison. 
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2.18.2 Sample processing 
Following scan acquisition the scan is automatically compiled after which it is available for 
processing. Compiled scans were opened and individual samples isolated by contouring selected 
scans and applying the contouring to the entire scan. Each sample was then analysed to 
determine relative volume and density based on a threshold which effectively separated the 
sample from background noise, in this case 50 (Figure 2-7). 
 
 
Figure 2-7. Analysis of µCT scanned samples. Following scanning each sample was analysed using the 
scanner’s proprietary software. The sample was isolated by drawing a contour to encompass all section 
after which it was thresholded at 50/1000 for analysis of volume and density. 
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 Cell lysis and homogenisation 2.19
2.19.1 Lysis of monolayers and trypsinised cells 
Cells were lysed using the RLT lysis buffer provided with the RNeasy mini kit following the 
manufacturer’s protocol. Prior to lysis cell monolayers were washed with PBS after which 350 µL 
of RLT buffer supplemented with 10 μl/ml β-mercaptoethanol was added. A cell scraper or 
vigorous pipetting was used to ensure cells were detached from the culture flask and the resulting 
lysate was transferred to a QIAshredder minispin column for homogenisation and removal of 
insoluble material.  This was centrifuged at for 2 minutes at 17000 g before the minispin column 
was removed and discarded and the tube capped; cell lysates were either processed for RNA 
extraction immediately or were stored at -80 °C until required.  
2.19.2 Lysis of cell pellets 
After 20 days in culture, particularly in the presence of PChM, all cell pellets were extremely 
resistant to lysis, as such the RNeasy mini kit was used with some modifications to the 
manufacturers protocol.  
Prior to lysis pellets were washed in PBS and frozen. Each pellet was then physically disrupted 
using a disposable, single use, DNAse, RNAse free pestle in the presence of a small amount of RLT 
lysis buffer supplemented with 10 μL/ml β-mercaptoethanol. Pellets were homogenised in this 
way in the tube in which they were cultured to ensure any cells not in the main body of the pellet 
were also lysed. RLT lysis buffer was then added in 2 aliquots over the pestle to wash off any 
cellular material to a total volume of 350 µL and the tube vortexed. To further disrupt 
proteinaceous material 150 µL of 2.5 mg/mL proteinase K238 was then added to the lysis buffer 
and incubated for 20 minutes at 57 °C with vortexing half way through and at the end. Lysate was 
then added to a QIAshredder column and centrifuged at 17,000 g before the minispin column was 
removed and discarded and the tube capped. All pellet lysates were then immediately processed 
for RNA extraction. 
74 
 
 RNA extraction 2.20
Prior to RNA extraction all pipettes and surfaces were treated with RNase ZAP. Total RNA 
extraction was carried out using the RNeasy mini kit. Lysates from pellets were processed 
immediately after lysis; frozen lysates were defrosted and placed on ice. 
One volume of 70% ethanol was added to the lysate and the resulting solution transferred to an 
RNeasy mini spin column.  This was centrifuged for 15 seconds at 17,000 g and the flow-through 
discarded leaving total RNA bound to the column membrane. To wash the membrane, buffer was 
added and the tube centrifuged repeatedly at 17,000 g, following each centrifugation the flow-
through was discarded (700 μL of buffer RW1, 15 seconds centrifugation, 500 µL of buffer RPE, 15 
seconds centrifugation, 500 µL of buffer RPE, 2 minutes centrifugation). The used collection tube 
was discarded and replaced with a fresh tube. The mini spin column was then centrifuged at 
17,000 g to remove any residual fluid. The collection tube was discarded and replaced with a final 
1.5 mL lidded collection tube. To elute the RNA from the membrane 10-25 µL of RNase free water 
was added to the column and allowed to soak the membrane for one minute, after which the 
column was centrifuged for 1 minute at 17,000 g. The eluent was re-pipetted onto the membrane 
and the column centrifuged a final time at 17,000 g for 1 minute. Extracted RNA was quantified 
using a Nanodrop 2000 spectrophotometer (Thermo Scientific) and stored at -80 °C until required. 
 Reverse transcription – polymerase chain reaction 2.21
RNA extracts were diluted in ultrapure RNAse/DNAse free dH2O to a concentration of 25 ng/µL for 
hTERT expression analysis. Reverse transcription-polymerase chain reaction (RT-PCR) was carried 
out in one step using a SuperScript III One-Step RT-PCR Platinum Taq HiFi kit. These kits contain 
Superscript III reverse transcriptase enzyme for cDNA synthesis, Platinum Taq DNA polymerse for 
amplification and the proofreading enzyme Pyrococcus species GB-D polymerase to improve 
amplification fidelity. This system also uses ‘hot start’ technology, which is the incorporation of 
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Taq DNA polymerase antibodies to block enzyme activity until they are denatured by the first 
melting cycle at 94 °C, to prevent premature and non-specific amplification.  
One µL (25 ng) of each diluted RNA sample was aliquoted to chilled 0.2 mL PCR tubes and kept on 
ice, a master mix of 6.25 µL 2x reaction mix, 1 µL of each relevant primer (10 µM) and 3 µL 
RNAse/DNAse free water per sample was prepared. Immediately prior to transfer to the thermal 
cycler, 0.25 µL per sample of SuperScript III RT/Platinum Taq High Fidelity enzyme mix was added 
to the master mix, 11.5 μL of master mix added to each sample and the tubes capped; if 
necessary the tube strip was briefly centrifuged and then transferred to a SensoQuest Labcycler 
(Geneflow) thermal cycler. The thermal cycler was programmed as follows: 
 One cycle of 50 °C for 30 minutes (reverse transcription step) 
 One cycle of 94 °C for 2 minutes (denature hot start antibodies and DNA melting) 
 40 cycles of: 
 94 °C for 15 seconds (DNA melting) 
 Annealing temperature as appropriate for primer pair for 30 seconds  
 68 °C for 1 minute (DNA extension) 
 One cycle of 68 °C for 5 minutes 
 15 °C ∞ 
Following completion of amplification samples were either fractionated immediately on agarose 
gels or stored at 4 °C prior to fractionation. 
2.21.1 Primer Sequences 
RT-PCR was carried out with custom primers (Life Technologies) for the housekeeping gene β-
Actin and hTERT with primer sequences as listed in Table 2-2. 
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Table 2-2. RT-PCR primer sequences. 
Gene name 
(protein 
product) 
Sense sequence 
(5’ to 3’) 
Antisense sequence 
(5’ to 3’) 
Annealing 
Temperature 
(°C) 
Product 
size 
(bp) 
ACTB 
(Actin, 
cytoplasmic 1) 
GCCACGGCTGCTTCCAGC AGGGTGTAACGCAACTAAGTC 55 477 
TERT 
(telomerase 
reverse 
transcriptase) 
GCAGCTCCCATTTCATCAGC CAGGATGGTCTTGAAGTCTG 58 343 
 
 Agarose gel electrophoresis 2.22
Following RT-PCR amplification samples were fractionated by agarose gel electrophoresis. Gels 
were poured approximately 1hour prior to use and consisted of 2% agarose in 1X tris-acetate-
EDTA (TAE) buffer (40 mM Tris Acetate, 2 mM Na2EDTA) with 0.7 µg/mL ethidium bromide. 
Ethidium bromide is a fluorescent DNA dye that intercalates with the double stranded DNA helix 
whereupon fluorescence emission following UV excitation (Figure 2-8A) is increased compared to 
non-complexed ethidium bromide allowing the visualisation of ethidium bromide-complexed DNA 
bands within the gel.  
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Figure 2-8. Ethidium bromide gel electrophoresis. (A) Ethidium bromide absorption (blue) and 
emission (red) spectra. (Chroma Spectra Viewer, https://www.chroma.com/spectra-viewer). (B) Direct load 
wide range DNA ladder. Fragment size (base pairs (bp)) indicated. The top 3 bands are not fully resolved at 
this percentage gel and these electrophoresis settings. 
 
Prior to loading each sample was mixed with a 2 μL aliquot of gel loading buffer and then carefully 
pipetted into the gel wells. To allow the determination of fragment size DirectLoad wide range 
DNA marker (Figure 2-8B) was also run. All gels were run for 1 hour at 100 V in 1X TAE buffer and 
were visualised by fluorescence at 254 nm in a UV transilluminator (Syngene); gel images were 
captured with Syngene Genesnap software. 
 Quantitative reverse transcription-polymerase chain reaction 2.23
Relative gene expression in cell pellets at day 0 and after 20 days in either MM or PChM was 
assessed using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using 
SuperScript™ III Platinum™ SYBR™ Green One-Step qPCR Kits. Sybr green is a DNA binding cyanine 
dye that exhibits greatly enhanced (>1000 fold increase) fluorescence when bound to double 
stranded DNA. qRT-PCR allows the determination of the abundance of the product during the 
course of amplification, with the product specified by the primer pair. As the product is amplified 
a fluorescent signal is generated which is measured at the end of each PCR cycle. At the end of 
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the PCR run the relative abundance of product in each sample can be determined by comparison 
of the cycle number that each sample has accumulated sufficient fluorescence to cross an 
arbitrary threshold. This threshold is determined by the thermal cycler and is set to be above 
background levels and lies within the exponential phase of product amplification for all samples. 
The cycle at which the threshold is passed (CT) was normalised for all samples and all PCR runs 
using the CT value for the housekeeping gene GAPDH (glyceraldehyde 3-phaosphate 
dehydrogenase) and relative expression calculated using the 2-ΔΔCT method.  
RNA extracts were diluted in ultrapure RNAse/DNAse free dH2O to a concentration of 7.5 ng/µL 
for expression analysis. Samples were prepared by aliquoting 1 µL (7.5 ng) of each diluted RNA 
sample to chilled 0.2 mL PCR tubes that were kept on ice, a master mix of 6.25 µL 2x reaction mix, 
1 µL of each relevant primer (10 µM), 0.025 µL ROX and 3 µL RNAse/DNAse free water per sample 
was prepared. Immediately prior to transfer to the thermal cycler, 0.25 µL per sample of enzyme 
mix was added to the master mix and the master mix thoroughly mixed and 11.5 μL of master mix 
added to each sample and the tubes capped; if necessary the tube strip was briefly centrifuged 
and then transferred to a Stratagene MX3005P real time thermal cycler. The thermal cycler was 
programmed as follows and as shown in Figure 2-9: 
 
 One cycle of 50 °C for 15 minutes (reverse transcription step) 
 One cycle of 95 °C for 5 minutes (denature hot start antibodies and DNA melting) 
 40 cycles of: 
 95 °C for 15 seconds (DNA melting) 
 Annealing temperature as appropriate for primer pair for 30 seconds  
 68 °C for 30 seconds (DNA extension) 
 Fluorescence determination 
 One cycle of 40 °C for 1 minute 
 Pre-programmed melt curve: 
 96 °C for 1 minute 
 55 °C for 30 seconds 
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 95 °C for 30 seconds 
 Fluorescence determination as temperature increased 
incrementally from 55 °C to 95 °C 
 
 
Figure 2-9. qRT-PCR thermal cycle programme. Segment 1 corresponds to the reverse transcription 
step, segment 3 to amplification of the product and segment 5 to the melt curve. 
 
2.23.1 qRT-PCR primer sequences 
Primers were designed using Primer3 primer designing tool239,240 from NCBI EntrezGene Reference 
sequence gene sequences. The exon coding sequence was identified from the whole gene 
sequence and a region of the exon coding sequence used in Primer3. Where possible all primers 
were designed to be exon spanning and preferably located on an exon/exon junction. Primer 
sequences are listed in Table 2-3. 
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Table 2-3. qRT-PCR primer sequences. 
Gene name 
(protein product) 
Sense sequence 
(5’ to 3’) 
Antisense sequence 
(5’ to 3’) 
Annealing 
Temperature 
(°C) 
Product 
size (bp) 
GAPDH 
(Glyceraldehyde 
3-phosphate 
dehydrogenase) 
GACTTCAACAGCGACACC TTCCTCTTGTGCTCTTGC 53 196 
COL1A2 
(Collagen alpha-
2(I) chain) 
GACTTTGTTGCTGCTTGC CAAGTCCAACTCCTTTTCC 51 242 
COL2A1 
(Collagen alpha-
1(II) chain) 
TGTCCTTCGGTGTCAGG GTCAGTTGGGCAGATGG 54 220 
COL3A1 
(Collagen alpha-
1(III) chain) 
AAGGACACAGAGGCTTCG CTGGTTGACCATCACTGC 52 210 
COL6A3 
(Collagen alpha-
3(VI) chain) 
CTTTGACTTTGACGAGTACC TGAATGACCACCTTCACG 51 150 
COL10A1 
(Collagen alpha-
1(X) chain) 
TTCATGGAGTGTTTTACGC GTCCAGGACTTCCGTAGC 55 222 
ACAN 
(Aggrecan core 
protein) 
TCTGAGGGTCATCACTGC CTTCTCCTTGGACACACG 56 217 
COMP 
(Cartilage 
oligomeric matrix 
protein) 
GGGAACTGCAGGAAACC GCTCTCCGTCTGGATGC 57 215 
SOX9 (SRY (Sex 
Determining 
Region Y)-Box 9) 
(Transcription 
factor SOX9) 
CCGAGCTCAGCAAGACG CTTGAAGATGGCGTTGG 55 218 
 
Following design, lyophilised primers were obtained from Life Technologies custom primer service 
and dissolved in RNAse/DNAse free water to 100 µM stock solutions and 10 µM working solutions 
and stored at -20 °C. 
2.23.2 qRT-PCR data analysis 
Relative gene expression in the form of 2-ΔΔCT fold change values were calculated241 using the 
software REST-2009242. Rest determines 2-ΔΔCT values from input CT values obtained from the 
thermal cycler MXPro QPCR software; it also performs statistical analysis using a randomisation 
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algorithm. The REST-2009 software reports expression changes in the form of box and whisker 
plots where the box represents the interquartile (middle 50%) values and the whiskers the outer 
quartiles with a dotted line at the median.  
2.23.2.1 Hierarchical clustering 
The previously calculated fold change values were used to produce heat maps of gene expression 
with the associated hierarchical clustering dendrograms of both samples and genes. Hierarchical 
clustering was performed within cell type, within transduced and parental cell type and across all 
data. The clustering was performed using the Hierarchical clustering algorithm in Gene Cluster 
3.0243 with associated data viewed in Java TreeView244. To produce a clustered data set fold 
change values were saved as a tab de-limited file which was then loaded into Gene Cluster 3.0. 
Data were first log transformed after which hierarchical clustering was done using an un-centred 
correlation similarity metric and average linkage clustering. Cluster 3.0 output files were then 
viewed in Java TreeView, heat map images exported and the correlation co-efficient for each 
cluster noted. 
 Pellet and tissue histology and immunohistochemistry 2.24
2.24.1 Porcine tissue control samples 
Porcine cartilage and tendon tissue samples were obtained to be used as a positive controls for 
histological and immunohistological staining. Full depth articular cartilage cores were removed 
from a porcine knee joint (provided by Dr Hareklea Markides) using a bone marrow biopsy 
Jamshidi needle, tendon tissue was excised from the same joint using scissors and a scalpel. 
Tissue was fixed overnight in 4% (w/v) paraformaldehyde at room temperature, washed in PBS 
and stored at 4 °C prior to paraffin embedding. 
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2.24.2 Embryonic chick femur control samples 
A fixed and paraffin embedded embryonic chick femur at E11 was kindly provided by Michael 
Rotherham to use as a tissue control. 
2.24.3 Paraffin embedding 
Pellets and tissue samples were dehydrated by alcohol series, firstly by immersing in 70% IMS for 
at least 1 hour followed by 90%, 100% and 100% isopropanol for 1 hour each before being 
transferred to melted paraffin wax at 60 °C in a wax embedder (Thermo Shandon) overnight. 
Isopropanol rather than ethanol was used as the primary dehydration agent as this removed the 
requirement for a clearing agent such as xylene or Histoclear as isopropanol, unlike ethanol, is 
fully miscible with melted paraffin wax. Following overnight incubation in wax, samples were 
transferred to fresh paraffin wax in an embedding mould, a labelled cassette added and 
transferred to the wax embedder cooling plate to solidify.  
2.24.4 3-Aminopropyltriethoxysilane coating of slides 
Standard Superfrost glass microscope slides were treated with 3-aminopropyltriethoxysilane 
(APES)245 to improve section adhesion prior to being used. To coat, clean slides were soaked in 
acetone for 2 minutes to remove any trace resides and air dried. Dry slides were then submerged 
in freshly prepared 2% (v/v) APES in acetone for a further 2 minutes. APES coated slides were then 
washed in 2 changes of dH2O and dried in an oven at 60 °C before being stored dust-free until 
needed. 
2.24.5 Paraffin embedded sample sectioning 
Prior to sectioning tissue blocks were trimmed to remove excess paraffin. Blocks were then 
located in the rotary microtome and sectioned at 10 μm; 2-3 discontinuous sections 
approximately 130 μm apart were taken from each pellet for each slide. Sections were carefully 
transferred to a tissue float bath with dH2O at approximately 50 °C and picked up on APES coated 
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Superfrost slides. Slides with sections were placed in an oven at 60 °C overnight and stored at 
room temperature prior to staining. 
2.24.6 Section de-paraffinisation 
Immediately prior to staining (histological or immunohistochemical) slides were de-paraffinised. 
Slides were warmed to 60 °C in an oven and immediately transferred to 100% xylene for 10 
minutes followed by fresh 100% xylene for a further 10 minutes to remove the infiltrated paraffin 
wax. To rehydrate, slides were exposed to 100%, 100%, 90%, 70%, and 50% IMS for 3 minutes 
each and then transferred to dH2O before staining immediately.  
2.24.7 Haematoxylin and eosin staining 
Deparaffinised and rehydrated tissue sections were immersed in Gill’s number 3 haematoxylin for 
30 seconds followed by washing with tap water until the effluent ran clear. If haematoxylin had 
not blued at this stage sections were immersed briefly in Scott’s tap water substitute and then 
dipped in eosin x 10 followed by washing and dehydration in 2 changes of absolute alcohol, 
clearing in100% xylene and mounting in DPX mounting medium. 
2.24.8 Toluidine blue staining 
Deparaffinised and rehydrated tissue sections were immersed in 0.04% toluidine blue in a 0.2 M 
sodium acetate buffer for 10 minutes at room temperature followed a tap water wash until 
effluent ran clear. Slides were transferred to a drying oven to remove any trace of water and 
mounted using DPX mounting medium246,247.  
2.24.9 Picrosirius red staining 
Deparaffinised and rehydrated tissue sections were immersed in 0.1% picrosirius red in saturated 
aqueous picric acid for 1 hour at room temperature followed by washing in 2 changes of acidified 
water. Stained sections were then dehydrated in 90% and 100% IMS for 30 seconds before 
84 
 
transfer to 100% xylene and mounting with DPX mounting medium. Images were acquired under 
brightfield and cross-polarised light. 
 Immunohistochemistry 2.25
2.25.1 Heat induced epitope retrieval 
Deparaffinised and rehydrated slides (2.24.6) were transferred to citrate buffer pH6 in a staining 
dish at 90 – 100 °C. This was placed in a in a vegetable steamer to maintain the temperature for 
20 minutes. The slides and staining dish were then removed from the steamer and allowed to cool 
for 20 minutes before washing with PBS. Slides were laid flat in a humidification chamber and the 
areas around the sections carefully blotted, sections were then isolated with a hydrophobic pen 
to localise fluids to the tissue sections during later steps. 
2.25.2 Enzymatic antigen retrieval 
Slides were de-paraffinised, rehydrated and the samples isolated with a hydrophobic pen before 
being laid flat in a humidification chamber. Approximately 25 μl of 0.1% trypsin in PBS was 
pipetted directly onto each section and the humidification chamber transferred to an oven at 
37 °C for 20 minutes. Slides were then washed 3 times for 5 minutes each with PBS. 
2.25.3 Primary antibody staining  
Following antigen retrieval (heat induced or enzymatic) excess PBS was blotted from around 
sections and blocking buffer consisting 1% BSA was carefully pipetted onto sections and incubated 
at room temperature for 1 hour. 
Excess blocking buffer was then carefully blotted from sections to receive primary antibody 
staining (buffer was left undisturbed on sections to be used as secondary antibody only controls). 
Antibody (collagen I, collagen II, collagen VI, collagen X and aggrecan) diluted in blocking buffer 
was then carefully pipetted onto tissue sections and the humidification chamber transferred to 
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4 °C overnight. As slides had to be stained in multiple batches a slide with porcine cartilage (chick 
femur for collagen X) was included with each batch to assess staining reproducibility. 
2.25.4 Secondary antibody staining 
Following primary antibody staining slides were washed thoroughly with PBS for 3 x 5 minutes 
after which all sections were flooded with 3% (v/v) hydrogen peroxide in methanol for 10 minutes 
to quench any endogenous peroxidase activity. Slides were again washed in PBS for 3 x 5 minutes 
and the appropriate biotinylated secondary antibody from either an anti-mouse, anti-rabbit or 
anti-goat ABC staining system kit, diluted as directed by the manufacturer, pipetted onto the 
sections and incubated at room temperature for 1 hour.  
After approximately 45 minutes the AB enzyme reagent from the kit was prepared by mixing 
50 µL of avidin, 50 µL of biotinylated horse radish peroxidase (HRP) and 2.5 mL of PBS. This 
mixture was allowed to stand for 30 minutes to allow the formation of the avidin-biotin complex 
before it was used.  
After 1 hour slides were washed thoroughly with PBS for 3 x 5 minutes before being treated with 
the pre-mixed avidin-biotinylated HRP complex for 30 minutes, after which slides were again 
washed in PBS. 
2.25.5 Staining with the diaminobenzidine substrate. 
Stock 3,3’-diaminobenzidine (DAB) was prepared as a 1% (w/v) solution in 10 x mL of dH2O and 3-
5 drops of 12 M HCl added before being shaken for approximately 10 minutes to ensure complete 
dissolution. This was aliquoted and stored at -20 °C until required. 
Immediately prior to staining a working solution of DAB was prepared consisting of 250 µL of 1% 
DAB, 250 µL of 0.3% (v/v) hydrogen peroxide and 5 mL PBS.  
To stain sections slides were washed briefly in dH2O, the excess blotted and sections covered with 
the DAB working solution for 1-3 minutes (timing was kept consistent for each antibody). DAB was 
86 
 
then removed immediately, the whole slide immersed in dH2O before dehydrating in 90% (v/v), 
followed by 100% alcohol, clearing in xylene and mounting with DPX mounting medium. 
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Pilot study to determine the 
viability of human umbilical cord 
blood as a source of MSCs 
3 Pilot study to determine the viability of human 
umbilical cord blood as a source of MSCs 
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 Introduction 3.1
Bone marrow aspirates are still in widespread use for MSC isolation; however, MSC like cells have 
also been isolated from a number of alternative tissues including adipose tissue, dental pulp, 
synovium and synovial fluid, peripheral blood, a number of foetal tissue and birth associated 
tissues including the placenta, UC and UCB125. Isolation of MSCs from bone marrow is a reliable 
process with several well supported methods usually relying on simple plastic adherence; 
however, there are significant drawbacks associated with bone marrow aspiration. Typically 
marrow is aspirated from the iliac crest of the pelvic bone, with significant pain and potential 
donor site morbidity being of particular concern.  
Considered to be biological waste products and therefore usually discarded after delivery, the 
birth associated tissues including the UCB represent a desirable and underused stem cell source. 
With the first successful UCB transplant for a haematological disorder (Fanconi’s anaemia) in 
1988248 and with greater than 30,000 transplants carried out to date147,249 UCB is a readily 
available source of cells with a well-established banking system. UCB units can now be used to 
treat in excess of 85 conditions250 and its availability has been particularly valuable for patients 
from ethnic minority groups251 due to the reduced stringency of HLA matching required with UCB 
compared to bone marrow. The use of UCB is also associated with a reduced incidence of viral 
transmission in comparison to bone marrow252. 
In addition to the HSCs, MSCs have been successfully isolated from UCB; however, the rates of 
successful recovery of MSCs from UCB are extremely variable and are generally much lower 
(29%141, 34%142, 40% 253, 43%143, 48%, 50%254, 90%144) than those achieved with bone marrow. 
UCB-MSCs have been found to have a similar morphology to bone marrow MSCs, are sometimes 
reported to have a greater proliferative capacity than bone marrow MSCs, and surface marker 
analysis as with many of the varied MSC sources yields similar, although not identical, results. 
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With bone marrow oxygen tensions reportedly between 1-8%, the mammalian reproductive tract 
ranging from 1.5-8% and foetal circulation at approximately 5%213 culture of cells under standard 
in vitro conditions exposes them to greatly increased oxygen levels compared to physiological 
norms. Culture of stem cells in environmental oxygen levels below the 21% O2 found in ambient 
air, often referred to as hypoxic conditions, is more representative of the in vivo environment, or 
physiologically normoxic state. Reduced oxygen culture has been reported to be beneficial to both 
cell recovery and proliferation218. This includes those MSCs recovered from birth associated 
tissues, e.g. Wharton’s jelly MSCs cultured in 2% O2 displayed more rapid population doubling 
times and greater proliferative capacity whilst retaining their immunophenotype and 
differentiation potency213,224. However, again there is a conflicting report where it was 
determined that reduced O2 made no difference to recovery
144. 
UCB-MSCs may have advantages over bone marrow MSCs including wider differentiation capacity, 
greater proliferation and reduced immune response that would make these cells an ideal choice 
for regenerative medicine. However, low recovery rates may have hindered research into their 
application as there are relatively few reports in the literature compared to alternative sources of 
MSCs. 
The work described in this chapter tests the hypothesis that UCB is a suitable source material for 
MSC recovery and that a 2% O2 environment leads to improved MSC recovery as assessed by cell 
and colony number. 
 Aim 3.2
The primary aims of this chapter were to: 
 Obtain ethical approval for a pilot study collecting UCB from 12 donors undergoing 
elective caesarean section at the Royal Stoke University Hospital. 
 Determine whether isolation of cells in a more physiological oxygen level (2% O2) relative 
to physiological hyperoxia (21% O2) is beneficial to cell recovery rates. 
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 Determine whether UCB is a viable source of MSCs for use in in vitro studies of MSC 
chondrogenesis. 
 Methods 3.3
The sequence of experiments for this chapter is summarised in Scheme 1. 
Following informed consent UCB was collected from the UC and placenta of 12 donors undergoing 
elective caesarean sections, as described in section 2.4, and transferred to the Guy Hilton 
Research Centre for processing in sterile conditions. The MNC count of the UCB was determined 
using the Millipore hand-held Cell Scepter (section 2.2.4) and samples were  plated in 10 ng/mL 
fibronectin coated tissue culture flasks as whole blood in DMEM (4.5g/L glucose) supplemented 
with 1% v/v L-Glut, 1% v/v NEAA and 1% v/v PSA. Seeding density (based on MNC/cm2), medium 
FBS content (% v/v) and O2 tension were the experimental variables as summarised in Table 3-1. 
 
Table 3-1. Summary of the UCB plating conditions. 
 
FBS (v/v) O2 (%) Seeding density 
5% 10% 2% 21% 
1x104 
/cm2 
1x105 
/cm2 
1x106 
/cm2 
2x106 
/cm2 
1x107 
/cm2 
UCB1-3          
UCB4-6          
UCB7-9     All MNCs divided equally between 2% and 21% O2 
UCB10-12     All MNCs divided equally between 2% and 21% O2 
 
To remove the majority of the erythrocytes UCB7-9 were Ficoll density separated as described in 
section 2.5, after which recovered MNC were plated evenly between 2% and 21% O2 culture in 
10% FBS supplemented medium. UCB10-12 were also Ficoll density separated followed by MACS 
separation of the cells based on CD45 antigen expression as described in section 2.6. Separated 
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CD45+ cells were plated in 10% FBS supplemented medium in T150s in 2% and 21% O2, CD45- 
cells were plated in T25s in 2% and 21% O2. UCB7-12 MNCs were also all plated on 10 ng/mL 
fibronectin coated tissue culture flasks. In all cases flasks received a 50% media change after 7 
days and 100% after 14 days with twice weekly media changes thereafter. 
Early results indicated that FBS batch may have been a key variable in the recovery of MSCs from 
UCB samples. To determine the influence of the FBS batch on MNC recovery commercially 
available, Ficoll separated human bone marrow MNC were plated as described in section 2.3.2. 
Cells were plated at 1x105 cells/cm2 in 10 ng/mL fibronectin coated flasks and 6-well plates in 
DMEM (4.5 g/L glucose) supplemented with 1% (v/v) L-Glut, 1% (v/v) NEAA and 1% (v/v) PSA in 
either 10% (v/v) FBS1 or FBS2 in both 2% and 21% O2. Flasks and plates received a 50% media 
change after 7 days and 100% after 14 days with twice weekly media changes thereafter. After a 
three week recovery period the 6-well plates were fixed with 95% (v/v) methanol for 10 minutes, 
washed and stained with haematoxylin and allowed to dry. Dry plates were scanned and the MSC-
like colonies counted.  Flasks were trypsinised (section 2.2.1) and cells were counted and sized 
using the Cell Scepter as described in 2.2.4. Cell morphology of cells in colonies was also 
examined.  
3.3.1 Statistical analysis 
Colony area, colony number, cell recovery, cell volume and cell size were all compared using two-
way ANOVA with Tukey’s multiple comparisons test to determine pairwise statistical significance, 
p≤0.05 was considered significant. Analysis was performed using Graphpad Prism V6.01. 
Unless otherwise stated all values quoted in the results are mean ± standard deviation. 
 
 
 
  
 
Scheme 1. Summary of the methodology adopted in Chapter 3.
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 Results 3.4
As indicated in the experimental plan the ethical approval of several bodies had to be gained prior 
to the collection of any samples. This process involved firstly getting approval for the study 
following review by the Keele University Joint Independent Peer Review Committee. Once 
granted the project was submitted to a NHS Research Authority Research Ethics Committee, and 
once REC approval was gained (REC reference 13/NE/0045) the project proposal was submitted to 
the Research and Development department of the University Hospitals of North Midlands NHS 
Trust (previously University Hospital of North Staffordshire NHS Trust). Final project approval was 
granted and the collections commenced in October 2013 and were completed in March 2015.  
In total informed consent was obtained from 15 donors with sample collection from 12 donors. 
The remaining 3 consenting donors delivered prior to the scheduled date for their elective 
caesarean section and UCB was therefore not collected from those potential donors. 
In accordance with the ethically approved protocol, all samples were acquired without any 
modification to the medical care that donors received. All prospective donors were identified and 
consent obtained by a single obstetrics Consultant; however, the surgery was performed by 
whichever surgeon was scheduled to be performing obstetric surgery on the scheduled date. As a 
result of this surgical practice, with regards to clamping and placental delivery, varied and led to a 
variable sample collection outcome. In particular, it was found retrospectively that some samples 
were collected following delayed cord clamping which led to a large reduction in the volume of 
blood that could be obtained (Table 3-2). For example UCB2 and UCB10, with total collection 
volumes of only 12.5 mL and 20 mL respectively, were both found retrospectively to have been 
collected following delayed cord clamping reducing the available volume of blood and increasing 
the extent of clotting prior to sample acquisition. Additionally the cord from UCB2 was also cut 
very close to the placenta resulting in a very short cord and corresponding loss of blood volume.  
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Table 3-2. Details of the 12 UCB samples obtained. Quoted volumes are inclusive of ACD 
anticoagulant at approximately 5 mL/30 mL blood. *Cords confirmed retrospectively to have delayed cord 
clamping. 
11/10/2013 UCB1 35 mL 
26/11/2013 UCB2* 12.5 mL 
07/01/2014 UCB3 40 mL 
26/02/2014 UCB4 40 mL 
09/05/14 UCB5 35 mL 
13/05/2014 UCB6 70 mL 
03/06/2014 UCB7 30 mL 
08/07/2014 UCB8 40 mL 
30/09/2014 UCB9 40 mL 
17/10/2014 UCB10* 20 mL 
24/03/2015 UCB11 60 mL 
27/03/2015 UCB12 65 mL 
 
The mean volume obtained was 41 ± 17 mL with a minimum of 12.5 mL and a maximum of 70 mL 
(Figure 3-1); collected volumes followed a normal distribution as assessed by the D'Agostino and 
Pearson omnibus normality test. 
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Figure 3-1. Box and whisker plot of UCB samples. Whiskers indicate minimum and maximum values, 
box area the interquartile range with the median indicated by the horizontal mid-point line. Volumes from 
all samples (N=12) are shown. 
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3.4.1 UCB1-3 
UCB1 was plated systematically in T25 flasks as described at four alternative seeding densities, in 
media containing 5% or 10% FBS at 2% or 21% O2. By the 100% media change at two weeks stage 
none of these systematically plated samples appeared to contain any attached cells and no 
colonies were observed to develop over the subsequent weeks. However, there was a volume of 
residual blood remaining after all T25 flasks had been seeded and this was also plated into tissue 
culture flasks rather than discarding valuable material. 
Firstly residual blood was plated at 2X106 cells/cm2 on fibronectin coated T150 flasks in 2% and 
21% O2. The 2% O2 flask was found to contain a single colony of cells that had the typical MSC 
morphology of elongated cells growing at high density (Figure 3-2A and B). At 30 days this colony 
had expanded to have an approximate diameter of 2 cm and was enzymatically passaged into a 
T12.5 flask. Following passage the cells underwent no further proliferation, instead adopting an 
enlarged, flattened morphology typical of senescent cells (Figure 3-2C). As these cells did not 
expand, further characterisation could not be carried out. 
The final volume of blood was placed into a single T150 tissue culture flask at 1.5X107 cells/cm2 in 
a in 2% O2, 10% FBS without fibronectin. This flask yielded approximately 5 small colonies 
containing around 10-20 cells and 1 larger colony as shown in Figure 3-2D-F. The cells in these 
colonies appeared to be relatively loosely attached to the substrate, as shown by the number of 
cells that are rounded up and only partially attached to the flask, and did not have the 
morphology typical of MSCs. Over the subsequent weeks increasing number of cells detached 
from the flask.
  
 
Figure 3-2. UCB1 recovered cell morphologies. Phase contrast micrographs showing the single colony of MSC like cells (A) and (B) that appeared senescent following 
passage (C). (D), (E) and (F) show small colonies of non-MSC like cells that subsequently detached from the flask.
A B C
D E F
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Due to an unavoidable supplier change all subsequent UCB samples had to be plated with a 
different batch of FBS.  
UCB2 did not yield any colonies of MSC like cells in any condition, instead only occasional rounded 
(Figure 3-3A) or irregularly shaped cells that were frequently granular and multinucleated were 
observed; these cells also appeared to have the potential to be somewhat proliferative in vitro as 
evidenced by loose colony formation Figure 3-3B and C).  
UCB3 had no adherent cells, instead containing only clusters of erythrocytes (Figure 3-3D) with 
the exception of one potential colony of cells at the periphery of a single flask (Figure 3-3E and F) 
seeded at 105 cells/cm2, 21% O2, 10% FBS, these cells did not appear to be fully attached with a 
rounded appearance and were insufficiently flattened to observe the cell morphology. As with 
colonies in UCB1 these cells did not proliferate and were lost over time. 
  
 
Figure 3-3. Cells from UCB2 and UCB3. Phase contrast micrographs of the occasional rounded cells observed from UCB2 (A) and the small colony of irregularly shaped 
cells (B) and (C). UCB3 yielded only clumped erythrocytes (D) with the exception of one possible colony (E) and (F); however, cells were not fully attached or flattened.
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3.4.2 UCB4-6 
As the only MSC like colony from UCB1-3 was obtained from blood plated at 2X106 cells/cm2, 
cords 4-6 were plated at this density only, the % FBS variable was also removed with all cells being 
plated only in a standard 10% FBS supplemented medium. This allowed scale up of the cell plating 
to T150 flasks to maximise the recovery potential. Blood was still plated in both 2% and 21% O2.  
Despite this scale up, UCB4-6 failed to yield any adherent cells in any condition. It was observed 
that the plating of whole blood led in some cases to the deposition of a dense layer of debris and 
erythrocytes, as this may have hindered cell adherence, UCB7-9 were separated by density 
centrifugation over Ficoll and the isolated MNCs plated rather than the whole blood.  
3.4.3 UCB7-9 
Plating of isolated MNCs from UCB7-9 resulted only in the isolation of the rounded adherent cells 
that went on to produce cells with varied morphologies (Figure 3-4. These cells were particularly 
numerous in UCB8, where there appeared to be substantial proliferation resulting in confluent 
flasks. Therefore characterisation of the immunophenotype of these cells was performed on half 
of the cells against the panel of antibodies to identify MSCs, whilst the remainder were re-plated. 
Cells were found to be extremely resistant to trypsinisation, requiring mechanical cell scraping to 
remove them from the tissue culture plastic surface. Following re-plating only small numbers of 
cells attached and they were no longer proliferative. 
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Figure 3-4. Cells recovered from UCB7 and UCB8. Phase contrast micrographs of cells recovered from 
UCB7 (A) and (B) and UCB8 (C) and (D) 14 days after plating UCB. 
 
Flow cytometry of UCB8 against a panel of markers used to identify MSCs (Figure 3-5) showed 
that in 2% O2 cells were very strongly positive for CD14 (81.0%), CD45 (92.7%) and HLA-DR 
(89.8%), the typical MSC markers CD73, CD90 and CD105 were negative. In 21% O2 cells were also 
strongly positive for CD14 (78.5%), CD45 (95.5%) and HLA-DR (90.0%). In addition to this a small 
subset of the population were also positive for CD90 (18.0%) and CD105 (21.2%) indicating a 
possible MSC sub-population; however, there was no evidence of this following re-plating of the 
cells in culture. 
 
  
A
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Figure 3-5. Immunophenotyping of cells from UCB8. Cells recovered in 2% and 21% O2 were assessed 
by flow cytometry against the panel of markers used to identify MSCs. (A) Overlay histograms of each 
antibody marker, (B) percentage positive cells compared to staining with the relevant isotype control.  
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3.4.4 UCB10-12 CD45 depletion using MACS technology 
As UCB7-9 yielded a population of cells strongly positive for leukocyte antigens CD14, CD45 and 
HLA-DR, with a possible population of MSCs detectable only by flow cytometry, UCB10, 11 and 12 
were subjected to CD45 positive cell depletion using magnetic separation with CD45 beads to 
separate all leukocytes from potential MSCs. Following isolation both the CD45 positive and 
negative cell fractions were plated on fibronectin coated plates in 2% O2 and 21% O2. 
Separation using the MACS system resulted in a pellet from the CD45- fraction that was primarily 
residual erythrocytes which pass freely through the column and a CD45+ fraction that was 
primarily leukocytes that are initially retained in the column plus small numbers of physically 
trapped erythrocytes resulting in a pinkish colour to the pellet (Figure 3-6). Any MSCs should be 
present in the CD45- population. 
 
 
Figure 3-6. UCB12 sample following MACS separation. Ficoll density separated MNC samples were 
separated using MACS CD45 beads. The CD45- fraction contains the majority of the residual erythrocytes 
and any MSCs as these pass through the separation column freely due to a lack of CD45 whilst the CD45+ 
fraction is primarily leucocytes.  
 
Using the UCB10 sample at the 50% media change cells were checked by flow cytometry for CD45 
expression (Figure 3-7). The CD45+ fraction were 97.2% positive (using 99% gating of the relevant 
isotype control) for CD45 while the CD45- fraction, which at this point consisted almost entirely of 
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erythrocytes, was CD45 negative (0.5% positive events) demonstrating effective separation of the 
CD45 positive cells using the magnetic separation kit.  
Despite CD45 depletion for all three UCB samples no MSC cells appeared to be present in either 
the CD45- flask, that contained only debris and erythrocytes, or the CD45+ flask which continued 
to yield rounded, attached cells that became granular, irregularly shaped and sometimes 
multinucleated as found with UCB7-9 (Figure 3-8).  
 
 
Figure 3-7. CD45 expression of CD45 MACS separated cells. The unfilled histogram is the IgG2a 
isotype control, the filled histogram is CD45. 
 
 
Figure 3-8. Cell morphology following CD45 MACS separation. Phase contrast micrographs of cells in 
the CD45- fraction and CD45+ fraction of CD45 MACS separated UCB MNCs after two weeks in culture. 
 
Of the twelve UCB samples collected and plated only the first sample yielded a visually identifiable 
colony of MSC like cells; as UCB1 was recovered with FBS1 (supplied by Lonza) whilst the later 
samples had to be recovered with FBS2 (supplied by Biosera) this change in FBS was investigated 
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as a possible causative factor in the lack of MSC cell recovery concomitant with the recovery of 
large numbers of non-MSC-like cells..  
3.4.5 The influence of FBS batch on MSC recovery from MNC preparations 
Prior to selection of the new FBS batch (FBS2) several options were batch tested for bone marrow 
MSC cell proliferation and the selected batch was found to be the most optimal of those available 
(Appendix B, Supplementary figure 1). FBS2 has also been used for MSC recovery from whole 
BMA with no unusual results. As all UCB samples with ethical approval had been collected at this 
point this investigation was performed using commercially available MNC isolated from BMA and 
a small reserve of FBS1. Following recovery, colony counts, cell counts, and cell size and 
morphology were all determined. 
3.4.5.1 Colony recovery 
Following a three week recovery period cells were fixed and stained with haematoxylin (Figure 
3-9), the plates were then scanned and both the percentage area occupied by stained cells and 
the number of colonies recovered were determined by image analysis in ImageJ. 
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Figure 3-9. CFU-F recovery of MSCs from MNCs. MSC CFU-F recovery from bone marrow MNCs in two 
alternative FBS batches, in both 2% and 21% O2. Cells are fixed and stained with haematoxylin. 
 
As a percentage of the total area cells from FBS1 occupied 89.5 ± 2.7% in 2% O2 and 85.3 ± 3.3% in 
21% O2 whilst FBS2 covered only 54.0 ± 24.7% of the available area in 2% and 47.7 ± 6.9% in 21% 
O2. The difference between recoveries in FBS1 versus FBS2 was significant (p≤0.05) in both 2% 
and 21% O2. As shown in Figure 3-9 there were no dense, isolated colonies found with culture in 
21% with FBS2, although more generalised cell staining was present. As a result colony counts 
(Figure 3-10) for FBS1 were 24.3 ± 2.5 in 2% O2 and 23.3 ± 3.5 colonies in 21% O2 whilst FBS2 
yielded 10.3 ± 3.5 colonies in 2% O2 and 0 colonies in any well at 21% O2. All results excepting 
colony recovery in FBS1 in 2% and 21% oxygen were statistically significant to at least the p≤0.01 
level. 
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Figure 3-10. CFU-F formation. Colony formation in 2% and 21% O2 with FBS1 and FBS2 was assessed 
both by percentage area covered by stained cells (A) and by colony count (B). Data are expressed as mean ± 
standard deviation, N=3, *p≤0.05, **p≤0.01, ****p≤0.0001. 
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3.4.5.2 Cell morphology following recovery 
The morphology (Figure 3-11) of the majority of the cells recovered in FBS1 in 2% or 21% O2 was 
consistent with that of MSCs, with elongated, bipolar, colony forming cells. Recovery in FBS2 at 
21% O2 resulted in very few MSC like cells with most cells being rounded and of various sizes 
consistent with the cells frequently seen with recovery from MNC cord blood preparations. Even 
where MSC like cells were present in FBS2 they appeared unable to form high density colonies 
although more dispersed clusters were occasionally found. This effect was less severe in 2% O2 
with cultures in FBS2 containing a mixture of both cell types with MSCs that were able to form 
high density cell colonies. 
3.4.5.3 Cell recovery 
Cell number at recovery was also determined by counting using the Millipore Cell Scepter that 
also provides information on cell size (diameter and volume). MSC like cells were much more 
easily trypsinised than other cells resulting in the majority of the cells counted being MSC like 
cells. FBS1 yielded similar numbers of cells in both 2% and 21% O2 at 29,400 and 
27,000 ± 2,000 cells/cm2. FBS2 cell yield was significantly (p≤0.05) improved over FBS1 in 2% at 
46,800 ± 6,321 cells/cm2 but significantly reduced compared to both FBS1 in 2% O2 (p≤0.01) and 
FBS2 in 2% O2 (p≤0.0001) with only 9,710 ± 2,683 cells/cm
2 recovered (Figure 3-12). 
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Figure 3-11. CFU-F cell morphology. Representative brightfield micrographs of cells isolated in 2% (A) 
and (C) or 21% O2 (B), (D), (E) and (F) in FBS1 (A) and (B) or FBS2 (C-F). Cells are fixed and stained with 
haematoxylin. 
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Figure 3-12. Cell recovery in FBS1 and FBS2 in 2% or 21% O2. Cells were trypsinised and counted 
using the Millipore cell Scepter. Data are expressed as mean ± standard deviation, N=3, *p≤0.05, **p≤0.01, 
****p≤0.0001. 
 
Cells recovered in FBS2 were smaller than in FBS1 at both 2% O2 (18.12 ± 0.08 µm/3.12 ± 0.04 pL 
compared to 20.88 ± 0.13 µm/4.77 ± 0.08 pL, p≤0.001) and 21% O2 
(19.77 ± 0.55 µm/4.05 ± 0.34 pL compared to 21.78 ± 0.40 µm/5.42 ± 0.30 pL, p≤0.01). Using 
either FBS batch cells were larger in 21% O2 than the corresponding cells in 2% O2, significantly so 
with FBS2 (p≤0.01) (Figure 3-13).  
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Figure 3-13. Cell size following recovery from MNCs. Following recovery cell size was characterised by 
diameter (A) and volume (B). Data are expressed as mean ± standard deviation, N=3, **p≤0.01, ***p≤0.001, 
****p≤0.0001.  
111 
 
 Discussion 3.5
The use of UCB for MSC isolation is an attractive prospect due to the established banking 
processes in place for UCB HSC transplantation and supposed naivety of the cells255; however, 
there is a limited body of literature available in support of the reliable and reproducible isolation 
of MSCs from UCB. One possible option for improving success rates is the application of a more 
physiologically relevant oxygen level during isolation and culture; an approach that has seen 
improvements in cell recovery and proliferation in other stem cell types221,230,220. Physiological 
compared to ambient oxygen levels (2% compared to 21%), along with variable FBS concentration 
(5% and 10%) and initial seeding density (1x104 MNCs/cm2 to 1x107 MNCs/cm2) were factors 
investigated in the pilot study described in this chapter. 
There were several logistical issues identified with the blood collection protocol that are likely to 
have had a deleterious impact on the study. The collected blood volume was very variable and 
was particularly limited where cord clamping and cutting had been delayed by the obstetric 
surgeon, a process that is recommended by the World Health Organisation (recommend clamping 
and cutting “not earlier than 1 minute after birth”)256. Delayed cord clamping and cutting is the 
process whereby following delivery the UC is not clamped or cut for between one to five minutes 
or potentially until the UC stops pulsing. A recent Cochrane review of the practice found that it 
made no difference to primary maternal outcomes e.g. the likelihood of severe post-partum 
haemorrhage; however, it is advocated by some as it increases blood volume and haemoglobin 
concentration in neonates as a result of placental transfusion (blood from the placenta is returned 
to the neonate circulation) and is associated with reduced iron deficiency in three to six month 
old infants257. Delaying clamping and cutting of the UC by three minutes results in a reduction of 
approximately 70% in the residual placental blood volume258. Total UCB sample volume has been 
identified as a key factor in the later successful isolation of MSCs with the suggestion that ≥90 mL 
is required for effective isolation144. This volume was not achieved in any sample taken herein and 
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other studies suggest that this would be unusually high for UCB collection. Katsares et al as part of 
an UCB characterisation study recovered 2,000 units of UCB immediately after delivery, with the 
placenta in utero and still only obtained an average volume of 60.64 ± 25.47 mL259 similar to Jones 
et al with a mean of 72.0 ± 0.27 mL260 from 9,205 collections carried out in varied circumstances. 
In addition to the lower volumes the necessary delay in accessing the UC due to the requirement 
to obtain blood for blood gas measurements often meant that blood had begun to clot before 
collection was completed, or in the case of samples with delayed clamping, started. As with blood 
volume evidence of clotting has been found to be deleterious to MSC isolation with no recovery 
from samples with evidence of either clotting or haemolysis103.  
The initial approach involving the plating of whole blood was one that has previously proved to be 
successful for the reliable isolation of MSCs from BMA samples230, and by the conclusion of the 
study (N=12) was the only technique that yielded any adherent cells that resembled MSCs (Figure 
3-2). However, problems with erythrocyte sedimentation and the resultant coating of the flask 
with a film of cells and cellular debris were encountered with some samples due to the necessity 
of plating the higher volumes of blood required to counter the lower incidence of MSCs described 
in UCB. As this debris layer may have provided a physical barrier to MSC adherence subsequent 
UCB samples were plated from Ficoll density separated MNC preparations. This variation of the 
initial protocol resolved the problem of high numbers of contaminating erythrocytes; however, it 
also resulted in a high incidence of isolation of rounded, strongly attached cells that in no way 
resembled MSCs. Finally, in an attempt to remove contaminating cell populations MNC 
preparations were depleted of CD45+ cells using immunomagnetic separation. The cell separation 
was successful; however, no MSCs were recovered from the CD45- fraction, whilst the CD45+ 
fraction continued to yield rounded strongly adherent cells. 
The contaminating cells that were frequently recovered in samples, particularly following Ficoll 
density separation, had a rounded morphology in early cultures which changed as cultures aged, 
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resulting in a diverse population of cells including granular cells and very large multinucleated 
cells; these are all very strongly adhered to the culture flask, being highly resistant to 
trypsinisation. The strong expression of CD14, CD45 and HLA-DR along with the mononuclear cell 
fraction origin and the morphology of these cells indicates that the cells are highly likely to be 
monocytes and later, their differentiated progeny macrophages and dendritic cells261–263. 
Monocytes are part of the innate immune response resulting in inflammation and phagocytosis. 
The cells develop initially in the bone marrow from common myeloid progenitor cells and migrate 
to the blood, in adult peripheral blood they constitute approximately 7-10% of total 
leukocytes264,265 and in circulating blood have a half-life of one to three days261. Circulating 
monocytes can be divided into three sub-types based on immunophenotype as shown in Table 
3-3. 
 
Table 3-3. Human monocyte sub-types. Adapted from Yang et al, 2014261.  
Monocyte 
sub-type 
% of 
monocytes 
Surface marker 
expression 
Function 
Classical 80-95 CD14++     CD16- Phagocytosis 
High levels of peroxidases and 
IL-10 
Intermediate 2-11 CD14++     CD16+ Pro-inflammatory 
Low levels of peroxidases and 
high IL-1β and TNFα 
Non-classical 2-8 CD14+       CD16++ Patrolling 
High IL-1β and TNFα, respond 
to DNA and RNA molecules 
 
Monocyte/macrophage-like cell recovery has been described frequently in studies endeavouring 
to isolate MSCs from UCB and their presence in cultures where MSC isolation is being attempted 
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has been recognised as a problem, with no successful recovery of MSCs where adherent 
monocytes were present103,266. 
In the first study successfully isolating UCB MSCs Erices et al140 nevertheless recovered a 
heterogeneous population of non-MSC cells in 74% of the units they tested. Following further 
characterisation they described the cells they found as osteoclast-like as they were strongly 
positive for tartrate resistant acid phosphatase (TRAP), CD45 and CD51/61 (integrin αVβ3/ 
vitronectin integrin receptor complex267) positive whilst lacking expression of CD64 (macrophage 
marker268). CD14 positive cells were present but the percentage of cells expressing this reduced 
from 53% at 3 weeks to 26% at 5 weeks140. This reduction in CD14 expression can be seen with 
changes in the monocyte differentiation status269. Similarly, in what they identified as their most 
optimal condition, Perdikogianni et al recovered cells with an MSC like morphology in 25% of 
samples; they also recovered adherent haematopoietic cells. The MSC-like cells that they did 
obtain were slow growing and could only be briefly expanded. Despite successfully isolating some 
MSC-like cells these were found to have limited proliferative capacity  meaning that insufficient 
cell numbers could be cultured for differentiation experiments270. The results seen with the 
experiments in this chapter were less promising, more closely mirroring those described by 
Alvarez-Viejo et al271 where only round cells with the appearance of monocytes were isolated 
from twenty UCB donors and Zeddou et al272 where despite assessing multiple culture conditions 
and trying both CD271+ and CD133+ enrichment and CD3, CD19, CD14 and CD38 
immunodepletion only 1 of 15 UCB samples yielded any MSC-like cells. They also describe 
isolating primarily strongly attached rounded cells presumed to be macrophages along with more 
elongated cells which were nevertheless CD73, CD90 and CD105 negative272. 
Other attempts to improve recovery rates have used both positive and negative immunoselection 
techniques to directly isolate MSCs or to remove contaminating haematopoietic cells. An 
approach using immunodepletion of committed lineage cells based on CD7, CD19, CD38 and 
glycophorin A expression was successful for Lee et al (although overall recovery rates are not 
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stated)273; however, the same approach made little difference in the study by Zeddou et al272. The 
recovery of MSCs from the pilot study herein was not improved by immunodepletion of 
haematopoietic cells using the CD45 common leukocyte antigen which would be expected to 
resolve the problem of contaminating monocytes if that was the only, or main issue impacting on 
recovery. 
Positive immunoselection might be expected to be a more successful approach, for example 
selection based on CD271 (low affinity nerve growth factor receptor (LNGFR))  is successful with 
bone marrow and adipose tissue MSCs and appears to select for cells that undergo improved tri-
lineage differentiation274, has also been attempted with UCB. Selection by CD271 of a clearly rare 
cell population would be would be extremely desirable for UCB, particularly for cells destined for 
musculoskeletal therapies; however, CD271 appears to be absent from cells from UCB with no 
positive population identifiable by flow cytometry or magnetic immunoselection270. 
In the wider context these results are less surprising, early bone marrow culture methods using 
Dexter-long term cultures were established and optimised to maximise haematopoiesis. These 
cultures described the formation of a confluent layer of adherent cells, the stromal layer, that 
supported the haematopoietic process275. Subsequently the cells isolated to form a marrow 
stromal layer have been compared to cells recovered in conditions optimised more towards MSC 
recovery, with the resulting MSCs comprising a much more homogeneous population of cells in 
comparison to the mixed stromal cells, where fibroblastic cells were present alongside adhered 
haematopoietic cells. A sub-population of the cells from the stromal layer, and most of the MSCs 
were positive for CD105 and CD166, both recognised as MSC markers. Additionally stromal layers 
contained cells positive for CD14 and CD45 i.e. monocytes/macrophages and similar Dexter long 
term cultures prepared from UCB appear to favour the isolation of monocytes and 
macrophages275. Both the MSCs and the mixed stromal cells had the capacity to support 
haematopoiesis although this capacity was more variable in MSCs compared to stromal cells, 
particularly from some donors276. The different cell populations isolated were primarily as a result 
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of alterations in media composition, the marrow stromal layer prompted to form in the presence 
of 12.5% FBS plus 12.5% horse serum supplemented with hydrocortisone whilst more a more 
homogeneous population of MSCs was recovered in 10% FBS only supplemented medium276. It is 
clear from this that factors present in various sera can significantly impact on the cells recovered 
from blood and bone marrow products. Furthermore, plastic adherence is one method used for 
the isolation of monocytes for in vitro work with monocytes, macrophages and dendritic cells, as 
monocytes will typically adhere readily to both endothelial cells or to plastic surfaces. Various 
sources of monocytes are used for this purpose including peripheral blood, bone marrow and 
UCB, with UCB being a good choice due to the high incidence of CD34+ cells from which dendritic 
cells can also be generated277.  
FBS batch variability was identified as a candidate likely to be at least partially responsible for the 
poor MSC recovery with FBS2 seemingly promoting recovery of monocytes to the detriment of 
MSC recovery compared to FBS1. FBS is a staple of cell and tissue culture systems providing a 
complex and variable mixture of vitamins, minerals, hormones, attachment/ECM proteins, growth 
factors and cytokines although these are variable and poorly characterised278 (see Appendix C for 
manufacturer Certificates of Analysis for FBS1 and FBS2). Although characterisation of low 
molecular weight proteins has rarely been attempted FBS has been found to contain a variety of 
factors that may influence cells’ behaviour including bFGF, IGF-II, glial growth factor (GGF) and 
TGF-β1 with these bovine growth factors having an effect on human cell types279.  
Although it could not be directly assessed on UCB MNC samples the FBS batch variability was 
found to be a crucial factor affecting successful recovery from Ficoll isolated bone marrow MNCs. 
Whilst experimental confirmation would be required the results from the bone marrow MNCs are 
likely to be translatable to UCB MNC preparations. Results from bone marrow MSCs may in fact 
represent a more conservative model of the situation as the monocyte content of adult peripheral 
blood at 39% of the total MNCs, was found to be much higher than that of bone marrow at 18% 
of the total MNC count, bone marrow cells are also likely to be less mature280. UCB monocyte 
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content in particular may also tend to be higher than that of adult peripheral blood with the UCB 
average monocyte count (0.8 ± 1.2 x 103 cells/µL) lying at the top end of the normal range for 
adults (0.1-1.0 x 103 cells/µL)259. It should be noted that although there are strong similarities 
between adult monocytes and UCB monocytes, there are nevertheless differences that could 
have impacted on the results281. 
Cell adhesion and differentiation of monocytes occurs in the presence of FBS and is typically 
enhanced using a variety of cytokines, most commonly M-CSF282, and a combination of GM-CSF 
and IL-4 that more commonly directs the differentiation towards dendritic cells283. These 
cytokines can be considered activating and thus pro-survival factors that cause the cells to 
undergo maturation and differentiation in the absence of which monocytes undergo apoptosis284. 
Supplementation of serum free culture media with a number of different cytokines (GM-CSF, M-
CSF, IL-4, IL-10, LPS, IFNγ) has been previously been noted to cause changes in monocyte 
adhesion285. GM-CSF has previously been shown to increase the adherence of monocytes to 
plastic surfaces and endothelial cells as well as increasing monocyte viability286. Similarly IL-3 
increases endothelial and plastic adhered monocyte cell numbers while the converse is seen with 
IL-4 decreasing cell attachment287.  
The attachment of cells to substrates is mediated by a number of attachment factors including the 
integrins, cell membrane spanning heterodimers of variable α and a β subunits. Integrins are 
responsible not only for adhesion but also transmit information from the cell surroundings, 
including the ECM, and activate intracellular signalling cascades affecting cell behaviour; multiple 
factors are known to affect integrin expression on cells. On monocytes TGF-β1 causes increased 
expression of both α and β1 integrin subunits, specifically α3β1 (VLA-3 (very late antigen-3)) and 
α5β1 (VLA-5 (very late antigen-5)). Upregulation of α3β1 can lead to increased cell adhesion to the 
ECM proteins laminin, type IV collagen and fibronectin and α5β1 to fibronectin
288. The flasks used 
in this study were fibronectin treated as this has been found to enhance recovery of MSCs from 
bone marrow and also from equine UCB samples289. This treatment may have been detrimental in 
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our study if changes such as those described with TGF-β1 treatment of monocyte cultures were 
induced in the UCB samples promoting monocyte recovery. However, the majority of UCB studies 
have not used fibronectin and nevertheless experienced significant monocyte contamination 
issues possibly due to their higher availability in UCB.  
There was a clear differential response to the FBS batch variation in 2% compared to 21% oxygen 
cultures of bone marrow MNCs, with physiological hypoxia moderating the deleterious impact of 
FBS2. Colonies of MSCs successfully developed in FBS2, albeit at much lower frequency than in 
FBS1 in 2% O2 whereas no colonies developed in FBS2 in 21% O2. MSC recovery has previously 
been shown to be enhanced in 2% O2 compared to 21% O2
230, although this was not the case in 
FBS1; however, if this was occurring in FBS2 then the higher number of MSCs earlier in culture 
could themselves moderate the number of monocytes that become attached during recovery. 
MSCs have been found to inhibit the differentiation of monocytes via secreted factors including 
IL-6290. The converse situation may also be true where enhanced recovery of monocytes had a 
direct, detrimental effect on MSC recovery. As noted in Table 3-3, as part of the innate immune 
response they can produce reactive oxygen species (ROS), nitric oxide, myeloperoxidase, 
inflammatory cytokines and initiators of angiogenesis. The various monocytes can produce a 
range of cytokines such as IL-1β, IL-6,  IL-10 and TNF-α261,291 the effects on MSCs from these would 
likely be many and varied.  
Cell numbers recovered in cultures in FBS2 were also greatly reduced in 21% O2 but in contrast 
were significantly enhanced compared to FBS1 in 2% O2. A large proportion of this difference is 
likely to be a result of more rapid proliferation in FBS2 once colonies had become established. 
This resulted in larger, denser colonies in 2% O2 FBS2 compared to FBS1 cultures, increased 
proliferation in FBS2 acted to offset the reduced CFU-F recovery rate, the increased proliferation 
from FBS2 was previously noted during FBS batch testing (Appendix B, Supplementary figure 1). 
Although increased proliferation, i.e. larger colonies, may give rise to the required cell numbers 
for cell therapies more rapidly, in practice these cells will have undergone mitosis more frequently 
119 
 
and thus represent an ‘older’ cell population. In comparison samples with higher initial CFU-F 
recovery of MSCs increasing the starting cell population numbers will require fewer population 
doublings and correspondingly cells will be ‘younger’. Furthermore both culture time, cell density 
and thus cell-cell contact, and various combinations thereof have been identified as factors 
affecting the subsequent differentiation capacity of MSCs292,293. The situation is further 
complicated by the possibility that oxygen tension can modulate multiple cell processes by both 
direct and indirect action for example changing the expression of cell attachment factors, cytokine 
receptors and any genes with HREs. Oxygen can also result in indirect effects for example as a 
result of changing the oxidative balance within the culture220,294–305.  
Taken together, although the mechanisms of action are unclear and remain topics for future 
studies, the results strongly support the removal of FBS from the culture system. There would be 
considerable benefits associated with the removal of FBS from the culture system including the 
removal of xenogeneic proteins and the risk of xeno-pathogen contamination. There are multiple 
possible options to replace FBS including defined media306, human serum, platelet rich plasma, 
platelet lysate or cord blood serum or plasma307, where use could be either on an autologous308 or 
pooled basis as appropriate. Inevitably there would still be batch variation with all of these 
biological products. Ultimately, particularly when trying to isolate rare populations of cells, only 
the identification of the components key to successful isolation, expansion and differentiation and 
the subsequent preparation of a defined medium alongside fully controlled procedures will 
reliably eliminate the problems described in this chapter.  
 Conclusion 3.6
There has been a flurry of clinical trials investigating the applicability of MSC therapies for a 
multitude of indications including their potential utility in cartilage repair therapies. Early studies 
used bone marrow MSCs; however, similar cells have since been identified in a multitude of 
different tissue types including the birth associated tissues that are typically discarded. With pre-
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existing and established facilities for UCB banking this tissue may prove to be an under-utilised 
pool of donor material. Unfortunately as described herein and extensively in the literature the 
isolation of MSCs from UCB is currently unreliable due most probably to both an intrinsically low 
presence of the cells within UCB, and sub-optimal conditions for their isolation. This Pilot study 
attempted to address this unreliability by modifying the culture conditions to include a 
physiologically relevant oxygen tension for the in vitro recovery steps.  
In this study only a single MSC-like cell colony was recovered from 12 donor samples, instead 
contamination of cultures with monocytes was the more common outcome and 
immunodepletion of CD45 positive cells did not improve recovery rates. FBS batch variability was 
identified as a particularly relevant culture variable and the batch in question was found to impact 
significantly and negatively on the isolation of MSCs from bone marrow MNCs which would 
usually be relatively reliable. The effect of FBS batch was also found to be further modulated by a 
varied oxygen environment with 2% O2 moderating the negative effects and being more 
permissive to MSC recovery. These observations on the potentially devastating influence of 
certain FBS batches have wide-ranging implications not only for isolation of MSCs from UCB but 
for the cell culture industry in general. They strongly support of the use of FBS free and ideally 
human serum free conditions for cell culture whenever possible. Furthermore this work highlights 
the extensive changes in outcome that can occur with oxygen modulation, a less frequently 
considered cell culture variable.  
Despite the issues encountered, as UCB is usually discarded its potential as a source of stem cell 
donor material should not be completely overlooked and continued work is required to improve 
upon current techniques. However, until refinements are made or unless very large numbers of 
UCB units are available the use of UCB is not practicable in a small laboratory setting. Alternative 
sources of MSCs from other birth associated tissues may prove to be more practical options with 
an increasing focus on UC tissue cells which reliably produce much larger numbers of cells with 
MSC characteristics such as surface marker expression and immune modulation309. 
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As the recovery rate of UCB MSC cells was so poor no cells could be carried forward for the 
investigation of their chondrogenic capacity and the following chapters use bone marrow aspirate 
derived MSCs.  
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 Introduction 4.1
As discussed in Chapter 1 cartilage damage and degeneration are common problems, becoming 
increasingly relevant in the western world due to an aging population65. Once tissue integrity has 
been compromised this avascular, alymphatic and aneural tissue, which contains only a small 
numbers of largely quiescent resident cells310, fails to heal naturally, leading to long-term tissue 
degradation24. Treatments other than prosthetic joint replacements have limited efficacy, so 
when a joint replacement is not appropriate, for example due to patient age, only the option of 
long-term pain management strategies remains. The large number of affected individuals 
combined with the apparent simplicity of the tissue has made the prospect of tissue regeneration 
via regenerative medicine strategies including cell therapies and tissue engineering highly 
attractive. As a result cartilage was one of the earliest targets of regenerative medicine strategies, 
beginning in the early 1970s311. 
Despite the numerous advances that have been made and the undoubted quality of life 
improvements for many patients312 the desired outcome of well integrated, hyaline-only cartilage 
has yet to be reliably achieved313. Arguably this may be as a result of the use of a non-optimal cell 
type or inadequate cell culture conditions, as many of the proposed therapies are reliant on an ex-
vivo cell expansion step. However, the in vitro study of key biological cellular processes, an 
understanding of which is likely to be vital to eventual clinical success, is difficult due to an 
inherent property of all somatic cells: replicative senescence189. 
Described and characterised by Leonard Hayflick in the 1960s, replicative senescence occurs in 
vitro after a fixed number of cell divisions176. Upon achieving this maximum, cells undergo 
characteristic changes including enlargement, altered secretory profiles, changes in tumour 
suppressor gene expression and SAβGal activity, and most importantly irreversible proliferation 
arrest. Additionally with every passage or population doubling of a cell population there can be 
changes in cell phenotype. Some of these changes are well described in the two cell types most 
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used for cartilage therapies: primary cartilage chondrocytes and MSCs. When cultured in vitro, 
particularly in a two dimensional environment, primary chondrocytes undergo a process of de-
differentiation becoming less responsive to pro-chondrogenic influences314. Chondrocyte 
senescence is increasingly implicated in the disease pathology with increased SAβGal activity in 
cells surrounding articular cartilage lesions, reduced mitotic activity and reduced telomere 
lengths, all correlating with increasing age315. 
As an alternative to chondrocytes, multipotent93 mesenchymal stem/stromal cells, as described 
by Friedenstein et al316, offer potentially greater proliferation, a more flexible response to 
differentiation cues and the prospect of an allogeneic therapy due to their immunomodulatory 
properties317. Unlike chondrocytes, MSCs are also available from numerous tissues including 
several that would otherwise be discarded318, removing the requirement for invasive surgery and 
healthy tissue removal. Both cell types have an adequate proliferative capacity for autologous cell 
therapies but show widespread variation in proliferation and then efficacy of differentiation 
potential between donors319, particularly as the donor age increases320. hESCs have greater still 
proliferative and differentiation possibilities, due to their properties of self-renewal and 
pluripotency153. However, numerous technical challenges concerning uniformity of differentiation 
and purity of cell populations must be resolved before these cells can be used safely due to the 
inherent capacity of undifferentiated cells to form teratomas. Despite these difficulties hESC 
derived cells are now entering early phase clinical trials164.  
Studies have suggested that the re-introduction of hTERT expression prevents continued telomere 
erosion to critically short lengths that causes cells to become senescent as a result of DNA 
damage signalling events321. Telomere regions have also been proposed to contain numerous 
irreparable DNA double strand breaks322,323 with ectopic telomerase expression reportedly 
resolving the DNA lesions by an as yet unknown mechanism324. In vivo, endogenous telomerase 
expression is detectable only in stem and early progenitor cells, somatic cells in some rapidly 
renewing tissues and in cancerous cells. In vitro expression appears more restricted and is only 
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consistently found in hESCs and cancer cells325. It has been demonstrated that replicative 
senescence can be avoided by the re-expression and activity of the telomerase reverse 
transcriptase catalytic subunit, hTERT200,207,208 which can support the maintenance of telomere 
length whilst also preserving or even enhancing cell function209.   
The work in this chapter tests the hypothesis that the re-expression of hTERT in cells with 
relevance to cartilage tissue engineering is sufficient to extend the proliferative capacity of the 
cells whilst maintaining the primary cell phenotype. 
 Aims 4.2
The aims of the work described in this chapter were: 
 Using a retroviral vector transduce primary chondrocytes, MSCs and hESC derived MSC-
like cells with hTERT. 
 Establish that hTERT is then stably expressed. 
 Investigate the effect of the transduction on: 
o Replicative capacity: determine whether the re-introduction of hTERT could firstly 
prevent the onset of replicative senescence in these cells and, 
o Determine whether hTERT affects the cell phenotype compared to that of the 
primary cells. 
 Methods 4.3
The sequence of experiments for this chapter is summarised in Scheme 2 and all materials and 
methods are described in full in Chapter 2. 
Primary human MSCs BMA13 were recovered from human BMA as described in section 2.3.1; 
recovered BMA13, commercial human chondrocytes OK3, and hESC-derived MSC-like 1C6 cells 
were retrovirally transduced with the catalytic subunit of telomerase hTERT or EV as described in 
section 2.7. Successfully transduced cells were selected using G418 with selected resistant cells 
126 
 
creating the cell lines BMA13H, BMA13EV, OK3H, 1C6H and 1C6EV. All cells were cultured in a 2% 
O2 environment prior to transduction and a 21% O2 environment during transduction and 
selection. All cells were then stored in liquid nitrogen until required for experiments. All 
subsequent cell culture steps were performed in a 2% O2 tri-gas incubator. 
hTERT expression at early and later time points was assessed by RT-PCR in all cells and cell-lines as 
described in sections 2.19-2.22. To determine the effects of hTERT transduction the proliferative 
capacity of the hTERT transduced, parental, and EV cells was determined as described in section 
2.8 by long-term cell culture to senescence, changes in the cell morphology were observed 
throughout the culture period and at early and late PD levels cells were assessed for SAβGal 
activity as per section 2.9.  
The forward scatter (relative size), side scatter (relative cell granularity/complexity) and the 
immunophenotype of transduced cells was determined by flow cytometry against an accepted 
hMSC marker panel as described in 2.12 (typically positive: CD73, CD90, CD105, typicaly negative: 
CD14, CD19, CD34, CD45, HLA-DR) and compared to that of the parental cell types. Similarly tri-
lineage differentiation capacity was assessed by inducing osteogenic, chondrogenic and 
adipogenic differentiation as described in sections 2.10-2.11.3 followed by histological staining 
with alizarin red S, alcian blue and Oil Red O as per sections 2.11.1-2.11.3.  
4.3.1 Statistical analysis 
The percentage of SAβGal positive cells and flow cytometry forward scatter and side scatter were 
compared using one-way ANOVA with Tukey’s multiple comparisons test to determine pairwise 
statistical significance, p≤0.05 was considered significant. Analysis was performed using Graphpad 
Prism V6.01. 
Unless otherwise stated all values quoted in the results are mean ± standard deviation. 
 
  
 
 
Scheme 2. Summary of the methodology adopted in Chapter 4.
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 Results 4.4
Three primary cell types underwent retroviral transduction with the hTERT gene as described in 
section 2.7. The pBABE-hTERT construct used confers resistance to G418 antibiotic treatment 
alongside insertion of the hTERT gene. Following gene transduction and selection with G418 
pBABE-hTERT and pBABE only empty vector (EV) transduced plates for OK3 (OK3H and OK3EV) 
and BMA13 (BMA13H and BMA13EV) and 1C6 (1C6H and 1C6EV) all retained cells resistant to the 
antibiotic treatment, control untreated plates were completely cleared during the same time 
period with the G418 treatment. Only small numbers of cells were retained following 
transduction in BMA13H/BMA13EV and particularly with OK3H/OK3EV, somewhat larger numbers 
were available with 1C6H and 1C6EV. Due to the very low cell numbers available and the 
extensive proliferation necessary to recover from this, insufficient cells were available from the 
OK3EV population to compare the phenotype of these cells with OK3H. However, some 
comparisons could be performed with BMA13EV and 1C6EV. As the aim of the introduction of 
hTERT was to attempt to arrest changes in the cell phenotype it was deemed more appropriate to 
compare transduced cells with early population doubling, non-transduced cell populations.  
4.4.1 Ectopic hTERT expression in transduced cells 
Following transduction, cells were expanded in 2% O2 and banked for future use. RNA was then 
isolated from both parental and transduced cell types to determine whether transduction had 
resulted in the expression of the hTERT transcript. This is essential as the pBABE-hTERT construct 
used does not contain a reporter gene to confirm successful transduction, although resistance to 
antibiotic selection is an indicator of this. β-Actin (ACTB) was included as a housekeeping gene to 
confirm the presence of amplifiable RNA, particularly relevant in samples where hTERT expression 
was absent. 
As shown in Figure 4-1, as expected the parental cell types, including the H1 hESC derived 1C6, did 
not express the hTERT transcript. In contrast all three of the transduced cell types clearly 
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expressed hTERT. RNA isolated from H1 hESC and the previously transduced and characterised 
9C12H cell line (Forsyth et al234), both cell types known to express hTERT, were included as 
positive controls.  
 
 
Figure 4-1. RT-PCR determination of hTERT expression. hTERT is expressed in transduced cells and is 
not present in non-transduced parental cell types. 9C12H and H1 are cell types known to express hTERT and 
are included as positive controls. ACTB confirmed the presence of amplifiable RNA in all samples. 
 
RNA was then isolated from cell cultures at a range of passages/PD to confirm that hTERT 
expression was maintained in daughter cell populations without a requirement for further periods 
of antibiotic selection and was stable as cells were continuously expanded. RNA isolated from the 
two available EV cell types was also included to confirm hTERT expression resulted from specific 
gene insertion not as a result of the transduction process (Figure 4-2).  
 
 
 
Figure 4-2. RT-PCR determination of hTERT expression stability. Continued hTERT expression is 
maintained across many passages/population doublings in all transduced cell lines. Neither the parental cell 
types nor the EV cells BMA13EV or 1C6EV express hTERT. ACTB confirms the presence of amplifiable RNA in 
all groups. 
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All of the created cell line populations maintained hTERT expression across multiple passages 
representing months of continuous expansion. In contrast no expression was detected in parental 
cell types at multiple time points, or in the two available EV cell populations. In hTERT negative 
cells ACTB expression confirmed the presence of amplifiable RNA.   
4.4.2 Cell proliferative capacity 
The introduction and expression of hTERT has the capability to extend the proliferative capacity, 
or even to immortalise, cells. To determine whether this had been achieved in OK3H, BMA13H or 
1C6H the cells were maintained in continuous culture, in 2% O2, in their respective MM alongside 
their non-transduced counterparts and the BMA13EV and 1C6EV cells until they had either 
undergone cessation of proliferation (failure to achieve confluence after ≥ 30 days) or, where 
proliferative capacity was extended, they had clearly exceeded the proliferative capacity of the 
non-telomerised cells (. Cell growth curves). 
OK3 cell proliferation continued for 24 PD after which cells no longer achieved confluency. The 
rate of growth prior to growth arrest was relatively stable with growth arrest occurring relatively 
abruptly. OK3H also exhibited a relatively stable growth rate that was comparable to that of OK3; 
however, growth slowed dramatically from PD35. This very slow growth rate was maintained for a 
prolonged period, with only 4 PD achieved over 172 days. Following this crisis period cell growth 
resumed at a rate similar to that prior to the growth crisis, continuing to PD55 whereupon cells 
were removed from culture having already achieved 31 PD more than the primary cell 
counterpart. 
BMA13 cells underwent 18 PD at a consistent rate before growth began to slow, with cells failing 
to reach confluence beyond PD23. EV transduced cells displayed similar growth characteristics, 
slowing from PD18 and ceasing at PD22. BMA13H underwent an additional 9 PD beyond the 
capacity of BMA13 before growth in these cultures also ceased. BMA13H cells recovered from 
131 
 
liquid nitrogen that had been banked at an earlier time point (PD8) on the growth curve initially 
proliferated well but ceased growth at a reduced PD23, comparable to non-transduced cells. 
1C6 cells had a rapid growth rate initially undergoing 20 PD in 40 days before slowing significantly 
with the subsequent 11 PD taking 104 days and proliferation ceasing at PD65. Cells transduced 
with the empty vector (1C6EV) had a reduced capacity in comparison, ceasing at PD45. In contrast 
1C6H demonstrated a greatly increased proliferation capacity, being expanded to PD115 before 
being removed from culture with no sign of proliferation slowing. Initial growth rates were slightly 
reduced compared to 1C6; however, remained very consistent throughout. 
Due to very slow growth rates following recovery from liquid nitrogen post-transduction all cells 
were supplemented with the mitogen bFGF. Growth curves for BMA13 both in both the presence 
and absence of bFGF are shown in Figure 4-4 and clearly show that, at least in this cell type, bFGF 
supplementation had the effect of slightly increasing the growth rate of the cells and extending 
the total proliferative capacity by 8 PD. 
 
 
 
  
 
Figure 4-3. Cell growth curves. Cells were serially passaged until proliferation ceased or until growth capacity had exceeded that of the relevant parental cell type. 
Curves are shown for primary chondrocytes OK3 and transduced OK3H (A), hMSCs BMA13, transduced BMA13H and empty vector BMA13EV (B) and ESC derived 1C6, 
transduced 1C6H and empty vector 1C6EV (C). 
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Figure 4-4. Growth curve of BMA13 in the presence and absence of bFGF. From PD5 bFGF was 
withdrawn from a culture of BMA13 at sub-culture and cells were subsequently cultured in the presence or 
absence of 4 ng/mL bFGF until senescence.  
 
4.4.3 Cell morphology 
Cell morphology was monitored throughout the proliferation period to record visible changes 
associated with both the transduction and with cell aging. Phase contrast photomicrographs were 
taken throughout the growth period and are shown at early, intermediate and late PD levels 
(exact PD as indicated) and with 4x (upper) and 10x (lower) objective lenses (Figure 4-5, Figure 4-6 
and Figure 4-8). All transduced cell populations, whether the transduction was performed with 
hTERT or EV, retained a morphology consistent with that of their parental cell population at early 
population doublings. Late PD primary non-transduced cells underwent changes in morphology 
that are consistent with a senescent phenotype including cell enlargement, an increase in cell 
processes and greater number of poorly attached/detaching cells.  
OK3 and OK3H (Figure 4-5) had a bi- or tri-polar appearance initially. During the OK3H crisis period 
that OK3H cells had in growth the morphology became much more irregular with multiple cell 
processes and intracellular vesicles. Many of the cells rounded up and detached from the flasks. 
Following the recovery from crisis the cells regained and retained morphology similar to the early 
PD cells. 
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BMA13H and BMA13EV like BMA13 (Figure 4-6) had predominantly bipolar cells that formed 
closely aligned colonies that at high cell densities gained a whorled appearance typically seen in 
hMSC colonies (Figure 4-7). At late PD levels both BMA13 and BMA13EV had more diverse cell 
morphologies with cells generally being larger, much more irregularly shaped and often only 
poorly attached to the culture plastic. In contrast, BMA13H cells at late PD were large and had a 
tendency to become much more polygonal, later appearing as highly refractive stellate cells 
(Figure 4-6L inset). 
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Figure 4-5. OK3 and OK3H cell morphology. Phase contrast micrographs of OK3 (A-F) and OK3H (G-L). 
Images were acquired at early (A, D, G, H), mid (B, E, H, K) and late (C, F, I, L) PD. The categorisation of 
‘early’, ‘mid’ and ‘late’ time points are relative to each cell type’s individual growth curve and exact PD are 
as indicated.  
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Figure 4-6. BMA13, BMA13H and BMA13EV cell morphology. Phase contrast photomicrographs of 
BMA13 (A-F), BMA13H (G-L).and BMA13EV (M-P). BMA13 and BMA13H images were acquired at early (A, 
D, G, H), mid (B, E, H, K) and late (C, F, I, L) population doublings. BMA13EV images were acquired at early 
(M, O) and late (N, P) PD. The categorisation of ‘early’, ‘mid’ and ‘late’ time points are relative to each cell 
type’s individual growth curve and exact PD are as indicated. 
 
 
Figure 4-7. Confluent BMA13, BMA13H and BMA13EV. Phase contrast photomicrographs of 
confluent BMA13 (A), BMA13H (B)and BMA13EV (C)at early PD demonstrating the whorled patterns 
typically seen with hMSCs at confluence. 
 
1C6 and 1C6H and 1C6EV were small, elongated cells. These cells always proliferated to form high 
density irregular colonies. At senescence 1C6 and 1C6EV cells often became much larger, colony 
areas contained considerable numbers of cells detaching from the culture plastic and an increased 
amount of cellular debris. In contrast 1C6H had little variation from the original morphology over 
a time period encompassing 75 PD. 
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Figure 4-8. 1C6, 1C6H and 1C6EV cell morphology. Phase contrast photomicrographs of 1C6 (A-F), 
1C6H (G-L).and 1C6EV (M-P). 1C6 and 1C6H images were acquired at early (A, D, G, H), mid (B, E, H, K) and 
late (C, F, I, L) population doublings. 1C6EV images were acquired at early (M, O) and late (N, P) PD. The 
categorisation of ‘early’, ‘mid’ and ‘late’ time points are relative to each cell type’s individual growth curve 
and exact PD are as indicated. 
 
4.4.4 SAβGal activity  
The presence of SAβGal in cells is considered to be an indicator that the cells are undergoing 
senescence. Primary cells that were judged to be at relatively early and late PD, determined from 
the growth curves, and their transduced counterparts were stained for SAβGal activity. SAβGal 
staining was peri-nuclear spreading out into the cytoplasm and ranged in intensity from a mild to 
moderate, to an intense degree of staining (Figure 4-9).For the purpose of quantification cells 
exhibiting any level of staining were counted as SAβGal positive cells. 
 
 
Figure 4-9. SAβGal staining of cells. Staining intensity ranged from mild (A), moderate (B) to intense (C) 
and surrounded the nucleus extending out into the cell cytoplasm. Brightfield images from a single field of 
view obtained with a 20x objective lens. Cells are counterstained with haematoxylin. 
 
Upon staining, all primary cells at low PD had relatively low levels of SAβGal activity. (Figure 4-10 
and Figure 4-11). Where cells were positive it was most frequently with mild levels of staining 
although occasional cells did stain more intensely. The BMA13 culture contained the greatest 
number of SAβGal positive cells (29.3 ± 4.9%) followed by OK3 (20.7 ± 7.9%) with 1C6 having the 
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lowest SAβGal positive cell count (9.1 ± 2.8%). BMA13EV and 1C6EV empty vector transduced 
cells at low PD were not significantly different to low PD parental cells at 26.1 ± 4.6% and 
11.2 ± 2.6% for BMA13EV and 1C6EV respectively.  
At higher PD all parental cells had significantly (p≤0.0001) increased levels of staining compared to 
low PD cells, with OK3 levels highest at 85.1 ± 7.2% and BMA13 at 81.7 ± 6.3%. 1C6 was 
somewhat lower at 39.2 ± 6.3% of cells stained; however, this still represents a mean 4.3 fold 
increase in the number of cells stained, comparable to BMA13 at a 2.8 fold increase and OK3 with 
a 4.1 fold increase. BMA13EV at late PD was again not significantly different to the non-
transduced population with 86.8 ± 3.8% cells stained positively whereas 1C6EV was significantly 
elevated at 62.7 ± 9.7% (p≤0.001). 
BMA13H and 1C6H remained at levels comparable to early PD parental cells (25.6 ± 4.4% and 
12.3 ± 2.5%). OK3H levels were significantly increased (42.3 ± 3.0%, p≤0.01) over early PD OK3 but 
remained significantly lower (p≤0.0001) than late PD parental cells. 
  
 
Figure 4-10. SAβGal staining. Brightfield micrographs of SAβGal staining of primary, mortal cells at early (A), (D) and (I), and late PD (B), (E) and (F), alongside hTERT 
transduced late PD cells (C), (F) and (K). Empty vector cells BMA13EV and 1C6EV at early PD (G) and (L) and late PD (H) and (M) are also shown. Scale bar = 100 µm.
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Figure 4-11. Quantification of cells with SAβGal activity. SAβGal positively stained cells as a 
percentage of the total cell number (A-C) and expressed as a fold change relative to the matched early PD 
primary cells. Data in (A-C) are expressed as mean ± standard deviation, N=4, **p≤0.01, ***p≤0.001, 
****p≤0.0001. 
 
4.4.5 Tri-lineage differentiation capacity 
The tri-lineage differentiation capacity of non-telomerised and hTERT transduced cells was 
determined and images of differentiated cells are shown in Figure 4-12. The ability to undergo tri-
lineage differentiation is a defining property of MSCs therefore was essential to confirm this 
property in primary cells and observe any changes in transduced cells. Control wells cultured in 
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MM for the duration of the experiment had no positive staining with alizarin red S or Oil Red O; 
however, some staining was apparent with alcian blue for sGAG particularly in 1C6 cells. 
Following culture in osteogenic differentiation media there was no evidence of mineralisation in 
either OK3 or OK3H, evidenced by a lack of alizarin red S stained bone nodules; in contrast 
BMA13, 1C6 and 1C6H all had strongly stained mineralised regions. BMA13H also stained 
positively demonstrating a retained capacity to undergo osteogenesis; however, stained regions 
were much more infrequent and smaller than in BMA13 primary cell cultures. 
Alcian blue staining for the sGAG produced during chondrogenesis was positive after culture in 
PChM in all but OK3H cells where there was no appreciable difference between culture in MM or 
PChM. Cells undergoing chondrogenesis often spontaneously fully (e.g. OK3 and BMA13H) or 
partly (e.g. BMA13 and 1C6) detached from the culture plastic and formed pellet like structures 
that were strongly positive for sGAG, this process is illustrated more clearly in Figure 4-13. 
Interestingly alcian blue staining in 1C6H, whilst still positive, appeared markedly reduced in 
comparison to 1C6 staining. 
Intracellular lipid droplets produced by cells undergoing adipogenesis were stained with Oil Red 
O. BMA13 and 1C6 were expected to undergo adipogenesis and stained strongly with Oil Red  
following culture in adipogenic media. Interestingly the OK3 and to a greater extent the OK3H 
cells also produced numerous lipid filled vesicles. The transduced cell types BMA13H and 1C6H 
both appeared to have reduced staining in comparison to BMA13 and 1C6 respectively. 
 
  
 
Figure 4-12. Tri-lineage differentiation of parental and transduced cells. Images of cells following culture in monolayer for 21 days in the presence of the 
appropriate pro-differentiation media supplements followed by fixation and staining. Osteogenic samples were stained with alizarin red S for calcium deposits, scale = 150 
µm. Chondrogenic samples were stained with alcian blue for SGAGs, images are from 1 well of a 24 well plate. Chondrogenic medium frequently caused cells to partially or 
fully separate from the substrate and contract into pellet-like structures. Adipogenic samples are stained with oil red O for lipid droplets, scale = 80 µm. Images of controls 
cells cultured in standard maintenance media and stained as appropriate are inset for comparison. 
PD level of cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD28, 1C6 PD36, 1C6H PD83. 
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Figure 4-13. Spontaneous pellet formation in monolayer chondrogenic cultures. Highly confluent 
monolayer cultures spontaneously formed pellets, particularly in response to culture in PChM. Pellet-like 
structures would form when confluent monolayers initially rolled in from the edges of the well (A). They 
would often remain attached to the walls of the wells (B) and (D) and could partially (D) or fully detach (C) 
and (E). 
 
4.4.6 Flow cytometry analysis 
Flow cytometry was performed to obtain information on cell size assessed by the forward scatter 
parameter, cell complexity or granulation assessed by the side scatter parameter and to compare 
the immunophenotype of all cell group against the MSC panel of markers specified by the 
International Society for Cellular Therapy 115. 
4.4.6.1 Cell size and complexity 
Forward and side scatter density plots showing relative size and complexity of all cell types are 
shown in Figure 4-14. Profiles of BMA13/BMA13H (Figure 4-14Cand D) and 1C6/1C6H (Figure 
4-14E and F) show similar, although not identical distributions with respect to both size and 
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complexity; however, OK3H (Figure 4-14B) is quite clearly distinct from OK3 (Figure 4-14A). Cell 
size (forward scatter) histograms show cell size relative to the signal obtained for 15 μm control 
beads (Figure 4-14G, H and I). 
Quantification of relative cell size (Figure 4-15) by forward scatter determined that all cell types 
were statistically different to all other cell types and that of the primary cells OK3 cells were 
largest with a mean value of 262 ± 9.3 followed by BMA13 at 203.6 ± 4.4 and finally 1C6 at 
179.3 ± 2.3. Transduced cells were all dissimilar to primary cells where OK3H and 1C6H were 
smaller at 190.5 ± 3.4 and 162.4 ± 1.6 respectively and BMA13H was larger than BMA13 at 
239.6 ± 9.6. 
Relative cell complexity is indicated by the side scatter parameter and is plotted in Figure 4-16, all 
cells were different to all other cells excepting OK3 (209.9 ± 2.8) and BMA13 (202.1 ± 9.9). OK3H 
and BMA13H both had higher side scatter values than their parental cell types at 295.2 ± 9.8 and 
254.8 ± 9.2 respectively. In contrast 1C6 had a higher measure of complexity at 189.4 ± 3.9 than 
1C6H at 167.6 ± 3.1.  
 
 
 
 
 
  
 
Figure 4-14. Flow cytometry results. Forward scatter (FS) and side scatter (SS) density plots for primary cells OK3 (A), BMA13 (C) and 1C6 (E) and transduced cells OK3H 
(B), BMA13H (D) and 1C6H (F). Cell size relative to 15 µm beads is shown in FS histograms (G), (H) and (I). PD level was as follows: OK3 PD10, OK3H PD66, BMA13 PD6, 
BMA13H PD17, 1C6 PD44, and 1C6H PD118. 
148 
 
 
Figure 4-15. Relative cell size.  Relative cell size box and whisker plots determined by flow cytometry 
forward scatter. The box indicates the interquartile range and the whiskers are minimum and maximum 
with the median indicated by horizontal line. All results are significant to all other results at ****p≤0.0001 
except OK3H to 1C6 where ***p≤0.001. PD level was as follows: OK3 PD10, OK3H PD66, BMA13 PD6, 
BMA13H PD17, 1C6 PD44, and 1C6H PD118.   
 
 
Figure 4-16. Relative cell complexity.  Relative cell complexity box and whisker plots determined by 
flow cytometry side scatter. The box indicates the interquartile range and the whiskers are minimum and 
maximum with the median indicated by horizontal line. All results are significant to all other results at 
****p≤0.0001 except BMA13 to 1C6 where **p≤0.01 and OK3 to BMA13 where there is no significant 
difference (ns). PD level was as follows: OK3 PD10, OK3H PD66, BMA13 PD6, BMA13H PD17, 1C6 PD44, and 
1C6H PD118.   
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4.4.6.2 Cell immunophenotype 
All cells were incubated with antibodies to CD14, CD19, CD34, CD45 , HLA-DR, CD73, CD90 and 
CD105 a combination that is considered to be a marker panel for hMSCs115. Staining was 
compared relative to the recommended non-specific isotype control, either IgG1 or IgG2a 
depending on the antibody. Histograms of fluorescence intensity for all markers are shown for 
OK3 and OK3H in Figure 4-17, for BMA13 and BMA13H in Figure 4-18 and 1C6 and 1C6H in Figure 
4-19. The percentage of cells that were considered positively stained was determined by gating 
the stained population with a gate that excluded 99% of all isotype control events; results are 
plotted in Figure 4-20.  
Both isotype controls stained equally across all cell types, also matching unstained cells 
demonstrating minimal non-specific fluorescence. CD19, CD34 and CD45, markers typically 
negative in MSCs were all considered negative in all cells at ≤ 2% positively stained cells indicating 
non-haematopoietic lineages. CD14 was slightly elevated in OK3 and OK3H at 12.1% and 5.7% and 
just barely elevated in BMA13 and BMA13H at 3.4% and 2.5% positive cells. HLA-DR was positive 
in 88.1% of cells for BMA13 but negative in all other cell types. The MSC positive markers CD73, 
CD90 and CD105 were positive in BMA13 in 99.9 %, 88.1 and 99.1% of cells respectively. In 
BMA13H expression was comparable for CD73 at 99.9% but halved for CD90 with only 42.5% 
positive cells. CD105 remained strongly positive although at a slightly reduced 95.6% positive 
cells. Interestingly OK3 and OK3H were also strongly positive for both CD73 and CD90 at 99.8% 
and 98.8% for CD73 and 98.1% and 97.1% for CD90. Expression of CD105 was also present but at a 
reduced level of 52.0% in OK3 and 42.6% in OK3H. 
1C6 is a hMSC-like cell type and as such would be expected to be positively stained with the hMSC 
markers. Cells stained positively for CD73 at 99.9% of cells but CD90 and CD105 were at reduced 
levels compared to the MSCs, with 66.0% positive cells with CD90 expression and only 11.7% 
positive cells with CD105 expression. CD73 expression was maintained at high levels (99.9%) in 
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1C6H but like BMA13H levels of CD90 were much lower, in this case almost completely removed 
at only 4.0%. However, CD105 expression increased somewhat to 18.8%.  
 
 
Figure 4-17. Immunophenotype of OK3 and OK3H. Expression of typically negative (CD14, CD19, 
CD34, CD45, HLA-DR) and typically positive (CD73, CD90, CD105) MSC markers in OK3 (A) and OK3H (B). 
Light fill = isotype control IgG1 or IgG2a, dark fill = antibody marker. Histogram region set to exclude 99% of 
isotype control events. PD level was as follows: OK3 PD10, OK3H PD66. 
 
 
151 
 
 
Figure 4-18. Immunophenotype of BMA13 and BMA13H. Expression of typically negative (CD14, 
CD19, CD34, CD45, HLA-DR) and typically positive (CD73, CD90, CD105) MSC markers in BMA13 (A) and 
BMA13H (B). Light fill = isotype control IgG1 or IgG2a, dark fill = antibody marker. Histogram region set to 
exclude 99% of isotype control events. PD level was as follows: BMA13 PD6, BMA13H PD17.  
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Figure 4-19. Immunophenotype of 1C6 and 1C6H. Expression of typically negative (CD14, CD19, CD34, 
CD45, HLA-DR) and typically positive (CD73, CD90, CD105) MSC markers in 1C6 (A) and 1C6H (B). Light fill = 
isotype control IgG1 or IgG2a, dark fill = antibody marker. Histogram region set to exclude 99% of isotype 
control events. PD level was as follows: 1C6 PD44, 1C6H PD118.   
 
    
 
 
  
 
Figure 4-20. Quantification of immunophenotype markers. Percentage positive events relative to relevant isotype control marker IgG1 or IgG2a with region set to 
exclude 99% of isotype control events. PD level was as follows: OK3 PD10, OK3H PD66, BMA13 PD6, BMA13H PD17, 1C6 PD44, and 1C6H PD118.  
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 Discussion 4.5
Regenerative medicine offers new therapies for difficult to treat indications like cartilage damage, 
that frequently rely solely or partly upon a cellular component. Unfortunately many of the 
clinically relevant cell types are subject to de-differentiation and all primary somatic cells are 
eventually subject to replicative senescence. This makes any long term, reproducible study of a 
stable cell population impossible. Immortalisation of clinically relevant cells with the essential 
catalytic subunit of telomerase, hTERT326–328 was investigated as a route to extend their in vitro 
longevity whilst simultaneously maintaining their differentiation capacity to extend their utility as 
a research tool. The re-expression specifically of the catalytic subunit, hTERT, rather than the 
other components of telomerase the TERC template RNA329 or the TEP1 protein has previously 
been determined to be the limiting step in telomerase activity, with a strong correlation between 
hTERT expression levels and telomerase activity330. This immortalization approach has particular 
applicability for cartilage based cell therapies as in addition to the phenomenon of replicative 
senescence, primary chondrocytes undergo rapid de-differentiation during in vitro culture with a 
corresponding loss of phenotype51,314. Importantly this includes the reduced expression of 
chondrocyte/chondrogenesis associated genes331 and reduced responsiveness to pro- 
chondrogenic signals332, making any long term study of these cells towards cartilage repair 
therapies challenging.  
Low levels of endogenous telomerase activity have occasionally been reported to be present in 
both human chondrocyte and MSC cell cultures333,334. Telomerase is active in hESCs; however, its 
activity is down-regulated as differentiation proceeds and cells accordingly undergo telomere 
shortening and eventually senescence202. As such it would not be expected to be constitutively 
active in the clonally derived MSC-like 1C6 cell population and cells should undergo senescence 
after extensive expansion in line with other somatic cells. The results described herein were in 
accordance with the majority of previous literature and telomerase expression was absent in the 
155 
 
primary non-transduced MSCs BMA1392,335–338, chondrocytes OK3339, and embryonic derived 
1C6234. Cells underwent replicative senescence in line with previous reports with regards to both 
proliferation capacity and SAβGal activity221,340,341. hTERT transduction resulted in persistent 
hTERT expression in all three cell types even after extensive expansion. However, despite this, a 
variable response with respect to proliferative potential was noted where 1C6H was the only cell 
type to undergo prolonged, uninterrupted proliferation. The minimal changes in proliferative 
capacity seen in BMA13H are in contrast to other publications reporting successful 
immortalisation of MSCs338,342. The senescence of these cells may therefore be due to an 
alternative mechanism, particularly as the cells were exposed to atmospheric oxygen levels during 
transduction with hTERT having previously been isolated and cultured in 2% oxygen. Oxidative 
stress during exposure to higher ambient O2 levels is a known risk factor for stress induced cellular 
senescence343 and has been implicated as a causative factor in the lack of immortalisation 
following hTERT transduction in other cell types despite telomere elongation222.  
To date there are only a very a limited number of reports published describing chondrocyte 
immortalisation, particularly in reference to human cells. Early experiments used viral proto-
oncogenes including the simian vacuolating virus 40 large T antigen (SV40-Tag)344 to immortalise 
cells and resulted in a variable impact on cell phenotype and a complex inverse relationship 
between cell proliferation and chondrogenic ECM synthesis, whereby only slowly proliferating cell 
populations exhibited ECM synthesis345,346. Immortalisation of chondrocytes with hTERT has also 
been described, with assessment of semi-quantitative changes in aggrecan and collagen II gene 
expression. However, ECM formation via the production and secretion of proteoglycan or proteins 
was not determined with the study relying only on semi-quantitative gene expression changes. 
Furthermore, although the cells appeared to retain some chondrogenic capacity aggrecan and 
collagen II expression were reduced in comparison to control chondrocytes339. However, the 
immortalisation process in chondrocytes may be more complex as others have determined a 
requirement for secondary transduction with human papillomavirus 16 oncogenes E6 and E7 in 
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addition to telomerase347. In low oxygen culture conditions similar to those employed here only 
one of three lines gained proliferative potential following hTERT transduction despite evidence of 
extended telomeres in all three348.  
Following transduction of cells with hTERT and a subsequent period of proliferation it is not 
unusual for cells to undergo a period of slow growth coincident with an increase in tumour 
suppressor gene expression and cell death, this period is often termed ‘crisis’ and following the 
crisis cells may recover to earlier proliferation rates222 (see Figure 4-21). These results where 
OK3H experienced an extended pause, or crisis period, suggest that a secondary event allowing 
bypass of key regulatory gene responses (e.g. pRb, p14ARF, p53, p21CIP1, or p16ink4a)349 may have 
occurred in a sub-population of cells during OK3H culture. This along with the ectopic hTERT 
expression allowed continued proliferation beyond the M2 checkpoint and potentially completes 
the immortalisation process of the cells. Whilst the results for 1C6H are not as definitive as OK3H 
there was a slowing of cell proliferation coincident with the onset of senescence in 1C6 that may 
also have represented a crisis period but in this case cells recovered to earlier proliferation rates 
very rapidly, possibly as a result of the more rapid proliferation rates of 1C6H cells in general. It is 
tempting to speculate that BMA13H may also have entered the crisis period but that 
circumstances allowing the bypass of M2 either did not occur at all, or in a sufficient number of 
BMA13H cells to enable a population level recovery; further experiments would be required to 
confirm whether this is the case and whether 1C6H and OK3H are indeed immortalised. Larger 
scale cultures of BMA13H may enable a sufficient number of cells to recover from a potential 
crisis to result in an immortalised population. 
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Figure 4-21. Possible route to cell immortalisation. Primary somatic cells are believed to pass through 
two ‘checkpoints’ where proliferation can be halted: M1 and M2. M1 may be bypassed by telomerase 
transduction; however, M2 may still prevent immortalisation or cause the cells to undergo a crisis period 
before immortal cells emerge. (Adapted from Choi and Lee, 2015
349
.) 
 
SAβGAL, a reported marker for senescent cells190, in our samples resulted in the expected higher 
level of staining of increasing numbers of cells in cultures approaching their maximum number of 
population doublings. However, it was observed that there was a low background level of activity 
in both earlier PD OK3 and BMA13, and more notably, high levels in OK3H although this was in 
conjunction with cells with no detectable SAβGal activity. It is possible that the OK3H is a mixed 
population with some cells undergoing senescence but alternatively there are multiple culture 
conditions where SAβGal, a lysosomal β-galactosidase350, is found in proliferating cell populations 
including cells proliferating under stress and in regions of cell confluence351,352. The presence of 
SAβGal activity despite ongoing proliferation is further evidence that mechanisms other than 
telomere length dependent replicative senescence are active in our cultures. Similar results were 
found by Zhu et al353 transfection with both hTERT and cyclin-dependent kinase 4 (CDK4) and 
further optimisation of culture conditions was necessary to produced differentiation competent 
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immortalised muscle satellite cells353.  It is possible that supplementation of the media with 
additional anti-oxidatives or performing the transduction in a more hypoxic environment would 
lead to more favourable outcomes. 
There are currently no known, unique markers for the identification of cells as MSCs, therefore of 
necessity MSCs are most commonly defined by the expression or absence of expression of a 
collection of cell surface markers alongside specific physical/behavioural features. Specifically: 
plastic adherence, expression of the surface antigens CD73, CD90 and CD105 and concomitant 
with the lack expression of CD14 or CD11b, CD19 or CD79, CD34, CD45 and HLA-DR; and the 
presence of demonstrable tri-lineage mesodermal differentiation capacity confirming 
multipotency115.  
In accordance with these requirements the BMA13 MSCs that were used in this study expressed 
CD73 (100%), CD90 (88%) and CD105 (99%) and lacked expression of CD14, CD19, CD34 and 
CD45; however, positive expression of HLA-DR (88%) was seen. Although surface expression of 
the HLA-DR antigen is typically negative on MSCs they have been shown to contain an intracellular 
reservoir of HLA-DR that becomes detectable at the cell surface following stimulation for example 
with IFN-γ354. HLA-DR has also previously been reported by others on MSCs in the absence of 
inflammatory stimuli; particularly relevant to the results herein HLA-DR was observed more so 
when cells were isolated from whole BMA rather than separated MNCs, and particularly in 
response to exposure to bFGF355,356. Subsequent differentiation of the HLA-DR positive MSCs can 
also lead to a reduction in HLA-DR surface expression354. Although seemingly undesirable from a 
transplantation perspective increased expression of HLA-DR on MSC does not appear to present a 
barrier to their application clinically, even with potential allogeneic applications, as MSCs 
expressing HLA-DR, like their HLA-DR negative counterparts, still do not cause an in-vitro 
proliferative response in mixed lymphocyte cultures354. 
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Interestingly we found that OK3 chondrocytes also expressed CD73 (100%), CD90 (98%) and 
CD105 (52%), positive expression of MSC markers on chondrocytes has been reported 
previously314,357,358 with a greatly increased expression of CD90 in response to monolayer 
culture314. Alternatively it has been proposed that these cells may be representative of a 
chondroprogenitor or MSC like cell type present within cartilage357,359. This is not strongly 
supported here as although OK3 appeared to readily accumulate the lipids associated with 
adipogenesis, there was no evidence of mineralisation under osteogenic conditions. 
Changes in immunophenotype occurred in all three cell populations in response to hTERT 
transduction and subsequent expansion. CD90 expression was reduced in both BMA13H and 
1C6H and CD105 was reduced in OK3H when compared to parental cells. CD73, CD90 and CD105 
expression decreases with increased passage number in MSCs360 so these changes may be 
indicative of a loss of MSC phenotype in BMA13H. High CD90 expression has also been linked to 
an enhanced osteogenic response in adipose derived MSCs123. The same group also found that 
low expression of CD105 also predisposed the cells to greater a greater osteogenic response; 
however, CD90 appeared to be the predominant factor123. Both BMA13H and 1C6H appeared 
qualitatively to have reduced osteogenic capacity following transduction, coincident with a 
reduced CD90 expression. Flow cytometry also identified that all three transduced cell lines 
differed in both relative size (FS) and granularity (SS). 
 Conclusion 4.6
The introduction of telomerase and sustained expression was confirmed in all three transduced 
cell types, successfully conferring enhanced proliferation and possibly immortality on both OK3H 
chondrocytes and 1C6H hESC derived cells. Despite reports from others that describe a stable cell 
phenotype and maintenance of differentiation capacity post transduction in a ranges of cell types, 
all three telomerised cell lines herein underwent measurable changes in phenotype. Differences 
included a reduction in cell surface marker expression, changes in cell size and a qualitative 
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reduction in differentiation capacity in comparison to the parental cell types. There is a paucity of 
comparators for chondrocyte immortalisation in the literature; the few reports that do exist also 
describe difficulties, with the process requiring changes in additional culture conditions or further 
genetic modification. MSC immortalisation is more common and typically more successful, 
suggesting that a feature of the culture and immortalisation protocol used in this study may be 
responsible for the poor results with BMA13H. Considering that all of the factors in this 
experiment with the exception of oxygen tension were not extraordinary, the most likely 
candidate for this is culture shock or oxidative stress. This may have been induced in the cells as a 
result of the necessity of performing the transduction in 21%, ambient oxygen conditions with 
cells that had previously been cultured in physiological hypoxia. As the genetic modification had 
to be performed at a different institution further investigation of the transduction process is out 
with the scope of this thesis but should be the subject of future studies of cell immortalisation. 
As the primary focus of this thesis is a comparison of chondrogenic capacity, and this was only 
qualitatively assessed in this chapter, the next chapter determines and compares the primary and 
transduced cells’ chondrogenic capacity quantitatively in a simple 2D environment.   
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production by cells in monolayer 
culture  
5 Chondrogenesis of cells in monolayer culture 
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 Introduction 5.1
There are several cell types currently under investigation for applications involved in the 
regeneration of damaged or degenerated articular cartilage. Presently indexed on Clinical 
trials.Gov361 there are 33 trials involving cartilage and MSCs with 14 listed as active, 43 with 
cartilage and stem cells with 18 active, and 48 involving cartilage and chondrocytes of which 18 
are active (Figure 5-1). Despite studies like these having been ongoing for decades the therapies 
involved have yet to be recommended for routine clinical practice, for example the NICE 
recommendation for ACI is in favour of continued clinical research but not currently for routine 
clinical use (NICE Technology Appraisal TA89362 (At the time of writing the NICE guidance is under 
appraisal). Patients undergoing these therapies often have significant symptomatic improvements 
but tissue regeneration is imperfect with fibrocartilage rather than hyaline tissue produced, 
impacting on long term treatment efficacy. 
 
 
Figure 5-1. Current clinical trials. Total number, and the number of currently active clinical trial indexed 
at ClinicalTrials.Gov using the search terms “cartilage and stem cell”, “cartilage and MSC” and “cartilage and 
chondrocyte”. Data retrieved 10/08/15. 
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Current treatments for cartilage problems largely revolve around the management of symptoms 
and include joint stabilisation with bracing, intra-articular steroid injections, pain management, 
treatment with non-steroidal anti-inflammatories and possibly joint debridement and lavage. 
These interventions assist in slowing continued degeneration and manage symptoms; however, 
they cannot reverse the damage done and ultimately disease progression often culminates with a 
prosthetic joint replacement363. In older and less active patient cohorts this may represent an 
acceptable outcome, although patients may have endured years of symptoms with the associated 
reduction in quality of life; however, for younger and more active cohorts total joint replacement 
is a less desirable outcome as the joint will frequently (9 % – 16%) require revision surgery within 
10 years363. The prospect of improved tissue regeneration alongside a limited repertoire of 
current therapies continues to drive interest in regenerative medicine cartilage therapies. Current 
sub-optimal outcomes are possibly as a result of the application of a non-optimal cell type and 
further in vitro characterisation of the cells typically used: MSCs and chondrocytes would be 
beneficial.  
Preliminary investigations of changes in cell phenotype are typically done in a simple monolayer 
system, with the changes being driven by the application of biochemical cues in the form of cell 
culture medium supplements, most significantly for chondrogenesis the use of TGF-β. 
In vivo the growth factor TGF-β acts both as an early promoter of chondrogenesis at the 
condensation stage and also acts later to prevent the onset of a hypertrophic phenotype364. 
During mesenchymal condensation TGF-β1 drives the production of N-cadherin and versican, key 
molecules in the cell-cell interactions during the condensation process. Later it inhibits numerous 
molecules associated with terminal differentiation and cartilage hypertrophy including type X 
collagen, VEGF, osteocalcin and MMP1313. To promote in vitro chondrogenesis supplementation 
of the culture media with members of the TGFβ superfamily is used, with either TGF-β1 or TGF-β3 
used most commonly for inducing chondrogenesis at an optimal concentration of 10 ng/mL365. 
TGF-β1 and 3 have both been identified as effective promotors of chondrogenesis, particularly 
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when used in combination with the steroid dexamethasone366, although more limited there is also 
evidence that TGF-β2 can also promote chondrogenesis. In addition to TGF-β and dexamethasone 
medium is usually further supplemented with ascorbic acid, an insulin, transferrin, and selenium 
mix, sodium pyruvate, and L-proline. This combination has been shown to be sufficient to 
promote chondrogenesis of cells in a monolayer, particularly in a low oxygen environment such as 
that employer for the work in this chapter367,368. 
This chapter continues work from Chapter 4 and further examines in a more quantitative manner 
the hypothesis that hTERT expression maintains the low PD primary cell phenotype during 
chondrogenesis in monolayer despite extensive in vitro cell expansion.  
 Aims 5.2
The aim of the work described in this chapter was to characterise the parental and transduced 
cells with respect to their response in a simple in vitro environment to a pro-chondrogenic 
influence via supplementation of the culture medium with, in particular, TGF-β3. As the key aim of 
cartilage regenerative medicine therapies is the recapitulation of the ECM the production of sGAG 
is a responsive marker of chondrogenesis. 
 Methods 5.3
The sequence of experiments for this chapter is summarised in Scheme 3. 
Parental, EV and transduced cells were all expanded in 2% O2 and then seeded in multi-well plates 
in MM overnight to allow cell attachment after which they were cultured for a further 20 days in 
2% O2, in the presence of either MM or PChM. Samples were acquired for digestion at days 0, 5, 
10 and 20 for both the monolayer and spent culture media and processed as described in section 
2.13. Stored spent culture media and cell digests were quantitatively assessed for sGAG content 
using the DMMB assay as described in section 2.14 and cell content of the monolayer determined 
via the PicoGreen DNA assay as described in section 2.15. 
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5.3.1 Statistical analysis 
Absolute monolayer and media associated sGAG, normalised monolayer and media associated 
sGAG and monolayer DNA content were compared using two-way repeated measures ANOVA 
with pairwise comparisons with Bonferroni correction of MM to PChM at each time point to 
determine statistical significance, p≤0.05 was considered significant. Analysis was performed 
using Graphpad Prism V6.01. 
Unless otherwise stated all values quoted in the results are mean ± standard deviation. 
 
 
 
 
Scheme 3. Summary of the methodology adopted in Chapter 5.  
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 Results 5.4
5.4.1 Monolayer associated sGAG 
sGAG associated with the cell monolayers was quantified using the DMMB assay on cell digests at 
day 0 (after overnight cell attachment) and following 5, 10, and 20 days in culture in 2% O2, in 
either MM or PChM (Figure 5-2 and Figure 5-3). For all three primary cell types, culture in the pro-
chondrogenic environment induced by the use of PChM resulted in the accumulation of large 
amounts of monolayer associated sGAG. This resulted in a maximal amount of sGAG by day 20 in 
OK3 (8.84 ± 2.25 µg) followed by BMA13 (5.61 ± 0.150 µg) and lastly 1C6 (5.24 ± 0.237 µg). This 
corresponded to fold changes relative to starting sGAG levels of 9.5 fold, 14.0 fold and 10.6 fold in 
OK3, BMA13 and 1C6 respectively. Primary cell cultures in MM also had increases, albeit smaller, 
in monolayer associated sGAG culminating, in day 20 quantities that were highest in 1C6 (3.68 ± 
0.377 μg), followed similarly by OK3 (3.56 ± 0.231 µg) and lastly, at much lower levels, BMA13 
(0.758 ± 0.074 µg) with corresponding fold changes relative to day 0 of 7.1 fold, 3.3 fold and 1.6 
fold respectively. The larger increases seen in sGAG in PChM compared to MM resulted in 
significantly higher sGAG in PChM compared to MM by day 5 (mean difference of 1.63 µg, p≤0.05) 
for BMA13  and day 10 for OK3  (mean difference of 2.25 µg, p≤0.05). In contrast, 1C6 initially had 
significantly more sGAG in MM with mean differences of 0.85 µg (p≤0.01) at day 5 and 1.20 µg 
(p≤0.0001) but by day 20 1C6 also had more sGAG in PChM than MM. As a result of these 
changes, by day 20 differences were greatest in OK3 (mean difference of 5.28 µg, p≤0.0001) 
followed closely by BMA13 (mean difference of 4.85 µg, p≤0.0001) and smallest in 1C6 (mean 
difference of 1.56 µg, p≤0.0001).  
Similar results were seen in cultures of BMA13H and 1C6H with PChM day 20 cultures having 
significantly more monolayer associated sGAG than MM cultures. In BMA13H changes were 
insignificant until day 20 and the extent of the fold change compared to day 0 and the size of the 
difference between cultures in MM versus PChM for both cell types in PChM, and for 1C6H in 
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both MM and PChM were decreased at day 20 compared to those of the corresponding primary 
cells. This resulted in mean differences of 1.08 µg (p≤0.0001) for BMA13H and 1.364 µg (p≤0.001) 
for 1C6H. In contrast OK3H maintained an inverse relationship to all other cultures for all 20 days, 
with cells in MM having more monolayer associated sGAG than cultures in PChM resulting at day 
20 in a mean difference 2.067 µg (p≤0.0001).  
Data in Figure 5-3D-F, where fold changes are expressed relative to the previous time point, allow 
a more detailed examination of the temporal changes in sGAG production with each time interval. 
These indicate that more sGAG was produced in the first five days in the majority of cell types, 
followed by a decrease in the rate of change between day 5 and 10, followed by more 
conservative changes thereafter. The exceptions to this trend were 1C6 cells cultured in PChM 
where there was a steady increase in sGAG with each time period and OK3H which had reduced 
sGAG within the first 5 days followed by a slight recovery; however, overall this resulted in little 
net gain. 
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Figure 5-2. Monolayer associated sGAG. sGAG associated with cell monolayers was quantified using 
the DMMB assay at day 0, 5, 10 and 20 for all cells after culture in MM or PChM. Data are expressed as 
mean ± standard deviation, N=3, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. PD level was as follows: 
OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84.
  
 
Figure 5-3. Fold change in monolayer associated sGAG. For comparison purposes data were expressed as mean fold change relative to the day 0 sGAG content of the 
monolayer (A-C) and relative to the previous timepoint (D-E). PD level was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84.    
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5.4.2 Media associated sGAG 
sGAG associated with the spent cell culture media was also quantified using the DMMB assay at 
day 0 (after overnight cell attachment) and following 5, 10, and 20 days in culture in either MM or 
PChM. All data were first normalised using appropriate media controls and are expressed 
cumulatively with the earlier time points in line with monolayer associated sGAG (Figure 5-4). 
As with monolayer associated sGAG, media sGAG increased over the course of the experiment, 
this increase occurred in all cell types and in both MM and PChM. Amounts at day 20 were largest 
by far in OK3 and OK3H MM cultures at 113.28 ± 1.026 µg and 96.316 ± 1.639 µg. This was 
followed by 1C6 at 17.769 ± 2.758 µg and BMA13 at 14.978 ± 1.745 µg. Again, as with monolayer 
associated sGAG, smaller amounts were identified in the media of transduced cells BMA13H and 
1C6H at 3.560 ± 0.666 µg and 5.445 ± 0.403 µg. However, in contrast to monolayer associated 
sGAG which was usually higher in PChM, media sGAG from PChM cultures was reduced compared 
to MM. In OK3 and in 1C6 levels were significantly lower, and by day 20 were 26.885 ± 3.298 µg 
(p≤0.0001) and 6.549 ± 0.376 µg or 0.24 and 0.37 times that in MM in OK3 and 1C6 respectively . 
BMA13H and 1C6H were also had significant reductions in PChM compared to MM with 0.61 fold 
(p≤0.05) and 0.78 fold (p≤.0.01) differences. BMA13 on the other hand was significantly increased 
in PChM compared to MM at 19.831 ± 0.445 µg (p≤0.0001) representing a 1.4 fold increase.  
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Figure 5-4. Media associated sGAG. sGAG associated with spent cell culture media were quantified 
using the DMMB assay at day 0, 5, 10 and 20 for all cells after culture in MM or PChM. Data are expressed 
as mean ± standard deviation, N=3, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. PD level was as follows: 
OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84. 
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5.4.3 Total sGAG changes 
Total sGAG at day 20 as a result of the contributions from the monolayer associated sGAG and the 
media associated sGAG are shown in Figure 5-5, with the contribution from each fraction 
expressed as a percentage of the total amount of sGAG in Figure 5-6A and as total fold change in 
Figure 5-6B. Cultures of all cells had an overall increase in total sGAG after 20 days in culture 
compared to starting amounts irrespective of culture media conditions. Larger total increases 
were detected in MM than PChM in all cases excepting BMA13, with increases in sGAG in MM 
ranging from 4.4 fold over day 0 values in 1C6H to 30.9 fold in OK3. This is in comparison to 
increases in PChM from 3.1 fold in OK3H to 14.7 fold in BMA13. All three primary cell types had 
greater fold increases and total sGAG production than their corresponding transduced cell types. 
The proportion of total sGAG associated with the monolayer by day 20 ranged from 3.0% (OK3H) 
to 25.2% (1C6H) in MM and 8.4% (OK3H) to 44.45% (1C6) in PChM. Culture in PChM overall led to 
a decrease in total sGAG due to a reduced media associated fraction, but this was concomitant 
with an increase in monolayer associated sGAG.  
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Figure 5-5. Total sGAG at day 20.  Day 20 summary of total sGAG by both monolayer and media 
contribution at day 20.  Data are expressed as mean ± standard deviation, N=3, *p≤0.05, **p≤0.01, 
****p≤0.0001. Black asterisks indicate significance between monolayer associated sGAG; grey asterisks 
indicate significance between media associated sGAG. PD level was as follows: OK3 PD6, OK3H PD50, 
BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84.
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Figure 5-6.Total sGAG. (A) Percentage of total sGAG contributed by the monolayer and media associated 
fractions. (B) Total mean fold change at day 20 relative to day 0. PD level was as follows: OK3 PD6, OK3H 
PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84.  
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5.4.4 DNA quantification 
DNA in all cell monolayers was quantified from digests using the PicoGreen fluorescent DNA assay 
(Figure 5-7 and Figure 5-8). In OK3 and OK3H cell cultures there was significantly more DNA in 
cultures in MM than in PChM by day 5 with a mean difference of 0.529 µg (p≤0.0001) in OK3 cells 
and 0.354 µg (p≤0.0001) in OK3H. In OK3 this represents a 6.1 fold increase from day 0 in MM and 
4.2 fold increase in PChM and in OK3H this is reduced to 2.6 fold and 1.5 fold increases in MM and 
PChM respectively. In OK3 by day 20 the difference between MM and PChM had narrowed to 
0.353 µg (p≤0.01) due to a steady increase in DNA resulting in a day 20 total fold increase of 4.9 
fold in PChM compared to a slight increase followed by a decrease in MM giving a day 20 total 
fold increase of 6.5 fold. In contrast to this, OK3H had a total fold increase of 3.7 in MM; however, 
there was no further increase beyond day 5 in PChM giving a total fold change of only 1.4. 
BMA13 responded very differently to OK3 cells with the inverse relationship of much larger 
increases in DNA in PChM compared to MM, where DNA content remained relatively static after 
an increase to day 5. This difference was significant by day 10 with 1.01 µg (p≤0.0001) and 
increased at 20 to 1.67 µg (p≤0.0001). Total fold changes were 4.4 fold in PChM and 1.5 fold in 
MM. BMA13H behaved similarly to BMA13 in PChM but had a slightly higher increase in MM 
resulting in a final difference of 0.800 µg (p≤0.05). 
Overall changes in DNA in 1C6 were more comparable to those in OK3 than BMA13, being more 
likely to have higher DNA in MM than in PChM, significantly so at day 5 (0.483 µg difference, 
p≤0.001) and 10 (0.432 µg, p≤0.001). However, by day 20 due to a gradual decrease in DNA in 
MM from day 5, and a gradual increase in DNA in PChM from day 5 there was no longer a 
significant difference between culture in MM or PChM. 1C6H initially appeared to be following 
the same trend as 1C6 with a larger amount of DNA in MM than PChM by day 5; however, this 
was not statistically significant and at day 10 and day 20 DNA in both MM and PChM had 
decreased.   
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Figure 5-7.Monolayer DNA content. DNA associated with cell monolayers was quantified using the 
PicoGreen assay at day 0, 5, 10 and 20 for all cells after culture in MM or PChM. Data are expressed as 
mean ± standard deviation, N=3, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. PD level was as follows: 
OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84. 
  
 
Figure 5-8. Fold change in DNA content. For comparison purposes data were expressed as mean fold change relative to the day 0 DNA content of the monolayer (A-C) and 
relative to the previous time point (D-E). PD level was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84. 
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5.4.5 Monolayer sGAG normalised to DNA  
As sGAG is associated with all cells even in the absence of a pro-chondrogenic stimulus 
normalisation of sGAG to DNA (μg/μg) enables a comparison of changes in sGAG due to increased 
or decreased cell numbers, as a result of cell proliferation or death, to be somewhat separated 
from increases in sGAG synthesis induced by pro-chondrogenic influences (Figure 5-9).  
Normalised sGAG in OK3 showed a 2.8 fold increase (p≤0.0001) in cultures in PChM 
(3.36 ± 0.707 µg/µg) compared to MM (1.20 ± 0.304 µg/µg) at day 20, similar to the 2.5 fold 
difference (p≤0.0001) seen in absolute sGAG levels. In contrast to this the difference in sGAG in 
BMA13 cultures in PChM compared to MM in absolute terms equated to a 7.4 fold increase 
(p≤0.0001) which decreased to 2.1 fold (p≤0.0001) (2.41 ± 0.142 µg/µg in PChM, 
1.17 ± 0.222 µg/µg in MM) when normalised to DNA as a result of the large increase in DNA 
content. As a result of minimal changes in DNA in 1C6 the difference at day 20 between MM and 
PChM cultures equated to a 1.4 fold increase (p≤0.0001) in both absolute and relative terms 
(8.50 ± 0.846 µg/µg in PChM, 6.05 ± 0.253 µg/µg in MM). 
Normalisation in the transduced cells had the effect of reducing the difference at day 20 in PChM 
to MM to 0.7 times and 1.8 times in OK3H (1.27 ± 0.107 µg/µg in PChM, 1.80 ± 0.070 µg/µg in 
MM, p≤0.0001) and BMA13H (0.737 ± 0.070 µg/µg in PChM, 0.417 ± 0.176 µg/µg in MM) 
respectively compared to absolute differences of 0.3 times and 3.0 times. The reverse was true in 
1C6H where reductions in cell numbers at later time points without a concomitant reduction in 
sGAG led to an increase in the difference in PChM compared to MM of 3.0 fold (12.3 ± 3.94 µg/µg 
in PChM, 4.03 ± 0.457 µg/µg in MM, p≤0.0001)compared to an absolute sGAG difference of 1.7 
fold. 
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Figure 5-9. Monolayer associated sGAG normalised to DNA content. sGAG associated with cell 
monolayers was normalised to DNA of the same monolayers to give a μg/μg ratio at day 0, 5, 10 and 20 for 
all cell types after culture in MM or PChM. Data are expressed as mean ± standard deviation, N=3, 
**p≤0.01, ***p≤0.001, ****p≤0.0001. PD level was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H 
PD16, 1C6 PD42, 1C6H PD84. 
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5.4.6 Media sGAG normalised to monolayer DNA  
The sGAG content of the spent culture media was normalised to the DNA level of the 
corresponding monolayer (Figure 5-10). Following normalisation, as with absolute media sGAG 
levels OK3 and OK3H MM cultures still had the highest sGAG at 38.085 ± 0.853 µg/μg and 
57.507 ± 1.879 μg/μg respectively followed by 1C6 MM cultures at 29.513 ± 6.624 μg/μg and 
BMA13 MM cultures at 22.941 ± 3.172 μg/μg.  
Following normalisation five of the six cell types had significantly reduced sGAG/DNA in the media 
of PChM cultures compared to the MM cultures. The difference was largest in OK3H where PChM 
had 0.24 times the sGAG of MM (p≤0.0001) and similarly OK3 with 0.27 times the sGAG in PChM 
compared to MM (p≤0.0001). BMA13, BMA13H and 1C6 had similar differences at 0.37 times 
(p≤0.0001), 0.34 times (p≤0.0001) and 0.36 times (p≤0.0001) the sGAG in PChM compared to MM 
respectively. Notably normalisation of the media sGAG brought BMA13 in-line with the results in 
the other primary cell types of higher sGAG in MM compared to PChM. In contrast, 1C6H was no 
longer significantly different at any time point although results expressed as normalised levels 
were more similar to 1C6 than when absolute sGAG levels were considered. 
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Figure 5-10. Media sGAG normalised to DNA. sGAG associated with spent cell culture media was 
normalised to DNA of the monolayers to give a μg/μg ratio at day 0, 5, 10 and 20 for all cell types after 
culture in MM or PChM. Data are expressed as mean ± standard deviation, N=3, *p≤0.05, **p≤0.01, 
****p≤0.0001. PD level was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H 
PD84. 
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5.4.7 Total normalised sGAG 
Total sGAG from both monolayer and medium fractions was combined and normalised to total 
monolayer DNA and is shown at day 20 in Figure 5-11 and as a fold change in Figure 5-12. As with 
absolute total levels, normalised total sGAG was significantly higher for all cell types except 1C6H 
in MM rather than PChM due to the large media sGAG contribution In MM normalised sGAG was 
highest in OK3H at 59.31 µg/µg followed by OK3 (39.29 µg/µg), 1C6 (35.56 µg/µg), BMA13H 
(33.91 µg/µg), BMA13 (24.11 µg/µg) and 1C6H (15.97 µg/µg). These values corresponded to 
14.09, 12.32, 3.18, 3.01, 3.76 and 7.10 fold changes from day 0 values respectively. 
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Figure 5-11. Total normalised sGAG at day 20. Day 20 summary of total normalised sGAG with both 
monolayer and media contribution at day 20.  Data are expressed as mean ± standard deviation, N=3, 
*p≤0.05,  ****p≤0.0001. Black asterisks indicate significance between monolayer associated sGAG; grey 
asterisks indicate significance between media associated sGAG. PD level was as follows: OK3 PD6, OK3H 
PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84. 
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Figure 5-12. Total normalised mean fold change. Total sGAG normalised to DNA mean fold change at 
day 20 relative to day 0. PD level was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 
PD42, 1C6H PD84. 
 
PChM culture values were highest in 1C6H (30.40 µg/µg) followed by 1C6 (19.17 µg/µg), BMA13H 
(17.36 µg/µg), OK3H (15.19 µg/µg), OK3 (13.60 µg/µg) and BMA13 (10.95 µg/µg) with 
corresponding fold changes of 14.92, 2.48, 1.39, 3.23, 4.46 and 2.02 fold respectively. Overall 
these results suggest that 1C6H may be the cell type most responsive to PChM as this had the 
greatest fold increase from day 0 however the results should only be interpreted with knowledge 
of absolute sGAG and DNA changes as much of the increase in 1C6H results from a reduction in 
DNA not an increase in sGAG synthesis. 
5.4.8 Empty vector cell cultures 
The available empty vector cells BMA13EV and 1C6EV were also treated as per the hTERT 
transduced and parental cells (Figure 5-13and Figure 5-14). 
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Figure 5-13. Monolayer and media associated absolute and normalised sGAG from empty vector 
cells. sGAG associated with cell monolayers and cumulative media sGAG was quantified using the DMMB 
assay at day 0, 5, 10 and 20 for all cells after culture in MM or PChM. Normalised data are expressed as a 
ratio of sGAG/DNA. Data are expressed as mean ± standard deviation, N=3, *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001. PD level was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H 
PD84. 
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Figure 5-14. Empty vector monolayer DNA content. DNA associated with empty vector cell 
monolayers was quantified using the PicoGreen assay at day 0, 5, 10 and 20 for all cells after culture in MM 
or PChM. Data are expressed as mean ± standard deviation, N=3. PD level was as follows: OK3 PD6, OK3H 
PD50, BMA13 PD6, BMA13H PD16, 1C6 PD42, 1C6H PD84. 
 
The BMA13EV response was comparable to the primary cell response with regards to the trends 
in the results; a significantly higher monolayer associated sGAG was seen from day 5 (p≤0.001) 
onwards resulting on 1.8 fold higher (p≤0.0001) sGAG content in PChM than MM by day 20. This 
was concurrent with a significantly decreased media associated sGAG in PChM, resulting in an 
overall reduction in total sGAG in PChM compared to MM. In contrast 1C6EV had a much lower 
response to PChM, although this still followed the same trends, with only a 1.4 fold increase in 
monolayer associated sGAG with the difference between the sGAG monolayer content in the two 
media types not reaching significance. There was also no evidence of cell proliferation in 1C6EV 
with DNA content of the monolayer remaining relatively unchanged from day 0. 
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 Discussion 5.5
During in vitro culture cells synthesise and secrete ECM molecules including sGAG containing 
proteoglycans to fill intercellular spaces369. In this work primary and transduced chondrocytes 
(OK3/OK3H), MSCs (BMA13/BMA13H) and hESC derived cells (1C6/1C6H) were seeded in a simple 
monolayer, 2D environment to quantitate their response to soluble pro-chondrogenic cues in the 
form of media supplementation with TGF-β3. This would be expected to increase proteoglycan 
and sGAG synthesis in cells undergoing chondrogenesis. Considering either total (monolayer plus 
media) sGAG or monolayer associated sGAG, chondrocytes produced higher levels than the other 
primary cell types, although they also showed a significant response to PChM. In comparison the 
transduced cells had a greatly reduced response and in the case of OK3H, as with the qualitative 
assessment, no increase in sGAG was seen in response to pro-chondrogenic signals. 
All cell types, in pro-chondrogenic conditions induced by TGF-β3370 or in standard MM, produced 
sGAG in measurable quantities associated with both the pellet and in relatively large amounts in 
the spent culture media. Interestingly total sGAG was generally determined to be higher in cells 
exposed to MM than in PChM, where much of the sGAG was found in the media rather than in 
association with the monolayer. Reports of sGAG quantities in media during in vitro culture vary 
ranging from negligible amounts371 to a large fraction (35-90% depending on the cell culture 
conditions) of the total sGAG produced372 this is in line with the range of values found across the 
cell types here which varied considerably. Media sGAG has been used as a proxy for total sGAG 
production373; however, these results do not support this technique, as we found large cell type 
dependent differences in the proportion of retained versus secreted sGAG, one is not necessarily 
indicative of the of the other. Evidence from other investigations into media sGAG indicates that 
the losses to the media from the monolayer are probably as a result of the inability of the ECM to 
retain the proteoglycan and associated sGAG which then diffuse into the media372; however, 
proteoglycan degradation due to catabolic activity cannot be ruled out as a potential cause.  
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Cells exhibited variable proliferation responses during the experiment in response to the MM and 
PChM. Chondrocytes in MM had a burst of proliferation in the first five days of culture which then 
plateaued. In PChM there was also the greatest amount of proliferation in the first five days that 
was followed by much smaller incremental increases at days five and ten. This suggests that 
chondrocytes proliferated until confluent and then switched to sGAG synthesis beyond day five. 
BMA13 exhibited a similar response in MM although maximum DNA levels were much lower than 
those in OK3 possibly due the formation of high density chondrogenic condensations. In PChM 
BMA13 had a continual increase in DNA in PChM meaning that a considerable fraction of the 
sGAG was attributable to cell proliferation. Nevertheless some cells had increased sGAG synthesis 
as normalised sGAG also increased and these results may be representative of a mixed cell 
population.  
Normalisation of the sGAG to DNA can effectively show whether the sGAG synthesis increases on 
a per cell basis and is a reliable measure when both are increasing or DNA is stable. However, as 
exemplified with 1C6H, it should never be considered in isolation without the absolute data. In 
1C6 DNA decreased probably due to over-confluence and cell losses, whilst sGAG remained high 
possibly due to its incorporation in a stable ECM. As a result of this the number of cells actually 
contributing to the sGAG in underestimated whilst sGAG per cell becomes overestimated. In a 
situation where both the numerator and the denominator are both affected, potentially in either 
direction, it is impossible to interpret the resulting ratio. 
Transduction with hTERT appeared to have had a particularly detrimental effect on monolayer 
associated sGAG with OK3H in both absolute and normalised terms. This may be reflective of the 
particular difficulties that seem to be associated with chondrocyte transduction347,348. Although 
the chondrocytes used were from a commercial supplier they were nevertheless from an elderly 
donor and may have accumulated age-related changes. Furthermore the transduction procedure 
is lengthy and cells continue to proliferate, and therefore de-differentiate, during this process and 
may have passed a critical point for successful re-differentiation. The cells are also polyclonal, 
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polyclonal expansion favours selection of rapidly growing cells over those with more favourable 
differentiation properties374; clonal expansion and colony characterisation and selection may 
enable the identification of a subpopulation of cells with a greater proliferative capacity; however, 
the requirement to expand cell numbers from a single cell level would make this impractical. To 
enable rapid assessment of the multiple cell types described herein experiments were performed 
in monolayer culture; however, it is accepted that a 3D environment can provide a more pro-
chondrogenic influence375,376.  
 Conclusion 5.6
To regenerate articular cartilage, transplanted cells must produce large quantities of sGAGs that 
are retained within the area of damaged tissue. All three primary cell types assessed herein 
produced and retained significant amounts of sGAG in association with the monolayer in response 
to a pro-chondrogenic influence. Two (1C6H and BMA13H) of three hTERT transduced cell types 
exhibited similar responses to non-transduced cell types particularly when sGAG was normalised 
to DNA level. However, in contrast, the hTERT transduced chondrocyte line OK3H performed 
poorly in response to PChM and had no increase in sGAG retained in the monolayer. These 
preliminary findings indicate that whilst hTERT transduction can be useful in prolonging cell 
proliferation, complex changes in cell phenotype and a loss of differentiated cell function can be 
induced in a variable and cell specific manner. 
To enable rapid assessment of the multiple cell types described herein experiments were 
performed in monolayer culture; however, it is accepted that a 3D environment can provide a 
more pro-chondrogenic influence375,376 and this is explored in Chapter 6. 
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Chapter 6 
 
Chondrogenesis of cells in pellet 
culture  
6 Chondrogenesis of cells in pellet culture 
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 Introduction 6.1
It is accepted that when chondrocytes are cultured in vitro in monolayer they undergo a process 
of de-differentiation87 becoming increasingly less responsive to pro-chondrogenic stimuli with a 
corresponding reduction in cartilage ECM molecule production. The reintroduction of a 3D culture 
environment concurrent with pro-chondrogenic growth factor supplementation366 is reported to 
be beneficial both to promoting the redifferentiation of expanded, dedifferentiated 
chondrocytes376 and to initiating chondrogenesis in MSCs, possibly as a result of mimicking the 
mesenchymal condensation stage of chondrogenesis during embryonic development377. The 
culture of cells in a 3D environment is more representative of their in vivo physiological situation 
allowing for increased interaction of cells both with each other and with a more complex 
extracellular environment, with the possibility of improved growth factor retention via 
sequestration by ECM molecules and the creation of a number of morphogenetic gradients378. 
3D environments can be created in vitro either by the incorporation of cells into biomaterials, 
most commonly gels, including agarose379, alginate376, and hyaluronic acid380,381, or simply by 
creating very high density cultures by centrifugation of cells into pellets382. Interestingly, despite 
speculation regarding the importance of recapitulation of mesenchymal condensations and the 
resulting cell-cell contacts, chondrogenesis in both hydrogel, with no direct cell-cell contact, and 
pellet cultures is reported to be equivalent383. 
Nevertheless although mechanisms have yet to be fully elucidated the results are relatively clear 
for example when cultured in 3D environments, either in an alginate hydrogel or pellets 
chondrocyte cultures had upregulated gene expression of the key chondrogenic markers SOX9, 
COL2A1 and ACAN along with a reduction in some hypertrophic markers when compared to 
monolayer cultures376. Similarly MSC chondrogenesis has previously been demonstrated to be 
partial in monolayer, whilst cells in monolayer do respond to pro-chondrogenic influences the 
response is significantly improved in 3D as evidenced by increased chondrogenic gene 
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expression384. Human adipose derived MSCs in monolayer have upregulated COL2A1 and ACAN in 
response to PChM, particularly in hypoxia, but the extent of upregulation reported was small at 2 
fold and 1.3 fold increased respectively. Relative expression of the transcripts was significantly 
increased by culturing the cells in 3D hydrogels368,385. 
The work described in this chapter further tests the hypothesis that hTERT transduced cells retain 
a capacity for chondrogenesis similar to that of the relevant primary cells and that chondrogenesis 
is enhanced in a 3D environment when compared to a 2D environment.    
 Aim 6.2
The overall aim of this chapter was to determine whether the additional cues provided by a 3D 
environment in the form of cell pellets, in addition to the influence of TGF-β3 as described in 
Chapter 5, impacted on chondrogenesis in the primary and transduced cells under investigation. 
The assessment of chondrogenesis was via a number of markers of chondrogenesis including 
pellet size, sGAG production, gene expression analysis and cartilage ECM production. 
 Methods 6.3
The sequence of experiments for this chapter is summarised in Scheme 4. 
Once a sufficient number of cells had been attained by expanding the cells in their respective 
MM, in 2% O2, pellets of all parental and transduced cells consisting of 2.5x10
5 cells/pellet were 
created by centrifugation from cell suspensions in both MM or PChM and cultured in 2% O2, as 
described in section 2.16. At day 1 and day 20 of culture pellets were harvested and fixed for 
imaging and sizing as per section 2.17 and for µCT as described in section 2.18. Pellets were also 
harvested at day 1 and day 20 for paraffin embedding and sectioning followed by histological 
staining as per section 2.24 with haematoxylin and eosin, picrosirius red for collagen and toluidine 
blue for sGAGs. Further sections were used for immunohistochemistry performed as described in 
section 2.25 for collagen type I, collagen type II, collagen type VI, collagen type X and aggrecan. 
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At day 0 (after approximately 30 minutes in either MM or PChM whilst cells were re-suspended in 
the media, centrifuged and the sample media then collected) and day 20 cell pellets and 
accumulated, collected spent culture media were proteinase K digested overnight as described in 
section 2.13. The resulting digests were assayed for sGAG using the DMMB assay as per section 
2.14, the same pellet digests were also assessed for DNA content using the PicoGreen assay as per 
section 2.15. Also at day 0 and day 20 pellets were lysed as described in section 2.19.2, RNA 
extracted as per section 2.20 and qRT-PCR performed as described in section 2.23 for the genes 
COL1A2, COL2A1, COL3A1, COL6A3, COL10A1, ACAN, COMP and SOX9. As pellet lysis proved to be 
difficult and recovered RNA levels low, in particular in MM cultures, triplicate pellets were 
combined and lysed together in triplicate to allow the analysis to be performed on the same 
samples for all genes (i.e. a total of 9 pellets were combined in 3 batches to produce 3 samples for 
each cell type for qRT-PCR). 
6.3.1 Statistical significance 
Pellet volume (calculated from images and by µCT), pellet density, absolute monolayer sGAG, 
normalised monolayer sGAG and pellet DNA were compared using two-way repeated measures 
ANOVA with Bonferroni corrected pairwise comparisons of MM to PChM at each time point and 
of day 0 to day 20 for MM and PChM to determine statistical significance, p≤0.05 was considered 
significant. Analysis was performed using Graphpad Prism V6.01. Relative gene expression 
statistical significance was determined using a randomisation algorithm as part of the REST 2009 
software, p≤0.05 was considered significant.  
Unless otherwise stated all values quoted in the results are mean ± standard deviation. 
  
 
Scheme 4.Summary of the methodology adopted in Chapter 6.
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 Results 6.4
6.4.1 Pellet formation and size determination 
Cell pellets of approximately 250,000 cells were formed by centrifugation at 300 g; following 
overnight culture in either MM or PChM the mechanically aggregated cells were visibly integrated 
into masses which could be detached freely from the microcentrifuge tube walls (Figure 6-1).  
 
 
Figure 6-1. Cell pellet formation. Centrifugation pelleted cells (A) that formed free floating masses 
within 24 hours (B). 
 
Pellets were paraformaldehyde fixed and the size (volume) determined and compared at day 1 
and day 20 of culture in MM or PChM. Fixed pellets were firstly imaged using light microscopy 
(Figure 6-2). Images at day 1 showed that pellets appeared to form via a process of aggregation to 
form a multi-layered sheet, which then folded or rolled from the edges towards the centre 
resulting in heterogeneous pellets. In general pellets became more spherical and homogeneous 
by day 20; however, some heterogeneity in light transmission was still sometimes present 
indicating heterogeneity in tissue depth or density, being particularly apparent with OK3H pellets 
(Figure 6-2B). 
  
 
Figure 6-2. Cell pellet images. Images were taken post-fixation of whole pellets after 1 day or 20 days of culture in MM or PChM. Scale bar = 500 μm. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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Pellet size was then determined by the acquisition of pellet diameters on both the long and short 
axes of the pellets from the images, with these values used to calculate the ellipsoid volumes 
shown in Figure 6-3. At day 1 pellets were larger in PChM than in MM with this trend becoming 
statistically significant in OK3 (p≤0.01) and OK3H (p≤0.05) pellets. Pellets were always smaller at 
day 20 than at day 1 with the difference being greater in MM than PChM and by day 20 pellets 
were always larger in PChM than in MM. The size differences between pellets cultured in MM and 
PChM at day 20 were greater in all three primary cell types, achieving statistical significance 
(p≤0.0001 for OK3, p≤0.05 in BMA13 and p≤0.01 in 1C6). Whilst the same trend for larger pellets 
in PChM compared to MM at D20 was present for transduced cells this did not reach statistically 
significant levels. 
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Figure 6-3. Calculated pellet volume. Cell pellet volumes for all samples were determined by taking 
diameter measurements from light micrographs and calculating the corresponding ellipsoid volume. Data 
are plotted as mean ± standard deviation, N=3. *p≤0.05, **p≤0.01, ****p≤0.0001. PD level for cells was as 
follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
While the determination of day 20 volumes was likely to be reasonably accurate when calculated 
from measured diameters due to the more spheroidal/ellipsoidal shape of the pellets, day 1 
pellets were much more variable in shape, often being relatively flat. This led to an over-
estimation of the pellet volume with this being highly dependent on the degree of curvature 
present. This was particularly the case for OK3H and BMA13H and this is reflected in the much 
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larger standard deviations in these pellets. As such, a second set of pellets was prepared and 
subjected to µCT analysis to improve accuracy for size comparisons and to gain more information 
about pellet morphology and density. 
µCT images confirmed that pellets form concave disks against the microcentrifuge tube walls that 
then roll or fold to eventually form a spheroid shape (Figure 6-4). This can also have the effect of 
forming folds or cavities within pellets. Although these are usually absent by day 20 some of the 
earlier gross structure was seen to persist, particularly after culture in MM. 
To obtain an accurate volume assessment a thresholded volume was obtained; with the threshold 
set to 50/1000. A lower threshold set to 50 included all material within the pellet in the volume 
determination whilst still separating the pellet from the background as shown in materials and 
methods 2.18.2. The upper limit of 1000 is the maximum and ensures that no denser material is 
excluded from the analysis. The μCT acquired volumes are shown in Figure 6-5. 
 
  
 
Figure 6-4. µCt determined pellet images. µCT images were taken post-fixation of pellets after 24 hours or 20 days pf culture in MM or PChM. µCT confirmed that 
pellets are formed by flattened, multi-layered cell sheets folding or rolling to eventually form spheroids. This can result in pellets containing folded structures or cavities 
that may persist to some extent for the culture duration. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD1, BMA13H PD16, 1C6 PD36, 1C6H PD107. 
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Figure 6-5. µCT determined pellet volume. Pellet volumes determined by 50/1000 threshold analysis of 
pellets at day 1 and day 20 after culture in MM or PChM for OK3 (A), OK3H (B), BMA13 (C), BMA13H (D), 
1C6 (E), and 1C6H (E). Data are plotted as mean ± standard deviation, N=3. *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD1, BMA13H PD16, 1C6 
PD36, 1C6H PD107. 
 
The improved accuracy gained from using this technique compared to image analysis is apparent 
in the reduced standard deviation error bar range and by a general increase in the significance p 
value. As with the previously calculated volumes from imaging, pellets at day 1 were still slightly 
larger on average after forming in PChM compared to pellet formation in MM (Figure 6-6), 
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although this was significant only in BMA13 (1.1 fold higher, p≤0.01) and 1C6H (1.2 fold higher, 
p≤0.01) only. By day 20 all pellets cultured in MM were significantly smaller than at day 1 ranging 
from a 0.061 fold decrease in 1C6H to 0.48 fold decrease in 1C6. Equally, all pellets excepting 1C6 
cultured in PChM were significantly smaller at day 20 than day 1 with the difference ranging from 
0.27 fold in 1C6H to 0.84 fold in OK3. The larger decreases in MM meant that at day 20 all pellets 
cultured in the presence of PChM were significantly larger than the corresponding MM pellets 
(Figure 6-6). The difference was smallest in 1C6 at 1.8 fold larger increasing to 5.3 fold larger in 
1C6H.  
 
 
Figure 6-6. Pellet size at day 20. Summary pellet volume data for all cell types determined by µCT at day 
20 (A) the fold difference in pellets cultured in MM compared to PChM at both day 1 and day 20 (B) and 
fold change in volume at day 20 compared to day 1 (C). Data in chart A are expressed as mean ± standard 
deviation, **p≤0.01, ***p≤0.001, ****p≤0.0001, N=3. PD level for cells was as follows: OK3 PD6, OK3H 
PD50, BMA13 PD1, BMA13H PD16, 1C6 PD36, 1C6H PD107.  
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6.4.1.1 Pellet density 
Relative density was also acquired by µCT and is shown in Figure 6-7, and with day 20 mean 
densities summarised and the difference expressed as a fold change at day 20 compared to day 1 
in Figure 6-8. There were no significant differences across all cell types between culture in MM or 
PChM at day 1. With the exception of 1C6H cell, pellets were on average denser at day 20 when 
cultured in PChM than when cultured in MM and were also denser at day 20 than day 1. 
Differences at day 20 between the culture in MM or PChM were significant with OK3H (p≤0.001), 
BMA13 (p≤0.0001) and 1C6 (p≤0.05). When cultured in MM pellets most pellets had a reduced 
density compared to day 1. This is despite the reduced volume of these pellets indicating that 
pellet contraction is unlikely to be the cause of the reduced pellet volume as this would have been 
likely to lead to an overall increase in pellet density. 
The exception to the trend in pellet density was 1C6H where the mean density in MM was larger 
than in PChM although this was not significant due to the large standard deviation. This increased 
overall density was due to dense regions within the pellets, in particular in one pellet, although a 
second also had some dense spots. Using µCT analysis these dense regions could be visually 
isolated from the bulk of the pellet by increasing the lower threshold for µCT analysis to 135, a 
level sufficient to isolate sub-chondral bone completely from the overlying cartilage (Figure 6-9).  
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Figure 6-7. µCT determined density analysis. Relative pellet density determined by 50/1000 threshold 
analysis of pellets at day 1 and day 20 after culture in MM or PChM for OK3 (A), OK3H (B), BMA13 (C), 
BMA13H (D), 1C6 (E), and 1C6H (E). Data are plotted as mean ± standard deviation, N=3. *p≤0.05, 
***p≤0.001, ****p≤0.0001. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD1, BMA13H 
PD16, 1C6 PD36, 1C6H PD107. 
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Figure 6-8. Relative pellet density at day 20. Summary pellet density data for all cell types determined 
by µCT at day 20 (A) and the mean day 20 density expressed as a fold change of the day 1 mean pellet 
density (B). Data in chart A are expressed as mean ± standard deviation, N=3, *p≤0.05, ***p≤0.001, 
****p≤0.0001. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD1, BMA13H PD16, 1C6 
PD36, 1C6H PD107. 
 
 
Figure 6-9. 1C6H µCT density analysis. 1C6H pellets cultured in MM contained regions that were much 
denser than any other pellet. These denser regions are shown in red in cross sections (A) and (C) and are 
visually isolated from the remainder of the pellet in (B) using a higher lower threshold of 135 during the 
analysis. Denser areas are equivalent in density to the subchondral bone found with full depth 
osteochondral plugs as shown in (D). PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD1, 
BMA13H PD16, 1C6 PD36, 1C6H PD107. 
 
6.4.2 sGAG production in pellets 
sGAG production at day 0 and after 20 days culture in MM or PChM was quantified by the 
spectrophotometric DMMB assay after pellet digestion with proteinase K and is shown in Figure 
6-10 and Figure 6-11. All 3 primary cell types had significantly increased sGAG by day 20 when 
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cultured in PChM compared to day 0, with BMA13 (4.906 ± 1.374 μg, p≤0.05) > OK3 
(4.617 ± 1.202 μg, p≤0.001)> 1C6 (2.886 ± 0.517 μg, p≤0.05). In contrast, culture in MM led to a 
non-significant reduction in sGAG in all three primary cell type pellets where the mean reduction 
in 1C6 (1.265 ± 0.044 μg) > BMA13 (1.221 ± 0.124 μg) > OK3 (0.616 ± 0.190 μg). This decrease in 
sGAG in after culture in MM concomitant with an increase in sGAG in PChM resulted in 
significantly higher amounts of sGAG for all three cell types at day 20 in PChM of 4.00 µg or 7.5 
fold in OK3 (p≤0.0001), 3.69 µg or 4.0 fold in BMA13 (p≤0.001) and 1.62 µg or 2.3 fold in 1C6 
(p≤0.01). 
In contrast to the primary cell pellets the transduced cell pellets had no significant increase in 
sGAG from day 0 levels by day 20 when cultured in PChM with 1C6H decreasing significantly by 
66% from 1.495 ± 0.117 μg to 0.515 ± 0.015 μg, p≤ 0.0001. As with the culture of primary cell 
pellets sGAG content still decreased over time in MM, significantly so in OK3H to 1.385 ±0.095 μg, 
p≤0.01 and 1C6 to a very low 0.118 ± 0.212 μg, p≤0.0001. Nevertheless, it is important to note 
that a partial response to pro-chondrogenic stimuli was still apparent in transduced cells indicated 
by the differential response to MM compared to PChM. As a result of this as at day 20 OK3H and 
1C6H pellets still had significantly more sGAG following culture in PChM than in MM by 2.0 fold 
(p≤0.0001) and 2.4 fold and (p≤0.05) respectively. BMA13H also had 1.6 fold more sGAG after 
culture in PChM compared to MM; however, this was not significant. 
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Figure 6-10. sGAG content of cell pellets. Total absolute sGAG content in pellets was quantified using 
the DMMB assay at day 0 in MM or PChM and at day 20 after culture in MM or PChM for all cell pellets. 
Data are expressed as mean ± standard deviation, *p≤0.05, N=3, **p≤0.01, ***p≤0.001, ****p≤0.0001. PD 
level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86.  
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Figure 6-11. Fold change in pellet associated sGAG. Absolute sGAG quantities determined by DMMB 
assay were used to calculate fold change in sGAG content at day 20 relative to day 0 levels. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
6.4.3 sGAG content of pellet media 
Media levels of sGAG were much lower overall than those from monolayer cultures (Figure 5-4); 
however, as with monolayer culture they were highest in OK3 and OK3H cell cultures compared to 
the other cell types (Figure 6-12). As the pellets were measured at day 0 following centrifugation, 
rather than after overnight culture as for the monolayer cells, day 0 values were essentially 0 and 
are therefore not shown, this also prevents the calculation of fold-change values. Statistically 
significant differences between MM and PChM at day 20 were found only for two comparisons: 
OK3H was higher in MM than PChM, 17.083 ± 1.941 μg compared to 5.213 ± 1.398 μg, p≤0.001 
and BMA13H was also higher in MM than PChM at 1.382 ± 0.196 μg compared to 
0.470 ± 0.163 μg, p≤0.01. These results are also in agreement with the monolayer culture 
experiments where culture in MM resulted in higher levels of sGAG than in PChM.  
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Figure 6-12. sGAG in spent culture media at day 20. sGAG content of the spent culture media was 
determined by DMMB assay. Data are expressed as mean ± standard deviation, N=3, **p≤0.01, ***p≤0.001. 
PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
6.4.4 Total sGAG changes 
Total sGAG at day 20 as a result of the contributions from the pellet associated sGAG and the 
media associated sGAG are shown in Figure 6-13 and with the contribution from each fraction 
expressed as a percentage of the total amount of sGAG in Figure 6-14A and as total fold change in 
Figure 6-14B. 
Cultures of all cells excepting 1C6H had an overall increase in total sGAG after 20 days in culture in 
PChM when compared to day 0 starting amounts with OK3 (10.6 fold) > BMA13 (2.3 fold) > 1C6 
(2.2 fold). Culture in MM led to overall increases in OK3, OK3H, BMA13H and 1C6 (5.4, 8.9, 1.2 
and 1.5 fold respectively) and decreases in BMA13 and 1C6H (0.46, 0.51 fold). In contrast to the 
monolayer total sGAG results the three primary cell types had larger total fold increases in PChM 
than MM due to a larger percentage contribution from the pellet associated sGAG compared to 
media associated sGAG. The media percentage contribution to the total ranged from 8.1% to 
92.7% in MM with a mean of 60.2 ± 31.7% and 0.0% to 70.4% in PChM with a mean of 
33.3 ± 30.1%. This compares to monolayer results of a mean of 88.9 ± 9.1% in MM and 
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69.2 ± 14.7% in PChM respectively. As a result of the reduced contribution from the media were 
in general reduced MM cultures  
As with the monolayer results, all three primary cell types had greater fold increases and total 
sGAG production than their corresponding transduced cell types when cultured in PChM. 
 
 
Figure 6-13. Total sGAG in pellets and spent culture media at day 20. Absolute sGAG contribution to 
total sGAG content from the pellet and spent culture media. Data are expressed as mean ± standard 
deviation, N=3, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. Black asterisks indicate significance 
between pellet associated sGAG; grey asterisks indicate significance between media associated sGAG. PD 
level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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Figure 6-14. Total sGAG. (A) Percentage of total sGAG contributed by the pellet and media associated 
fractions. (B) Total mean fold change at day 20 relative to day 0. PD level for cells was as follows: OK3 PD6, 
OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
6.4.5 DNA content of cell pellets 
DNA content of all pellets at day 0 and day 20 was determined using the PicoGreen DNA assay 
(Figure 6-15 and Figure 6-16). The DNA content of pellets decreased significantly in all primary cell 
pellets cultured in MM from day 0 values with pellets containing 24.7% of the starting DNA in OK3 
(p≤0.01), 52.6% (p≤0.05) in BMA13 and 39.8% (p≤0.0001) in 1C6. Transduced cells OK3H and 
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BMA13H retained more DNA over the culture period, ending at 90.7% (p≤0.01) and 59.1% 
respectively (p≤0.01). 1C6H on the other hand had a very low DNA content, ending the 
experiment at day 20 with only 12.6% (p≤0.0001) of the starting DNA content.  
The DNA content also decreased in two out of the three primary cell types in PChM, although as 
with the sGAG content, much less so, with primary pellets having 90.4%, 120.4% and 95.9% of the 
starting DNA amount in OK3, BMA13 and 1C6 respectively with no change being significant. In 
contrast two of the three transduced cell types had pellets that were significantly reduced 
compared to day 0 DNA values with BMA13H at 83.2% (p≤0.05) of the starting DNA and again 
representing a very large decrease, 1C6H down to just 20.5% (p≤0.0001) of initial levels. 
The different behaviour of cells with respect to final DNA content in the two media types resulted 
in all pellets in MM having less DNA than pellets in PChM with a significant difference in DNA 
content by day 20 in four out of six cell types. The magnitude of the difference was greater in 
primary cells with OK3 having 70.7% (p≤0.001) more DNA in PChM than MM, OK3H 14.4% 
(p≤0.01), BMA13 32.4%, BMA13H 29.2% (p≤0.001), 1C6 57.9% (p≤0.0001) and 1C6H 30.8%.  
These differences in DNA content were not always only attributable to changes isolated to the 
primary pellets; pellets, particularly in PChM often had secondary smaller pellets form during the 
culture period (Figure 6-2Ec and Ed). These are believed to be as a result of cell condensations 
forming on the walls of the microcentrifuge tubes which may then detach ( Figure 6-17). In some 
cases these small pellets remain separate but imaging indicates that these can also become 
integrated with the primary pellet as shown in Figure 6-4E d.  
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Figure 6-15. Cell pellet DNA content. Total DNA content was determined using the PicoGreen assay for 
all cell pellets following digestion with proteinase K. Data are expressed as mean ± standard deviation, N=3, 
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. PD level for cells was as follows: OK3 PD6, OK3H PD50, 
BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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Figure 6-16. Fold change in pellet DNA content. Absolute DNA quantities determined by PicoGreen 
assay were used to calculate fold change in DNA content at day 20 relative to day 0 levels. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
 
Figure 6-17. Cellular material on microcentrifuge tubes. Photographs of 1.5 mL microcentrifuge tubes 
illustrating the formation of cellular material after 20 day culture in MM or PChM and magnification under 
brightfield microscopy. Cells are stained with haematoxylin for visualisation. Scale bar=500 µm. 
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6.4.6 Pellet sGAG normalised to DNA 
Normalisation of pellet associated sGAG to DNA had little effect on the trends previously 
observed across OK3, OK3H, BMA13 and BMA13H for absolute sGAG levels. In PChM BMA13 
remained the highest sGAG producer at 2.23 ± 0.31 µg/µg followed by OK3 at 1.87 ± 0.41 µg/µg 
and lastly 1C6 at 1.13 ± 0.29 µg/µg. OK3H and BMA13H were reduced in comparison at 
1.45 ± 0.03 µg/µg and 0.46 ± 0.14 µg/µg respectively (Figure 6-18). Again as with absolute level 
these values were significantly higher than those obtained for pellets cultured in MM with the 
difference greatest in BMA13 at 2.68 fold higher (p≤0.001) followed by OK3 at 2.68 fold higher 
(p≤0.001), OK3H at 1.69 fold higher (p≤0.0001) and BMA13H not significantly different (Figure 
6-19). 
Post-normalisation 1C6 and 1C6H cell pellets cultured in PChM were no longer significantly 
different to MM pellet cultures (0.97 and 0.97 fold differences respectively), and most strikingly 
normalised levels in 1C6H were similar to 1C6 levels at 1.20 ± 0.15 µg/µg and 1.16 ± 0.03 µg/µg 
and in MM and 1.18 ± 0.08 µg/µg and 1.13 ± 0.29 µg/µg in PChM. 
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Figure 6-18. Pellet associated sGAG normalised to DNA content. sGAG associated with cell pellets 
was normalised to DNA of the same pellets to give a μg/μg ratio at day 0 and day 20 for all cell types after 
culture in MM or PChM. Data are expressed as mean ± standard deviation, N=3, *p≤0.05, **p≤0.01, 
***p≤0.001, ****p≤0.0001. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H 
PD16, 1C6 PD36, 1C6H PD86. 
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Figure 6-19. Fold change in normalised pellet associated sGAG. sGAG was normalised to DNA 
(µg/µg) and expressed as fold change at day 20 relative to day 0. PD level for cells was as follows: OK3 PD6, 
OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
6.4.7 Media sGAG normalised to pellet DNA 
Likewise normalisation of media sGAG generally had little effect on the trends and differences 
noted with absolute media sGAG levels (Figure 6-20) with the exception of OK3, where results 
following normalisation were then similar to each other and to previous monolayer results, with 
significantly more sGAG in MM than PChM cultures for both OK3 and OK3H at 2.5 fold more 
(p≤0.04) and 3.6 fold more (p≤0.001) respectively. 
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Figure 6-20. Media sGAG normalised to pellet DNA. sGAG associated with spent cell culture media 
was normalised to DNA of the corresponding pellets to give a μg/μg ratio at day 20 for all cell types after 
culture in MM or PChM. Data are expressed as mean ± standard deviation, N=3, *p≤0.05, ***p≤0.001. PD 
level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
6.4.8 Total normalised sGAG 
When normalised pellet associated and media associated values are considered together (Figure 
6-21) the day 20 data show similar trends to the absolute data. Total normalised values are 
highest in OK3 and OK3H with greater normalised sGAG in MM (OK3 11.93 µg/µg, OK3H 
11.47 µg/µg) than in PChM (OK3 6.27 µg/µg, OK3H 4.31 µg/µg). The higher levels total levels in 
MM are again due to the larger contribution from the media associated fraction, this contribution 
may also appear higher once normalised as total sGAG throughout the experiment is normalised 
to the final DNA amount, which in MM decreases significantly from day 0 values. Further 
temporal investigation would be required to more clearly determine changes throughout the 
whole experimental time period. Across the other cell types although the media contribution is 
much lower than for OK3 and OK3H, with the exception of BMA13, MM cultures still have higher 
total sGAG than PChM cultures with levels in MM of 2.62 µg/µg in 1C6H, 2.60 µg/µg in 1C6, 
0.993 µg/µg in BMA13H and 0.927 µg/µg in BMA13. PChM cultures had total normalised sGAG 
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values of 1.17 µg/µg for 1C6H, 1.67 µg/µg for 1C6,0.624 µg/µg for BMA13H and 2.32 µg/µg for 
BMA13 with this almost entirely as a result of the pellet associated fraction. 
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Figure 6-21. Total normalised sGAG at day 20. Day 20 summary of total normalised sGAG with both 
pellet and media contribution at day 20.  Data are expressed as mean ± standard deviation, N=3, *p≤0.05, 
***p≤0.001, ****p≤0.0001. Black asterisks indicate significance between pellet associated sGAG; grey 
asterisks indicate significance between media associated sGAG. PD level for cells was as follows: OK3 PD6, 
OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
6.4.9 Gene expression  
Relative gene expression was determined by qRT-PCR for ECM protein genes COL1A2, COL2A1, 
COL3A1, COL6A3, COL10A1, ACAN, COMP and transcription factor SOX9. Following initial analysis 
it was apparent that basal levels of expression were often somewhat different in the transduced 
cells in comparison to the parental cells therefore expression was determined both relative to the 
parental cell type day 0 MM control for all parental and transduced groups, and separately for 
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transduced cells relative to the transduced day 0 MM sample using REST-2009 software which 
also provides the error range and the statistical significance determined by a randomisation 
algorithm242.  
To determine similarities in gene expression profiles across all of the genes examined hierarchical 
clustering was performed using Gene Cluster3.0 and visualised with Java TreeView with relative 
gene expression changes determined for each cell type relative to day 0 MM sample for that cell 
type. Clustering was first considered within cell type (Figure 6-22), then between transduced and 
non-transduced within cell-type (Figure 6-23) and finally across all results (Figure 6-24), 
correlation coefficients for all clusters of both samples and genes are listed in Table 6-1. 
Day 0 correlations between groups were poor with only low correlation indicating a degree of 
variability across samples possibly as a result of rapid gene expression changes induced while 
pellets were being prepared, when cells were exposed to either MM or PChM for approximately 
30 minutes before lysis. Within each cell type the two day 20 results from both MM and PChM 
clustered most closely with each other and not with either day 0 result indicating similarities in 
expression patterns induced by pellet formation and culture irrespective of whether this was in 
MM or PChM. The correlation was strongest (i.e. the expression pattern was most similar) in 
OK3H (0.967879) followed by OK3 (0.949404), 1C6H (0.939310), 1C6 (0.887813), and BMA13 
(0.766945), the exception to this was BMA13H where there were only weak correlations between 
all groups (≤0.204302) indicating very dissimilar gene expression after culture in either MM or 
PChM.  
Clustering of pellets from transduced and parental cells together showed that expression after 
culture in either MM or PChM for OK3/OK3H and 1C6/1C6H remained more likely to be clustered 
within rather than between cell types at day 20 indicating the differences between the gene 
expression patterns of the paired cell types were greater than the differences induced within a 
cell types by culture in MM or PChM despite their shared origin. In contrast BMA13 and BMA13H 
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day 20 PChM clustered with a correlation of 0.800285, indicating a similar response to a pro-
chondrogenic environment; BMA13H day 20 MM was distinctly different with a weak negative 
correlation with all other clusters (-1.92969). Again, although there were strong paired 
correlations in gene expression across the groups there were no particular common trends in 
gene clustering. 
Finally all groups were compared simultaneously (excluding day 0 MM for clarity as this is 
inherently defined as unchanged by the 2-ΔΔCT method and did not cluster strongly with any other 
group when included), this also provides the strongest information for gene clustering analysis as 
all changes are included. When all groups were considered together day 0 values were in general 
poorly correlated with day 20 with the exception of BMA13H and BMA13 day 20 MM cultures 
indicating distinct differences following pellet formation and culture. OK3H and 1C6H day 20 
remained strongly correlated independent of culture in MM or PChM. However, the gene 
expression changes in the two primary cell types OK3 and 1C6 correlated more highly with each 
other when cultured in both MM and PChM (0.961132 in MM and 0.955835 in PChM) than with 
the same cell type in both MM and PChM indicating strong similarities in expression patterns 
between the two cell types.  
 
 
 
 
  
 
Figure 6-22. Heatmaps of relative gene expression.  Hierarchical clustering to determine correlations in expression patterns was performed for each cell type across 
all genes. (A) OK3, (B) BMA13, (C) 1C6, (D) OK3H, (E) BMA13H, (F) 1C6H. Red indicates upregulated genes, green downregulated genes and black no change in expression. 
All expression changes are determined relative to the day 0 MM condition. The closer the dendrogram cluster pair indicator to the heatmap the stronger the correlation in 
gene expression. PD level of cells as as follows: OK3 PD6, OK3H PD50, BMA13 PD1, BMA13H PD18, 1C6 PD36, 1C6H PD107. 
  
 
Figure 6-23. Heatmaps of relative gene expression. Hierarchical clustering to determine correlations in expression patterns was performed for each parental and 
transduced cell pair across all genes. (A) OK3/OK3H, (B) BMA13/BMA13H, (C) 1C6/1C6H. Red indicates upregulated genes, green downregulated genes and black no change 
in expression. All expression changes are determined relative to the day 0 MM condition. PD level of cells as as follows: OK3 PD6, OK3H PD50, BMA13 PD1, BMA13H PD18, 
1C6 PD36, 1C6H PD107. 
 
  
 
 
Figure 6-24. Complete gene expression hierarchical clustering dendrograms and heatmap. Samples (excluding the day 0 MM) were subjected to hierarchical 
clustering to find between sample group correlations in expression patterns. Red indicates upregulated genes, green downregulated genes and black no change in 
expression. All expression changes are determined relative to the day 0 MM condition. Each cluster is assigned a number or letter and the corresponding correlation 
coefficients are listed in Table 6-1. PD level of cells as as follows: OK3 PD6, OK3H PD50, BMA13 PD1, BMA13H PD18, 1C6 PD36, 1C6H PD107. 
224 
 
Table 6-1. Dendrogram clustering correlation coefficients. Each cluster (referred to as a node in the 
software) has been assigned a letter or a number and the corresponding correlation coefficients reported 
by Cluster 3.0 are listed. (A) Sample clustering dendrogram information, (B) Gene clustering dendrogram 
information. Coefficients are listed in decreasing numerical order, i.e. strongest positive correlation first. 
 
 
A more detailed analysis of the PCR data is presented in the form of the box and whisker plots of 
up- and down regulation of genes in Figure 6-25 OK3, Figure 6-26 OK3H, Figure 6-27 BMA13, 
Figure 6-28 BMA13H, Figure 6-29 1C6 and Figure 6-30 1C6H.  
When gene expression in the transduced cells day 0 MM expression was relative to the parental 
day 0 MM media there were differences apparent in the basal expression levels, particularly in 
OK3H compared to OK3 where 4 genes were expressed at levels > 2 fold higher (COL1A2, COL3A1, 
COL6A3, ACAN) with 2 of these (COL3A1 and ACAN) being deemed significant at p≤0.05. Similarly, 
1C6H day 0 MM had upregulation in comparison to OK3 day 0 MM in all 8 genes with significant 
upregulation in COL1A2, COL2A1, COL3A1, ACAN, COMP and SOX9. As such all determinations of 
gene expression changes were expressed relative to the specific cell type day 0 MM to establish 
changes due to intervention not inherent differences post transduction. 
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At day 20 of the 96 expression changes determined a majority of 60% (67) were upregulations 
with 76% (51) of these being statistically significant (p≤0.05), of the remaining 30% (29) 
downregulations 45% (13) were statistically significant. Significant downregulation was almost 
exclusively seen in the MSCs BMA13 and BMA13H where for BMA13 MM 6 genes were 
downregulated, 3 significantly (COL2A1, COL3A1 and ACAN), and for BMA13H MM all 8 genes 
were downregulated, all but ACAN significantly so. ACAN was also significantly downregulated in 
BMA13 cultured in PChM. Otherwise only COL2A1 was significantly downregulated in 1C6H in 
both MM and PChM. 
Of the upregulated expression changes at day 20 all eight genes examined were most upregulated 
in either the primary chondrocytes OK3 (COL1A2 8.9 fold, COL3A1 39.5 fold, COL10A1 1272 fold, 
ACAN 11.47 fold) or the transduced chondrocytes OK3H (COL2A1 49.52 fold, COL6A3 12.73 fold, 
COMP 8135 fold, SOX9 133.1 fold).  
BMA13 and BMA13H cultures showed the greatest variation in gene expression as a result of 
culture PChM compared to MM. In contrast for OK3/OK3H and 1C6/1C6H several genes were 
found to be significantly upregulated in either MM or PChM as indicated in  
Figure 6-31. 
 
 
 
 
 
  
Figure 6-25. Box and whisker plots of relative gene expression in OK3 cell pellets. Changes in gene expression were determined using the 2CT with expression 
relative to the day 0 MM sample. The box represents the interquartile range, the whiskers the outer quartiles and the line the median expression. N=3x3 pellets, *p≤0.05. 
Cells were used at PD6. 
  
Figure 6-26. Box and whisker plots of relative gene expression in OK3H cell pellets. Changes in gene expression were determined using the 2CT with expression 
relative to the day 0 MM sample. The box represents the interquartile range, the whiskers the outer quartiles and the line the median expression. N=3x3 pellets, *p≤0.05. 
Cells were uused at PD50. 
  
Figure 6-27. Box and whisker plots of relative gene expression in BMA13 cell pellets. Changes in gene expression were determined using the 2CT with 
expression relative to the day 0 MM sample. The box represents the interquartile range, the whiskers the outer quartiles and the line the median expression. N=3x3 pellets, 
*p≤0.05. Cells were used at PD1. 
  
Figure 6-28. Box and whisker plots of relative gene expression in BMA13H cell pellets. Changes in gene expression were determined using the 2CT with 
expression relative to the day 0 MM sample. The box represents the interquartile range, the whiskers the outer quartiles and the line the median expression. N=3x3 pellets, 
*p≤0.05. Cells were used at PD18. 
  
Figure 6-29. Box and whisker plots of relative gene expression in 1C6 cell pellets. Changes in gene expression were determined using the 2CT with expression 
relative to the day 0 MM sample. The box represents the interquartile range, the whiskers the outer quartiles and the line the median expression. N=3x3 pellets, *p≤0.05. 
Cells were used at PD36. 
  
Figure 6-30. Box and whisker plots of relative gene expression in 1C6H cell pellets. Changes in gene expression were determined using the 2CT with expression 
relative to the day 0 MM sample. The box represents the interquartile range, the whiskers the outer quartiles and the line the median expression. N=3x3 pellets, *p≤0.05. 
Cells were used at PD107. 
  
Figure 6-31. Genes upregulated in both MM and PChM. Venn diagrams of genes statistically significantly upregulated (p≤0.05) in OK3 (A), BMA13 (B), 1C6 (C), OK3H 
(D), BMA13H (E), and 1C6H (F) in MM and PChM, overlap indicates genes upregulated in common in both MM and PChM. All expression changes are determined relative to 
the day 0 MM condition. The condition in which upregulation had a greater magnitude indicated in parentheses for common genes.  
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6.4.10 Pellet histology 
6.4.10.1 Haematoxylin and eosin staining 
H and E staining was first performed on porcine articular cartilage tissue sections shown in Figure 
6-32. The cartilage tissue had variation in the depth of colour obtained from eosin staining 
depending on the cartilage tissue zone. 
 
 
Figure 6-32. H and E staining of porcine articular cartilage. Brightfield micrographs of 10 µm 
sectioned porcine articular cartilage stained with H and E to illustrate normal articular cartilage structure. 
Full depth cartilage is illustrated in (A), the superficial and upper middle zone in (B), the middle zone in (C) 
and the deep zone in (D). Scale bar=250 µm (A), 50 µm (B), (C) and (D). 
Pellet tissue sections were then stained for all pellets in both MM and PChM at day 1 (allowing 
approximately 24 hours for pellet formation) and day 20 (Figure 6-33). 
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Figure 6-33. H and E staining of pellets at day 1. Brightfield micrographs of H and E stained 10 µm 
sections of pellets after 24 hours cultured in MM or PChM. Scale bar=100 µm. PD level for cells was as 
follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
 
By day 1, immediately following pellet formation, differences in cell morphology could be seen 
following H and E staining with the appearance of elongated cells at the periphery of pellets, 
especially in BMA13, and more rounded cells within the pellet cores (Figure 6-34A). As a result of 
pellets forming via folding rather than overall contraction of the mass around the centre it was 
possible for these more elongated cells to be folded into the pellet centre (Figure 6-34B). At this 
early stage there were no overt differences in the appearance of pellets cultured in MM or PChM. 
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Figure 6-34. H and E staining.  Brightfield micrographs of elongated cells (arrows) at the periphery of 
pellets at day 1 (A) Scale bar = 50 µm, (B) scale bar = 100 µm. 
 
By day 20 H and E staining showed clear differences between pellets cultured in MM compared to 
PChM that were most apparent in OK3 and BMA13 primary cell pellet cultures (Figure 6-35). OK3 
pellets cultured in MM were very small and had minimal staining of a continuous intercellular 
ECM with the exception of a region around the edge of the pellet. BMA13 also had minimal 
intercellular staining; additionally the pellets were poorly integrated appearing friable and prone 
to splitting during sectioning. In contrast, culture of OK3 in PChM led to the production of a more 
continuous ECM with a reduced cell density particularly towards the centre of the pellet. BMA13 
on the other hand had clear regional variation in ECM and cell morphology with a more 
cartilaginous appearance in a broad peripheral band encompassing around half the visible area 
with cells sometimes located in lacuna-like structures and at a much reduced cell density. Cells 
located more centrally were smaller and more numerous with no evidence of lacuna 
development. 
OK3H and BMA13H in MM at day 20 were similar in appearance to day 1; culture in MM was less 
detrimental to the overall formation of pellets than with the corresponding primary cells. 
However, the changes seen in primary cells in PChM were also less apparent in the transduced 
cells. 1C6H pellets, in contrast to the other transduced cell pellets, were very small with only 
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minimal intercellular matrix apparent in both MM and in PChM, pellets had a spongy or porous 
appearance with considerable amounts of discontinuity in the ECM, with the exception of a 
narrow peripheral band or capsule encompassing the pellet. 
  
 
Figure 6-35. H and E staining of pellets at day 20. Brightfield micrographs of H and E stained 10 µm 
sections of pellets after 20 days cultured in MM or PChM. Scale bar=100 µm. PD level for cells was as 
follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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6.4.10.2 Picrosirius red staining 
Picrosirius red staining was first performed on porcine articular cartilage and tendon sections as 
shown in Figure 6-36. Picrosirius red results in red staining where collagen is present on a yellow 
background as a result of the picric acid content. Cartilage tissue stained relatively uniformly 
throughout for collagen with no obvious fibre formation whilst tendon had strong collagen 
alignment with a wave-like pattern highlighted by staining as expected. 
 
 
Figure 6-36. Picrosirius red staining of porcine cartilage and tendon. Brightfield micrographs of 10 
µm tissue sections of porcine cartilage superficial and middle (A) and deep and calcified (B) zones and 
tendon tissue illustrating the strong collagen alignment. Scale bar=100 µm. 
 
Pellet sections were then stained for all pellets following culture in both MM and PChM at day 1 
(Figure 6-37) and at 20 days (Figure 6-38). At day 1, after 24 hours of culture there was some 
evidence of collagen fibre formation in most of the sections. Although for the most part the fibres 
remained small imbuing sections with a pinkish hue there were also regions of intensely red 
positive staining indicating very rapid changes within the cells leading to patchy collagen synthesis 
by day 1 staining. By day 20 all pellets cultured in MM still stained only weakly for collagen with 
the exception of 1C6 where staining intensity was of a similar level to that of pellets cultured in 
PChM. All primary cell pellets cultured in PChM stained strongly for collagen throughout the 
pellet, tending to be stronger and more fibrous at the periphery. None of the sections had the 
smooth/uniform appearance found in articular cartilage with all having some degree of fibrous 
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staining as collagen surrounded the cell lacunae. This was particularly apparent in the BMA13 
PChM pellets where staining was highly heterogeneous with strong regional variation in the pellet 
appearance and contrasted with OK3 where staining was much more uniform but still obviously 
surrounding lacunae. Transduced cell pellets all stained more weakly for collagen than the 
corresponding parental cell pellet. 
Images of picrosirius red stained sections were also acquired under cross polarised light (Figure 
6-39). Samples under cross polarised light are only visible if birefringent material is present, i.e. 
organised collagen fibres; picrosirius red staining enhances this and the resulting birefringent 
fibres are coloured according to their size and degree of organisation. Large highly organised 
fibres result in orange/red images with increasingly smaller and less organised fibres showing 
yellow and then green. 
Images obtained under polarised light show more clearly the trends in collagen deposition. 
BMA13 in PChM contains large amounts of large organised fibres encapsulating the pellet with 
smaller fibres in the centre. 1C6 also has considerable birefringence; however, there were fewer 
orange/red fibres and an increased number of green fibres indicative of a finer collagen network. 
OK3 had little evidence of central collagen fibre organisation but did have a relatively narrow 
band of encapsulation. Transduced pellets clearly contained much less organised collagen fibres 
then primary pellets with only minimal birefringence apparent. 
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Figure 6-37. Picrosirius red collagen staining at day 1. Brightfield micrographs of picrosirius red 
stained 10 µm sections of pellets at day 1 after 24 hours culture in MM or PChM. Scale bar=100 µm. PD 
level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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Figure 6-38. Picrosirius red collagen staining at day 20.Brightfield micrographs of picrosirius red 
stained 10 µm sections of pellets at day 20 cultured in MM or PChM. Scale bar=100 µm. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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Figure 6-39. Picrosirius red cross-polarised light collagen staining at day 20. Cross-polarised light 
micrographs of picrosirius red stained 10 µm sections of pellets at day 20 cultured in MM or PChM. Scale 
bar=250 µm. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 
1C6H PD86. 
 
 
 
  
242 
 
6.4.10.3 Toluidine blue staining  
Toluidine blue staining was first performed on porcine articular cartilage and E11 chick femur 
sections as shown in Figure 6-40. Toluidine blue is a metachromatic stain that results in purple 
staining where sGAG is present with blue staining of background structures e.g. nuclei. Cartilage 
stained strongly purple throughout with blue nuclei still visible within lacunae. The metachromatic 
nature of toluidine blue is best shown in the chick femur where only regional production of sGAG 
in areas that are undergoing endochondral ossification is apparent.  
 
 
Figure 6-40. Toluidine blue staining of porcine cartilage and E11 chick femur. Brightfield 
micrographs of 10 µm tissue sections of porcine cartilage superficial and middle (A) and deep and calcified 
(B) zones and E11 chick femur tissue illustrating metachromatic toluidine blue staining. Scale bar=100 µm. 
 
Pellet sections were then stained for all pellets in both MM and PChM at day 1 (Figure 6-41) and 
after 20 (Figure 6-42) days of culture in MM or PChM. 
At day 1 there was no overt metachromatic staining apparent in any cell pellet. After 20 days in 
MM there was no staining in BMA13 pellets, some staining peripherally in OK3 and faint diffuse 
staining of 1C6. In contrast pellets cultured in PChM had increased metachromatic staining; this 
was apparent throughout the pellet ECM in OK3 pellets with some regions with slightly stronger 
metachromatic staining, more zonally, but more intensely in BMA13 and throughout 1C6 although 
only relatively weakly. Strongly stained regions in BMA13 coincided with the regions that also 
stained strongly for collagen with picrosirius red. Staining of transduced cell pellets was again 
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reduced in comparison to parental cell pellets. These staining results are in agreement with sGAG 
quantification by DMMB assay.  
 
 
Figure 6-41. Toluidine blue sGAG staining at day 1. Brightfield micrographs of toluidine blue stained 
10 µm sections of pellets at day 1 cultured in MM or PChM. Scale bar=100 µm. PD level for cells was as 
follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86.  
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Figure 6-42. Toluidine blue sGAG staining at day 20. Brightfield micrographs of toluidine blue stained 
10 µm sections of pellets at day 20 cultured in MM or PChM. Scale bar=100 µm. PD level for cells was as 
follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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6.4.11 Pellet immunohistochemistry 
6.4.11.1 Tissue controls 
Antibodies against collagen I, collagen II, collagen VI, collagen X and aggrecan were first tested on 
positive control tissue samples with immunoperoxidase staining (Figure 6-43). All tissue samples 
were positive for the tested antibody and no non-specific staining was seen on any of the 
secondary antibody only negative controls. 
  
 
Figure 6-43. Positive control antibody staining. Positive controls for immunoperoxidase antibody 
staining using collagen I staining of porcine tendon (A), collagen II staining of porcine cartilage (B), collagen 
VI staining of porcine cartilage (C), collagen X staining of E11 chick femur (D) and aggrecan staining of 
porcine cartilage (E). (A), (B), (C) and (E) are brightfield images; (D) is taken under phase contrast to view 
unstained regions. Cartilage sections are oriented with the articular surface at the top of the image. 
 
Pellet sections were then stained with the all of the above antibodies. For all stains a negative 
control with the secondary antibody only were performed on the same slide for all samples and a 
positive tissue control was included. Again, there was no evidence of any non-specific staining 
when the primary antibody was omitted from the staining protocol. 
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Type I collagen staining in primary cell pellets (Figure 6-44) appeared to be slightly stronger 
following culture in MM compared to PChM with slightly stronger staining at the pellet periphery 
compared to the interior. Both OK3H and 1C6H barely stained for collagen type I; however, it was 
present with strong staining through BMA13H pellets in both MM and PChM. 
 
 
Figure 6-44. Collagen I day 20 immunoperoxidase staining. Representative brightfield images of 
collagen I immunoperoxidase stained sections of all pellets at day 20. Scale bar=100 µm. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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All pellets were positive to some extent for type II collagen (Figure 6-45). Interestingly ECM 
staining for collagen II was most apparent in OK3 MM cultures, these cultures also had 
significantly upregulated COL2A1 when assessed using qRT-PCR. In other pellets the staining 
tended to be more localised to the cells and was more evident as a thin band at the periphery of 
the pellets. 
 
 
Figure 6-45. Collagen II day 20 immunoperoxidase staining. Representative brightfield images of 
collagen II immunoperoxidase stained sections of all pellets at day 20. Scale bar=100 µm. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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All primary cell pellets, with the exception of BMA13 in MM, stained strongly for collagen VI 
throughout the pellet (Figure 6-46). There generally appeared to be more abundant staining in 
PChM cultures than in MM although OK3 had strong positive staining throughout in MM. Pellets 
made with transduced cells again stained more weakly than the parental cell pellets particularly in 
1C6H cultures. Interestingly some staining patterns were evident, for example in 1C6 MM, that 
could also be seen with the generalised picrosirius red collagen staining. 
 
 
Figure 6-46. Collagen VI day 20 immunoperoxidase staining. Representative brightfield images of 
collagen VI immunoperoxidase stained sections of all pellets at day 20. Scale bar=100 µm. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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Regional collagen X staining (Figure 6-47) could be seen in primary cell pellets cultured in MM, 
particularly so in BMA13. In comparison PChM cultures had less collagen X staining that was more 
localised to cells although again this was most apparent in BMA13 cultures. The transduced cells 
overall stained less positively for collagen X with little difference between MM and PChM but 
within this group staining also seemed strongest in the BMA13H MSC group.  
 
 
 
Figure 6-47. Collagen X day 20 immunoperoxidase staining.  Representative brightfield images of 
collagen X immunoperoxidase stained sections of all pellets at day 20. Scale bar=100 µm. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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In accordance with previous toluidine blue staining and DMMB quantification of sGAG, aggrecan 
staining (Figure 6-48) was most prominent in OK3 and BMA13 pellets following culture in PChM. 
As with toluidine blue staining in OK3 was present throughout the pellet and with BMA13 
faithfully mirrored the distinct regions where toluidine blue staining was observed. Similarly with 
OK3 cultured in MM there was a band of positive staining peripherally. Staining was much less 
apparent and more diffuse in 1C6 pellet cultures. Staining was reduced in comparison in 
transduced cells, being almost entirely absent in BMA13H cultures  
 
Figure 6-48. Aggrecan day 20 immunoperoxidase staining. Representative brightfield images of 
aggrecan immunoperoxidase stained sections of all pellets at day 20. Scale bar=100 µm. PD level for cells 
was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6 PD36, 1C6H PD86. 
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 Discussion 6.5
The adoption of a 3D culture format has several benefits including the re-creation of an in vitro 
milieu more reminiscent of the in vivo situation of cells, particularly as experienced during pre-
cartilaginous condensations. It is associated with increased cell-cell contacts, has the potential to 
create dynamic morphogenetic gradients-including with oxygen and nutrients, a reduced 
influence from an artificial substrate- usually tissue culture plastic, and the benefit of reducing de-
differentiation in chondrocytes in vitro, the application for which pellet culture systems were 
initially used382. This work explored the use of a 3D pellet culture system to further extend the 
assessment of chondrogenesis carried out in Chapter 5 on the three primary cell types and the 
telomerised cell lines.  
The formation of stable pellets with a significant increase in a cartilage-like ECM was identified 
only in the three primary cell types and there was a strong requirement for pro-chondrogenic 
conditions. Biochemical analysis of the sGAG content of pellets in PChM found that this was 
approximately equal in both chondrocytes and MSCs whilst being somewhat lower in hESC 
derived cells. In contrast to monolayer cultures increases in sGAG were entirely attributable to 
increased sGAG synthesis not cell proliferation as there were no significant changes in DNA 
content in PChM. Despite this biochemical equivalence, gene expression analysis showed that 
MSCs rapidly down-regulated genes associated with chondrogenesis and produced a 
heterogeneous and fibrous tissue in comparison to chondrocytes where collagen fibres were 
small and sGAG deposition more widespread. hESC derived 1C6 cells produced an intermediate 
tissue type with features of both the chondrocytes and MSCs although gene expression 
similarities to chondrocytes rather than MSCs suggest that they may have the capacity to undergo 
a more sustained period of chondrogenesis compared to the bone marrow MSCs. Transduced cell 
chondrogenic responses were all considerably reduced in comparison to primary cells; however, 
interestingly the 3D environment elicited the greatest chondrogenic response amongst the 
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transduced cells in OK3H whereas no positive response was previously seen in 2D culture as 
shown qualitatively in Chapter 4 and quantitatively in Chapter 5.  
All of the cells used in this study, whether primary or transduced readily formed cell pellets, the 
formation of pellets at early stages was observed in both MM and PChM at approximately equal 
speeds, this is in contrast to results reported by Johnstone et al where MSC pellets did not 
properly aggregate in a standard MM (DMEM 10% (v/v) FBS)382; however, that study used rabbit, 
rather than human bone marrow derived cells. Pellets from all cells were consistently significantly 
larger at day 20 after culture in PChM rather than MM although overall pellets in both conditions 
were smaller at day 20 compared to day 1. The cause of the changes in the sizes of the pellets 
seemingly varied depending upon culture media condition. In MM pellets became much smaller 
and generally less dense, concomitant with this was a significant decrease in pellet DNA content 
indicating that the reduction in size was due to a loss of pellet material, or disaggregation, over 
the course of the experiment. This material may in turn have contributed to the sGAG media 
associated fraction which was often higher in MM. In the absence of a pro-chondrogenic stimulus 
standard MM, even inclusive of FBS, was able to support neither long-term pellet stability nor cell 
proliferation. This was particularly the case for 1C6H cells which experienced dramatic shrinkage 
and greatly reduced DNA in both MM and PChM. This can be attributed to the hTERT transduction 
and/or subsequent cell expansion as 1C6 cells readily formed pellets in the same MM condition. 
Interestingly 1C6 pellets in MM were much more stable than those of OK3 and BMA13 this may 
be a specific feature inherent to these cells; alternatively, it may also be a result of the different 
MM formulation used for the hESC-derived cells in comparison to the chondrocytes and MSCs. 
1C6 and 1C6H were cultured routinely in MM consisting of KO-DMEM rather than DMEM, and 
media was supplemented with 100 mM dexamethasone as per their previous culture condition 
following initial isolation. Dexamethasone is included in PChM for all cells and is effective in 
promoting chondrogenesis in MSCs when paired with TGF-β386.  
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In contrast to MM, PChM cultures generally had a relatively static or slightly reduced DNA content 
concomitant with increased density indicating that pellets continued to contract beyond the day 1 
size. Although ongoing cell proliferation is sometimes reported during pellet chondrogenesis387 it 
would not be unusual for proliferation to cease388, as appeared to be the case in this study. As the 
media DNA content was not determined further experiments, e.g. bromodeoxyuridine staining, 
would be needed to confirm a lack of proliferation rather than a balance of cell proliferation and 
loss.  
Changes in pellet sGAG in MM also generally correlated with changes in size, density and DNA 
content and by day 20 MM cultured pellets all contained significantly less sGAG than PChM pellets 
with the exception of BMA13H where the difference was not significant. In contrast pellets in 
PChM, in the case of primary pellets had significantly increased sGAG, and in the case of OK3H 
and BMA13H maintained day 0 sGAG levels. 1C6H pellets, as with DNA, had significantly less sGAG 
demonstrating that 1C6H pellet culture is unsupportable in the long term in either MM or PChM. 
OK3 and BMA13 pellets cultured in PChM in particular also proved to be extremely difficult to 
disaggregate for RNA analysis even with the application of mechanical force and chemical 
dissociation, indicating a large increase in the biomechanical properties of the aggregates.  
Quantification with DMMB showed that both the OK3 and BMA13 pellets in PChM had similar 
sGAG levels at the conclusion of the experiment; however, further histological analyses showed 
distinct differences between the pellets formed. In particular culture of OK3 in PChM resulted in 
relatively homogeneous deposition of sGAG, aggrecan and collagen with evidence of fibrous 
tissue mainly restricted to the pellet surface. BMA13 on the other hand was clearly stained very 
heterogeneously for sGAG, aggrecan and collagen with strong positive staining around the 
periphery of the pellet and minimal staining in the centre. It should be noted that the peripheral 
staining of BMA13 was not uniform as was the case with the fibrous encapsulation of the OK3 
pellets. Instead the staining appeared as a broad semi-circular band of staining which was then 
connected with a narrower band. Regional variations in staining of pellets have previously been 
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attributed to biochemical gradients, of for example nutrients or oxygen that results in a nutrient 
deficient or hypoxic core. In various circumstances the creation of a hypoxic core has been 
described as either beneficial389 due to the positive effects of hypoxia on chondrogenesis or 
detrimental when a necrotic region has formed390.  
The pattern of staining seen in this work is reminiscent of the curve of the cell pellet formed by 
the initial centrifugation step that was very clear when pellets were subjected to µCT analysis. As 
noted, the cells on the periphery of centrifuged pellets can become elongated in comparison to 
those in the bulk; these peripheral cells are then folded into the central mass of the pellet as it 
becomes more spherical. It is possible that these early differences in cell phenotype result in the 
elongated external cells behaving differently than the central mass cells even after their 
relocation within the pellet. Changes such as elongation in cells can be induced by the higher 
tension at the periphery of masses and are mediated by changes in the cell cytoskeleton; these 
changes can induce significant downstream effects on cell behaviour including influencing cell 
differentiation. Higher stresses can influence MSCs such that they are directed more towards the 
osteogenic lineage391, a tendency which the cells already appear to have innately. Studies where 
centrifuged cells are compared to naturally aggregated micromasses generally report more 
optimal results in the micromasses indicating that the centrifugation technique impacts on the 
subsequent cell biology even within the same population392,393. The overall result of this is that 
while biochemical cues remain important cells are also receiving potentially competing cues as a 
result of mechanical forces and spatial patterning. The results herein suggest that MSCs are more 
sensitive than the chondrocytes to these competing cues, probably due to their multipotent 
nature. As this was well beyond the scope of this thesis this suggested effect of spatial or 
mechanical patterning could not be investigated to any great extent. However, a preliminary 
experiment showed that an increase in BMA13 pellet size resulted in strikingly similar patterns of 
sGAG staining to at least a similar proportion of the pellet (Supplementary figure 2) indicating the 
unlikelihood of BMA13 pellet heterogeneity being a simple morphogen gradient mediated effect. 
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Gene expression data should be interpreted with several caveats in mind. Firstly the expression is 
representative of only a single time point. In this case day 20 was chosen as chondrogenesis 
should be well established and markers of hypertrophy, especially relevant to MSCs, should be 
becoming apparent if they are being expressed. Secondly mRNA levels are not necessarily 
representative of protein levels due to variations in translation, accumulation and 
degradation394,395. Indeed the protein may not be expressed at all and if it is, its activity regulated 
by many other factors. Nevertheless expression data can be informative particularly where 
sample availability is limited.  
Overall the gene expression data was quite variable with large error bars; however, this may be 
due to the mRNA contribution to the total mRNA pool of the cells that adhered to the walls of the 
microcentrifuge tubes. These cells appeared after some time in culture and represent an adherent 
population potentially undergoing chondrogenesis at a different rate or not at all. It should also 
be noted that as is vastly more common, relative expression analysis using the 2-ΔΔCT calculation 
was performed, if baseline gene expression is already elevated e.g. from hypoxic culture then 
changes in expression may be less apparent. For future studies the adoption of absolute 
quantification strategies should be considered particularly when some genes may be present in 
very low abundance e.g. COL10A1 which was at the limits of detection in this study in some 
starting samples. When relative upregulation of these genes is calculated large changes are seen 
even where the absolute abundance may be low. 
The gene expression data for the OK3 chondrocytes and hESC derived 1C6 was in general 
agreement with the histological staining and hierarchical clustering revealed that the two cell 
types had similar patterns of expression although changes in expression levels overall were much 
lower in 1C6. In both of these cell types the genes under consideration were often also 
upregulated in the MM condition although to a lesser extent most probably indicating that cells 
are responding to the transfer to 3D culture; however, other results indicate that this is 
insufficient to produce significant cartilage tissue. Perhaps most significantly SOX9 expression was 
256 
 
still upregulated in these cell types at day 20 suggesting a capacity for continued chondrogenesis 
with increased time in culture. 
In contrast BMA13 had significant down-regulation of SOX9 at day 20 and therefore the 
associated suppression of the endochondral ossification pathway. Most other chondrogenic genes 
were also down-regulated at this time point, including aggrecan for which strong positive staining 
was seen histologically. This, along with upregulation of COL1A2 and COL10A1 suggests that the 
BMA13 cells had progressed rapidly through the chondrogenic phase and were becoming 
hypertrophic in accordance with the progression of endochondral ossification. Pellet culture of 
MSCs has previously been shown to reduce the expression of hypertrophy markers but does not 
remove them completely376.  
The limited ability of all of the cell types described herein to form cartilaginous tissue in the 
absence of adequate pro-chondrogenic stimuli may be one explanation for the variable outcomes 
from clinical trials. Following implantation the complex milieu of the in vivo environment may not 
provide adequate or appropriate cues for cells to initiate and sustain chondrogenesis, or may 
even be ‘hostile’ due to hypoxia, inflammation, and high mechanical forces; in this eventuality the 
results described here, particularly for cells in MM, strongly suggest that the cells are unlikely to 
undergo successful chondrogenesis even where they may have exhibited that capacity in more 
pro-chondrogenic conditions. Liu et al396 assessed the ability of an extended in vitro culture period 
in pro-chondrogenic conditions to promote the maintenance of a cartilaginous tissue type in 
MSCs implanted subcutaneously. MSCs are prone to osteogenesis when implanted ectopically95 
and there is no evidence as yet that they spontaneously form any other lineage specific tissue 
type397 in the absence of the appropriate pro-differentiation stimulus. This tendency of MSCs 
towards osteogenesis is also reflected in the in vivo results of MSC implantation where fibrous, 
endochondral and even mineralised tissue can form even after in vitro chondrogenic 
differentiation. The Liu study, like this study, found that hMSCs required a pro-chondrogenic 
stimulus when in a 3D environment, in their case a scaffold based construct. As with the pellets in 
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this study, in the absence of PChM constructs shrunk continually over the course of the 
experiment and formed fibrous tissue. Interestingly they also showed that a much longer in vitro 
pro-chondrogenic differentiation period (12 weeks compared to 4 weeks) led to the formation of 
an apparently stable cartilaginous tissue following in vitro subcutaneous implantation. Perhaps 
most importantly for potential cartilage regeneration therapies the implanted pre-differentiated 
tissue continued to become more cartilage-like396. 
 Conclusions 6.6
The work in this chapter successfully extended and supported the results described in the 
previous two chapters. The formation and culture of the cells under investigation into 3D pellets 
in both standard culture conditions i.e. a sub-optimal chondrogenic environment and in a pro-
chondrogenic, TGF-β3 supplemented environment illuminated key differences in chondrogenesis 
in each cell type. It was clear that stable cell pellets undergoing robust chondrogenesis and ECM 
synthesis were only formed in the three primary cell types and that they were absolutely reliant 
upon a pro-chondrogenic environment to do so. In the absence of the appropriate cues cell 
pellets gradually diminished in size, DNA content and, with some slight exceptions, positive 
staining for the major chondrogenic ECM proteins assessed. In the clinical context if any of these 
cells were implanted into a defect that could not provide adequate pro-chondrogenic cues it 
would likely result in an unsuccessful treatment. Chondrocytes and MSCs were found at 20 days 
to have biochemically equivalent sGAG contents but significant differences in the spatial 
distributions of the ECM proteins. This resulted in highly heterogeneous and fibrous tissue 
formation in the MSC pellets, a highly undesirable outcome for articular cartilage regenerative 
therapies that would likely result in failure. hESC derived cells appeared to have an intermediate 
propensity to undergo chondrogenesis with reduced sGAG compared to MSCs and chondrocytes 
but also producing a somewhat less fibrous tissue than MSCs. Gene expression analysis also 
highlighted key variations, specifically MSCs in contrast to the other primary cells no longer 
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expressed SOX9 and appeared to have progressed to a hypertrophic phenotype. By most of the 
measures discussed transduced cells were inferior to primary cells and in confirmation of the 2D 
results they certainly do not represent a suitable replacement for primary cells. However, 
interestingly there were indications, such as the sustained differential response to MM and PChM 
and SOX9 expression and in particular the improvement seen by transferring OK3H from a 2D to a 
3D environment, which suggested that the transduction whilst clearly significantly impacting upon 
the cells’ chondrogenic potential had not completely abrogated the chondrogenic response.   
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 Summative discussion 7.1
Articular cartilage damage and degeneration is a problem for which an ideal solution is yet to be 
identified. Progress on regenerative medicine alternatives to joint replacement is being made 
with corresponding improvements to patient outcomes yet the problems that were identified 
relatively early on in the development of new techniques, primarily around the production of an 
inappropriate ECM, still persist today. The native articular cartilage is hyaline in nature whist 
fibrocartilage is often, at least regionally, found in biopsies of repair tissue. To date two cells types 
have been the primary component investigated for cell-based therapies, firstly the articular 
chondrocyte itself and latterly the bone marrow MSC, future therapies are also likely to extend to 
include pluripotent stem cell derivatives. These cell types all have associated advantages and 
disadvantages as summarised in Table 7-1. Further consideration is also being given to the cell 
source where phenotypically similar cells are available from multiple potential sources, 
particularly with MSCs where cells are being isolated from an increasing diversity of sources.  
The aims of the work in this thesis were essentially threefold, firstly to establish whether 
physiological hypoxia levels, determined to have a positive impact on the recovery of bone 
marrow MSCs, hESCs and chondrogenesis, improved the recovery rate of MSCs from human UCB 
samples as these are a readily available cell source for allogeneic therapies. The second aim was 
to investigate the chondrogenic capacity of clinically relevant cells, particularly with respect to 
their ability to produce a homogeneous, cartilaginous ECM. Finally, to determine whether hTERT 
transduction could extend in vitro proliferative capacity and prevent senescence whilst also 
maintaining cellular chondrogenic capacity. 
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Table 7-1. Key advantages and disadvantages associated with cell types with potential cell 
therapy applications. 
Chondrocytes 
 Cells may already have the desired chondrogenic phenotype. 
 No ethical concerns with the cell source 
- Limited availability – low cell density in tissue requires larger biopsies 
which may not be possible.  
- Acquisition of tissue for cell isolation may case donor site morbidity in 
previously healthy regions. 
- Cells are not suited to in vitro expansion, undergoing de-differentiation. 
- Although biopsy regions may be macroscopically healthy cells may already 
be undergoing detrimental phenotypic changes. 
MSCs 
 Available from multiple tissue sources. 
 No ethical concerns surrounding their acquisition 
- The ideal source of MSCs has yet to be identified. 
- MSCs appear to follow an intrinsic hypertrophy/endochondral ossification 
pathway which cannot yet be completely prevented. 
Pluripotent 
cells and  
derivatives 
thereof 
 Can be expanded to potentially unlimited numbers. 
 More naïve cell type – greater differentiation potential. 
 iPSC technology may allow for autologous pluripotent stem cell products. 
- Ethical concerns surrounding hESCs. 
- Uncertain epigenetic status of iPSCs. 
- Potential for teratoma formation if undifferentiated cells persist in a cell 
therapy product. 
- More complex differentiation requirements. 
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UCB was found not to be a viable source of MSCs, at least on a small laboratory scale, due to lack 
of reliable recovery. With current techniques yet to identify a unique MSC marker to enable 
positive selection, UCB should be considered a more suitable source for haematopoietic cells. 
However, the study did direct further investigation into FBS batch variability with the results 
having wide-ranging implications regarding the importance and continued use of FBS. FBS has 
been and continues to be used extensively in cell culture experiments, even being used in many 
clinical trials if produced in compliance with appropriate good manufacturing practice (GMP) 
regulations398. Although technically already a pooled product as each batch is produced from 
many foetuses, there nevertheless remains huge batch to batch variability and the nature of this 
remains largely unknown as FBS is not well characterised278 (For information Certificates of 
Analysis for FBS1 and FBS2 are included in Appendix C). Whilst the effects of FBS on cell recovery 
from biological products have been clearly highlighted in Chapter 3 it is likely that there are also a 
multitude of other cellular processes that are also being affected in unknown ways and inevitably 
with down-stream effects. 
The effect of oxygen tension on UCB MSC recovery was also compared in Chapter 3. Whilst 
determination of the effects on recovery from UCB could not be directly assessed due to overall 
poor performance, the single colony of MSC-like cells that was recovered was found in a more 
physiologically relevant 2% O2 environment suggesting that it may prove to be a superior option 
for future work. Subsequent controlled investigation with bone marrow MNC preparations 
revealed a strong ameliorating effect of 2% O2 on the poor recovery of MSCs concomitant with 
large numbers of monocytes that was found in 21% O2 when FBS2 was used. Whilst the cause 
remains unconfirmed as it would require considerable further investigation, there are several 
possibilities as discussed more fully in Chapter 3.  
In order to address the second and third aims three clinically relevant cell types were expanded 
and then transduced with hTERT. Human articular chondrocytes (OK3), MSCs, and as no cells were 
obtained from UCB these were bone marrow derived (BMA13), and hESC-derived cells (1C6). 
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Subsequently cell proliferation capacity, phenotype, and chondrogenic differentiation capacity 
was compared across all primary and transduced cells.  
When comparing chondrogenesis across the three primary cell types, chondrocytes remained the 
most optimal. These cells produced the highest sGAG levels in both 2D and in 3D. Although on this 
measure BMA13 was similar, chondrocytes appeared to more readily switch from a proliferative 
to a synthetic phenotype. In 3D culture they had the greatest overall and most persistent 
upregulation of chondrogenic genes particularly SOX9 the master regulator of chondrogenesis, 
and the matrix that the cells produced stained homogeneously for sGAG and for collagen with 
minimal fibrous tissue apparent. The tissue produced can by these measures be judged to be the 
most hyaline-like and therefore the most likely to result in the most successful clinical outcome. 
The results from the other two primary cells were in comparison sub-optimal, BMA13 whilst 
promising on the basis of sGAG synthesis retained a more proliferative phenotype in 2D culture 
although significant sGAG was produced. In 3D the cells no longer maintained a proliferative 
phenotype as DNA content of pellets did not increase, instead they developed many features of 
hypertrophic cartilage with down-regulation of chondrogenic genes and up-regulation of type X 
collagen. Pellets also stained very heterogeneously for sGAG and collagen, with thick highly 
organised collagen fibres throughout much of the pellet indicating fibrocartilage development. It 
has been suggested that MSCs may experience a lag period prior to the onset of differentiation 
due to their stem cell state399 and extended culture has proved beneficial in some cases386. 
Nevertheless, these results would suggest that this is not the case here as MSCs appeared to 
progress rapidly through a chondrogenic phase where aggrecan was deposited and to 
hypertrophy associated with down-regulation of the ACAN and SOX9 genes by day twenty. Overall 
these results are typical for both chondrocytes and MSCs and support much of the available 
literature73,83,385,38684,400. Alternative sources of MSCs, including those resident in the joint 
compartment, may provide cells more suited to chondrogenesis and there has been a recent 
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interest in the application of synovial MSCs70 and cells from the infra-patellar fat pad401 as 
alternatives to bone marrow. 
Additionally attempts to improve chondrogenesis particularly in MSCs by further refinement of 
the culture condition are ongoing400. A factorial screening experiment of multiple growth factor 
supplementation on an array of chondrogenic ‘wanted’ and ‘unwanted’ genes found no condition 
in which optimal gene expression for chondrogenesis of MSCs could be achieved, those conditions 
that up-regulated wanted genes also up-regulated unwanted genes, the study concluded that 
TGF-β1, 2 or 3 combined with dexamethasone supplementation still provided the overall best 
outcome366. This combination was used in this study and therefore the results can be interpreted 
with confidence. 
1C6 may present a slightly different case and the results were interesting from the perspective of 
potential future use. The cell response to the PChM appeared to be muted in comparison to that 
of both the chondrocytes and the MSCs, less sGAG was produced overall and pellets were 
somewhat fibrous, although much less so than BMA13; however, sustained up-regulation of 
chondrogenic genes including SOX9 was seen. These results suggest capacity for chondrogenesis 
but that the cues may not be sufficient in standard PChM, unsurprising when the complex 
routines employed for hESC chondrogenic differentiation156,157 are compared to the simple PChM 
used in these experiments. In support of the results seen with 1C6, in a recent report the 
chondrogenic capacity of another H1 derived MSC-like cell type was compared to that of bone 
marrow MSCs completely independently, with similar results to those here. The response of the 
H1 derived cells in that case was improved by the addition of BMP7 to cultures402 and this may be 
an option in future work. 
Following transduction both the chondrocytes OK3H and the 1C6H hESC derived cells gained 
considerable proliferative capacity, bypassing replicative senescence and appearing to be 
immortal, MSCs BMA13H on the other hand had only a very modest increase in expansion 
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capacity. However, the telomerised cells in all cases deviated from the parental cell phenotype 
with expanded cells displaying changes in immunophenotype and differentiation capacity. 1C6H 
cells in particular appeared to perform particularly badly in pellet culture whilst the parental cell 
line exhibited modest chondrogenesis. Nevertheless the telomerised cells, including 1C6H, 
retained some degree of differential response to PChM compared to MM indicating that some 
chondrogenic capacity was retained. Surprisingly OK3H which exhibited no response to PChM in 
monolayer culture had improved chondrogenic capacity in 3D pellets. It is possible that further 
improvements in driving chondrogenesis could be measured using the OK3H cell response and 
that OK3H could be sensitive to further improvements. 
There are many reports of the successful application of hTERT transduction to immortalise cells 
whilst preserving their phenotype. However, these tend to be spread across multiple cell types 
and are sometimes contradictory as others report varied degree of success either with respect to 
immortalisation or preservation of the initial phenotype202,203,207,328,338,403–412. Whilst reports of its 
use for chondrocytes are very limited and have often reported mixed success, there is more data 
available for MSCs where success is often reported. This is suggestive of a difference in the system 
applied here, and the possible candidate identified is the oxygen culture environment. The use of 
a physiologically relevant 2% oxygen level in culture prior to transduction in combination with 
transduction in ambient oxygen levels may have provided a hyperoxic insult that had long term 
effects on the resultant transduced cell phenotype294,413,414.  
All cell populations used in this study were polyclonal; however, variations are known to occur 
within the cell types used. MSC isolated from bone marrow are well known to be a mixture of 
cells with varied potency109,110 and similarly isolated chondrocytes behave differently depending 
on the tissue zone of origin, for example gene expression of key matrix molecules differs with 
middle and deep zone chondrocytes producing higher levels than superficial zone chondrocytes in 
addition to other basal metabolic differences415. Whilst polyclonal populations continue to be 
used heterogeneity in the outcome will likely continue to be a problem. Furthermore, and most 
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significantly with the transduced cells due to the extent to which they were expanded, there is 
evidence that slower growing clones that arise during cell culture are eliminated by apoptosis 
when in direct contact with faster growing cells416. This process appears to be analogous to that of 
‘cell competition’ as described originally during Drosophila development as the process by which 
cells can be categorised as ‘loser’ cells or ‘winner’ cells  within the context of the local 
environment with the loser cells being slower growing and eventually undergoing apoptosis417. 
This would favour the selection of more rapidly proliferating cells potentially to the detriment of 
cells with greater differentiation capacity. Unfortunately unless greater amounts of starting tissue 
become available the concept of monoclonal cultures would be difficult to implement on a 
routine basis. Furthermore cell expansion to useful numbers from a single starting cell would 
result in much greater cell aging. 
The concept that more proliferative cells are less likely to undergo differentiation has merit. The 
two processes of proliferation and differentiation are exclusive, with cells developing and 
exhibiting the features of a differentiated phenotype during interphase418. Cells that spend less 
time in interphase due to more rapid cell cycling are therefore less likely to exhibit the features 
associated with a differentiated phenotype. The hESC-derived progenitors used here proliferate at 
a greater rate than the MSC and the chondrocytes and appear to have a less differentiated 
phenotype. The transduced cells all had a reduced capacity for differentiation in comparison to 
the primary cells. hTERT in addition to its canonical role has other more direct effects on the cell 
cycle202,206. One possibility to ‘rescue’ cells that are more proliferative to potentially increase their 
differentiation capacity is the application of conditional immortalisation, where the factor driving 
proliferation can be removed in some way, or transient immortalisation. Transient rather than 
permanent expression of hTERT is sufficient to extend cellular lifespan and should be 
considered406. Conditional or transient immortalisation has been successfully used in several cell 
types including fibroblasts406, beta cells419, MSCs405 and chondrocytes345. Interestingly 
overexpression of hTERT in the undifferentiated H1 hESC cell line, the parental line of 1C6, has 
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independently been found to affect the differentiation capacity of the cells with reduced 
expression of germline differentiation markers and increased expression of the pluripotency 
marker OCT4202. If 1C6 does not reflect a fully differentiated cell type and 1C6H even less so it is 
possible that the results herein represent a very similar response and explain why ectopic 
expression in 1C6H resulted in very poor differentiation. 
 Conclusions 7.2
Whilst desirable due to relative ease of access and existing infrastructure the use of UCB for MSC 
isolation cannot be supported, at least on a small scale, by the results herein. Monocyte 
contamination of MNC preparations, exacerbated as a result of FBS batch variability and 
influenced by oxygen tension, was identified as a possible confounding factor. However, despite 
modifications to the protocol to remove all leukocytes with the CD45 antigen, recovery could not 
be improved. These results indicate either that MSCs are only present in vanishingly small 
numbers in UCB or that considerable refinement to culture conditions could be required for 
reliable isolation. The results also strongly support a move away from FBS to defined serum-free 
conditions. 
A direct comparison of chondrogenesis in three cell types: chondrocytes (OK3), MSCs (BMA13) 
and hESC-derived cells (1C6) favoured the continued use of chondrocytes in articular cartilage 
therapies. Whilst chondrocytes and MSCs were biochemically comparable, there were significant 
gene expression changes suggesting that MSCs were becoming hypertrophic. The ECM produced 
by chondrocytes was also considerably less heterogeneous and fibrous than that produced by 
MSCs with chondrocytes more hyaline-like and MSCs more fibrocartilage-like. hESC-derived cells 
were less responsive to the pro-chondrogenic signals and produced an intermediate tissue type; 
however, prolonged SOX9 expression suggest that they may have further unexplored capacity for 
chondrogenesis. Based on current results; however, chondrocytes still represent the gold 
standard for cell therapies. 
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The use of hTERT transduction was successful in extending the proliferation capacity of OK3 and 
1C6 but not BMA13; however, it was unsuccessful in maintaining the phenotype of all cell types 
by multiple measures in the current differentiation model. Detailed analysis revealed that 
responses to pro-chondrogenic signals were greatly diminished although not completely nullified 
in all three cell types therefore they cannot be considered to be a replacement for primary cells in 
articular cartilage research. Future optimisation of the immortalisation process may produce cell 
lines with much greater utility. 
 Future perspectives 7.3
The work described in this thesis has raised a number of considerations for future work as 
detailed below. 
The successful culture of MSCs from UCB as shown is not a trivial matter with a number of critical 
parameters identified that should be taken into account in future studies of this nature. Studies 
would clearly benefit from being much larger in order to establish optimised protocols and 
effectively observe the effects resulting from modifying isolation parameters. As such, future 
work would greatly benefit from either the use of, or collaboration with, an UCB bank as a donor 
source or alternatively cord blood collection from the placenta in utero by a trained team to 
maximise the volume of material collected and to minimise the risk of clotting and haemolysis. 
Future studies attempting to isolate UCB MSCs and potentially from other sources should 
consider the option of serum free culture to remove what are clearly severe confounding factors 
when FBS is used.  
The detrimental effects of FBS batch on MSC recovery were clearly reduced by culture in 2% O2 
compared to 21% O2 when recovering from BMA MNC preparations; this would suggest that 
culture in 2% O2 is also likely to be beneficial to recovery from UCB; however, the mechanisms 
involved are currently unknown and would be of great interest to future work for both MSC and 
HSC recovery.  
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The immortalisation of cells, particularly chondrocytes to create a phenotypically stable cell line 
would clearly be invaluable for cartilage research, as such further investigations towards this 
should be investigated. One possibility for the lack of success with hTERT immortalisation is the 
detrimental effect of oxidative stress in the cultures. It would be of interest to repeat the 
transductions described here in a stable physiological oxygen level to determine whether it could 
then be a successful approach. hTERT transduction in concert with other promoters of 
chondrogenic differentiation may also be an option. 
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 Appendix B – Supplementary figures  9.4
9.4.1 FBS batch testing results 
 
Supplementary figure 1. FBS batch test results. Cell proliferation results from batch testing of three 
new FBS batches (FBS2-5) compared to original batch FBS1. MSCs were seeded to 6 well plates and cultured 
in MM supplemented with 10% (v/v) of one of each of the FBS batches and cultured until the best 
performing batch was approaching confluence at which point cells were trypsinised and counted with a 
Neubauer Haemocytometer. FBS1 and FBS2 refer to the same FBS1 and FBS2 as previous chapters. N=3, 
mean ± standard deviation. 
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9.4.2 The influence of BMA13 pellet size on sGAG deposition 
 
Supplementary figure 2. Spatial patterning of chondrogenesis independent of cell pellet size. 
Cell pellets formed from 2.5x10
5
 (A) and 5x10
5
 (B) BMA13 cells after 20 days culture in PChM. The pattern 
of sGAG production is strikingly similar independent of pellet size suggesting that it is not simply a result of 
nutrient diffusion dynamics. 
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 Appendix C - Certificates of Analysis for FBS batches 9.5
9.5.1 FBS1 (Lonza) 
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9.5.2 FBS2 (Biosera) 
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